var title_f33_30_34272="Timolol: Pediatric drug information";
var content_f33_30_34272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Timolol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/27/25014?source=see_link\">",
"       Timolol (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/9/16534?source=see_link\">",
"       Timolol (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12844 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-218.28.111.102-3C51B1EE61-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34272=[""].join("\n");
var outline_f33_30_34272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34273="Male self-catheterization PI";
var content_f33_30_34273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Putting in a catheter (Men)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    You can sit on the toilet to put the catheter in your penis. Put the other end of the catheter over the toilet or another container.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34273=[""].join("\n");
var outline_f33_30_34273=null;
var title_f33_30_34274="Posterior urethral valves";
var content_f33_30_34274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Posterior urethral valves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An oblique membrane associated with the verumontanum, the congenital obstructive posterior urethral membrane (COPUM), appears to be the cause of posterior urethral valves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34274=[""].join("\n");
var outline_f33_30_34274=null;
var title_f33_30_34275="Acute myeloid leukemia (AML) treatment in adults";
var content_f33_30_34275=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/30/34275/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34275/contributors\" id=\"au3198\">",
"       Richard A Larson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/30/34275/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34275/contributors\" id=\"se407\">",
"       Bob Lowenberg, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/30/34275/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34275/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/30/34275?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ACUTE MYELOID LEUKEMIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Acute myeloid leukemia (AML) is a type of cancer of blood and bone marrow cells. It affects a group of white blood cells called myeloid cells. Normally, myeloid and other blood cells are produced in the bone marrow (the spongy area in the middle of bones) in a carefully controlled fashion. In someone with AML, the blood cell production process is abnormal and large numbers of immature myeloid cells are produced and may be released into the blood stream. Sometimes, the number of white blood cells in the circulation is abnormally high because of overproduction of malignant blood cells.",
"    </p>",
"    <p>",
"     The overproduction of myeloid cells prevents the bone marrow from producing other important blood cells, including red blood cells, other types of white blood cells, and platelets. This results in a variety of body-wide symptoms, including anemia, bleeding, and an increased risk of infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GENERAL INFORMATION ABOUT ACUTE MYELOID LEUKEMIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A number of chemotherapy medications are effective against AML. The goal of treatment is to kill the malignant cells without damaging the residual normal bone marrow cells. Studies are underway to find the best medicines, doses, and treatment schedules for AML.",
"    </p>",
"    <p>",
"     Researchers have discovered that the genetic makeup of the abnormal myeloid cells can vary, which affects how you respond to treatment. Your treatment can be tailored based upon a careful analysis of your genetic material. These genetic changes are due to mutations that are acquired within bone marrow stem cells and thereby affect all of the daughter cells that are produced. It is not known how these mutations develop. They are generally not thought to be inherited but rather develop by chance. Treatment of AML also depends upon your specific subtype of AML and on your age (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Acute myeloid leukemia treatment in older people'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     The usual treatment of AML is divided into two phases: induction of remission and postremission therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      INDUCTION OF REMISSION IN ACUTE MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     The initial phase of treatment is referred to as remission induction or \"induction\" therapy. Induction therapy is given with the goal of decreasing the number of leukemia cells to an undetectable level and restoring the production of normal blood cells. Most of the cells in your body divide and multiply slowly and are not affected by chemotherapy. However, certain cells, such as those in the bone marrow (where the blood cells are produced), the hair follicles, and the cells lining the gastrointestinal (GI) tract are multiplying rapidly. As a result, chemotherapy is most likely to cause side effects such as anemia (lowered red blood cell count), susceptibility to infection (lowered white blood cell count or low hemoglobin level) and bleeding (lowered platelet count). Other side effects include temporary loss of hair, sores in the mouth, upset stomach, and diarrhea. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"      \"Induction therapy for acute myeloid leukemia in younger adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The most common remission induction regimens include cytarabine, given continuously for seven days through an intravenous (IV) line. An anthracycline drug, such as daunorubicin or idarubicin, is also given in a single IV dose for the first three days of treatment. This is sometimes known as the \"7+3\" regimen. These drugs kill AML cells over the first 7 to 14 days; it then takes the normal bone marrow about 14 days to recover and produce normal blood cells again.",
"    </p>",
"    <p>",
"     This phase of treatment takes approximately four weeks and is almost always performed while you stay in the hospital. The induction phase usually consists of one or two cycles. A cycle of chemotherapy refers to the time it takes to give the drugs and the time required for the body to recover.",
"    </p>",
"    <p>",
"     Induction therapy frequently results in a complete remission of the AML, meaning that there are no visible leukemia cells in the blood or bone marrow when examined under a microscope and that the bone marrow is functioning normally. However, such remissions are usually short-lived unless additional, postremission therapy is given.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14409079\">",
"     <span class=\"h2\">",
"      Complete remission",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first goal of AML treatment is to achieve a complete remission. Complete remission means that there is no visible evidence of leukemia cells in the blood or bone marrow and the bone marrow is functioning normally. A bone marrow biopsy and blood testing are done to determine",
"     <span class=\"nowrap\">",
"      when/if",
"     </span>",
"     this occurs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     Post-remission therapy is given with the intention of killing leukemia cells that can remain in the bone marrow or blood, but are undetectable under the microscope. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link\">",
"      \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There are three basic treatment choices for post-remission therapy: additional chemotherapy, stem cell transplantation from a donor (",
"     <strong>",
"      allogeneic",
"     </strong>",
"     hematopoietic stem cell transplantation), or stem cell transplantation using your own stem cells (",
"     <strong>",
"      autologous",
"     </strong>",
"     hematopoietic stem cell transplantation). The \"best\" post-remission treatment depends upon several factors, including how aggressive or resistant to treatment the AML is:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People with favorable risk disease are usually advised to continue with chemotherapy. Many of these patients are cured in this way.",
"      </li>",
"      <li>",
"       People with unfavorable risk disease are usually advised to have an allogeneic stem cell transplantation.",
"      </li>",
"      <li>",
"       The best treatment for intermediate risk disease is not clear; participation in a clinical trial is recommended, when possible. (See",
"       <a class=\"local\" href=\"#H13\">",
"        'Clinical trials'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Additional chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy given after remission is called remission consolidation or postremission chemotherapy, and often includes high-dose cytarabine. Consolidation chemotherapy is usually given in the hospital monthly over several days. Consolidation chemotherapy is given for approximately three to four months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Stem cell transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stem cell transplantation, also called bone marrow transplantation or hematopoietic stem cell transplantation, is a treatment in which you are given very high doses of chemotherapy or total body irradiation (TBI). This treatment is intended to kill cancer cells, but it also destroys all normal cells developing in the bone marrow. This means that your body's normal source of critical blood components (ie, the bone marrow) is no longer functional.",
"    </p>",
"    <p>",
"     After the treatment, you must have a healthy supply of young blood cells (called stem cells) reintroduced, or transplanted using transfusion. The transplanted cells then re-establish the blood cell production process in the bone marrow. The new stem cells also generate a new immune system. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Stem cell transplantation is not recommended for all patients with AML. Serious, and sometimes even fatal, complications occur more commonly after stem cell transplantation than with chemotherapy. In certain groups of people, there is no clear benefit of stem cell transplantation over chemotherapy. However, transplantation may be appropriate in some people, such as those with more aggressive forms of AML, those who have had a relapse following remission, and those who do not achieve remission after initial induction therapy.",
"    </p>",
"    <p>",
"     There are two main types of stem cell transplantation: allogeneic and autologous.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Allogeneic",
"       </strong>",
"       transplantation uses stem cells from a healthy donor, ideally a sibling with a similar genetic makeup (called an HLA-matched related donor; MRD). The HLA genes are inherited from both parents and govern your immune system. If you do not have a sibling with similar genetic characteristics, an unrelated person with a similar genetic makeup may be used (called a matched unrelated donor; MUD). Other possibilities include the use of a sibling with partially similar genetic characteristics (partially matched family member donor) or cord blood stem cells collected from a newborn's umbilical cord.",
"       <br/>",
"       <br/>",
"       Allogeneic transplantation treats AML in two ways. First, high doses of chemotherapy or radiation are given immediately before the transplant, which kills the leukemia cells present in the blood and bone marrow that might be resistant to lower doses of chemotherapy. Second, when cells from another person are injected, the donor stem cells develop into immune cells that can identify the leukemia cells as foreign and launch an immune attack that helps destroy any remaining leukemia cells. This is called the \"",
"       <strong>",
"        graft versus leukemia",
"       </strong>",
"       \" or \"graft versus tumor\" effect.",
"       <br/>",
"       <br/>",
"       Unfortunately, this response can lead to a complication called \"",
"       <strong>",
"        graft versus host disease",
"       </strong>",
"       \", in which the immune response includes an attack on your own healthy organs. Symptoms can include severe skin rash, diarrhea, liver damage, and other problems. Still, allogeneic transplantation is generally preferred over autologous transplantation in people with AML.",
"      </li>",
"      <li>",
"       In an",
"       <strong>",
"        autologous",
"       </strong>",
"       transplant, your own normal stem cells are collected while you are in complete remission. Shortly afterwards, high dose chemotherapy or radiation is given. In some cases, the cells are treated to remove any lingering leukemia cells that may be present, although this is experimental. After the stem cells are collected, they are frozen for use at a later time. After your chemotherapy or radiation is complete, the harvested cells are thawed and returned by IV infusion.",
"       <br/>",
"       <br/>",
"       Because the transplanted stem cells do not come from another person, there is no \"graft versus host\" disease. This helps reduce some of the side effects of treatment, but in general it also makes autologous transplantation somewhat less effective than allogeneic transplantation in fighting the leukemia, because of the lack of a \"graft versus leukemia\" effect. Autologous transplantation is less often recommended for treatment of AML for this reason.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ACUTE MYELOID LEUKEMIA TREATMENT IN OLDER PEOPLE",
"     </span>",
"    </p>",
"    <p>",
"     In general, people over 60 years old do not respond as well to treatment for AML. This is related to the following factors:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Difficult-to-treat leukemia cells may be more common in older people. This means that the AML that occurs in older people tends to be more resistant to standard chemotherapy drugs.",
"      </li>",
"      <li>",
"       In older people, the presence of other disorders, such as diabetes, kidney, lung, or heart disease, increases the risk of treatment-related complications.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Treatment decisions for older people with AML are best made on a case by case basis. In otherwise healthy older people, even those &gt;75 years of age, whose leukemia is not \"high-risk\" according to genetic testing, induction chemotherapy is generally recommended. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"      \"Treatment of acute myeloid leukemia in older adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In older people with slowly progressing AML, severe underlying health problems, or high risk and unfavorable AML, the expected benefit of chemotherapy may not be worth the anticipated discomfort, hospitalization, and potentially toxic side effects. Less intensive chemotherapy regimens are under development for older patients and enrollment on a clinical trial of one of these regimens may be suggested. If the potential risk of chemotherapy is greater than the potential benefit, supportive care may be recommended. Supportive care generally includes blood transfusions for anemia and antibiotics as needed for infections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Which treatment is right for me?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You and your family should get information from your healthcare provider about your type of AML, expected benefits of various treatments, possible side effects and toxicities, and your long-term outlook. These discussions are critical to determining the best course of action for you. Many new drugs or drug combinations are currently being studied for patients with AML. The best treatment for you may include a clinical trial so that you can have access to the latest new drugs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TREATMENT OF RELAPSED OR RESISTANT ACUTE MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     A limited number of treatments are effective in the treatment of AML. Thus, if your AML does not respond to or if your AML relapses after initial chemotherapy, management is more difficult:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Approximately 50 percent of people with long first remissions (greater than one year) benefit from a second remission induction attempt with daunorubicin and cytarabine or with high-dose cytarabine (HDAC), but the duration of the second remission is usually shorter than the first. Because of this, stem cell transplantation should be considered for anyone who relapses after his or her initial treatment (once a second complete or partial remission is obtained).",
"      </li>",
"      <li>",
"       People who relapse within 12 months of their initial diagnosis usually have AML with a high degree of drug resistance and therefore have a lower rate of achieving a second complete remission. Medicines specifically approved for use in patients with relapsed AML or experimental agents may be useful in this setting, followed by stem cell transplantation if a remission occurs.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29498?source=see_link\">",
"      \"Treatment of relapsed or refractory acute myeloid leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      LONG TERM MONITORING OF ACUTE MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     Once you are in complete remission and have completed post-remission therapy, you will need long term monitoring so that any relapse can be detected and treated. Relapse is most likely to occur within the first two years after completion of induction chemotherapy, and becomes less common later.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your chances of being cured of AML depend upon a number of factors, including your age, other health conditions, how aggressive your AML is, and whether you have been treated with chemotherapy before your AML diagnosis. In one study, approximately 65, 40, and 15 percent of people with favorable, intermediate, and unfavorable risk disease, respectively, were alive five years after diagnosis.",
"    </p>",
"    <p>",
"     However, when discussing chances of cure, it is important to remember that these numbers represent averages and do not necessarily predict what will happen to you. A complete discussion of prognosis of AML is available separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link\">",
"      \"Prognosis of acute myeloid leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many patients with leukemia will be asked to enroll in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your doctor for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804396976\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027261\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/4/14402?source=see_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/13/38098?source=see_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027287\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14168?source=see_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=see_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29498?source=see_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12888?source=see_link\">",
"      Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Cancer Institute",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.gov/cancertopics\">",
"        www.cancer.gov/cancertopics",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Cancer Society",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.org/\">",
"        www.cancer.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"        www.leukemia-lymphoma.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Marrow Donor Program",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.marrow.org/\">",
"        www.marrow.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The American Society of Clinical Oncology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"        www.cancer.net/portal/site/patient",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/30/34275/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/30/34275?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34275/abstract/1\">",
"      Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011; 152:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34275/abstract/2\">",
"      Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_30_34275=[""].join("\n");
var outline_f33_30_34275=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ACUTE MYELOID LEUKEMIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GENERAL INFORMATION ABOUT ACUTE MYELOID LEUKEMIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           INDUCTION OF REMISSION IN ACUTE MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ACUTE MYELOID LEUKEMIA TREATMENT IN OLDER PEOPLE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TREATMENT OF RELAPSED OR RESISTANT ACUTE MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           LONG TERM MONITORING OF ACUTE MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34276="Tissue damage in monopolar electrosurgery";
var content_f33_30_34276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Tissue damage in monopolar electrosurgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Range of currents and tissue damage in monopolar electrosurgery",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34276=[""].join("\n");
var outline_f33_30_34276=null;
var title_f33_30_34277="Complete metaplasia";
var content_f33_30_34277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric complete metaplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 296px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEoAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwAlt4WaUkSQ3siohQHGXHG4npgitG/sGsoGLPGZsj5Exzj1rP1SKYzzsrALHy7l+vHUHv8AhVqW8i+2JcIZDKVQRg4YP65FfUu+jR6cWtjWt9LvdW+zx6RBPdTNy0rcIDjoT7V1tv8ADLULmFBf3tvBtXaFRS5X1545qCP4ktpumR2tpaWsk0ZCbiSoY+u0Vh6j4v1jW9SW0mvI44W5EcHyjHuetcTeIk/dtFfeyf3r0WiNLXfCDabELeyuoppdu0krz9ap29vb2kSW9jEI7yMHfNIOBnqc9/pVE6zaxXckb3U0K+VtYq+d7eufpWI2p2qW8kYsluBJI6rLLJtBGOM/StIwqNWk7mlnb3ilqMdgdRe0adZkkX9+83IAHrjtXOWsccmhX9sbCRLVnL2jfdV2H8waguL66mv1slWGe3WEsksa8nAyRnv9Ky/DcurarqMuni5mukkKrAh5CvnjaO3pXocjUbt7GU2nY3PhX4Bn8U+LvLv59pRPNYAcKucY+tfYmlWEGl6dBZWaBLeBQiL6CuU+GXhA+GtPae+2vqtyoEzgD5VHRRj9a7G5ZwgWIZZjjPZfevnsfiniKlk/dRyVZJu0djmr/TJvEM9xE2rXMdgkhSSGKMJuI6ru6kVxHxYjup7jQPCGgI6W0r+bevGQMRLjCt9TXX6vqstrOmhaDCXu9pLMRwme5PuTXmesaVr2ja5aPdtI7XFwrXMsXKbc/LEPr1NVhk+ZNtabL9S4x097bsdDb2NvFeyW4ANwvyRErnYv8TZrp7GDZaskfyrtwGArL020uI7jzJ1Rppc5AGNoJzitPSJI7qdbMT7mZmyFOSFGfyqKjuXJm74Us/s2lqzj5pDuGeu3tV+6uRbJNO7fuo1yQB3qaEKtuFA2qowB6AV4R8SfiAt3cXuk2N2GmgJDxrwCR2B71lQoSxNS0TGEfaTsafin4jI1w0NrqEaLv2lSQrL7/SvCNb1bXtH18ajqfmy27z5iuIm3ROuemfpVPWtIsL+4WbVbyPTryVdwV5ASw7Eiuq0WGx0XTorA3c120wDrFKMxPz27V9LRw9PDq0Ve/l+p1cib5Ys07fRLS61OHWdPLxIp84wn+96A1m+JfDMur6tb3cLAyFlV1ZtpU5z/AFrpra5gsispbfFKfMCgfcI6r9RUr6jNcaiWRYyCBzjbkjvUxnOMro2VFHBap4BuZ9RkudPkWNDklHJHI64NX/ETz2GnaRc6Y0kLwqTJOuRIXB4yRzjFdTJLdJewMpHyMSAOxOc/zrS0uytHBW6G6LnO/pVOu0k5a2HKirFVPjTqVx4RMSo8d2gELzgjec8Z9M+9croXjTXtIkN6Nc1PU4ZmKGC7YNsIwSfrzWr4h8O2UiT21ih8+4P7sLjG4cg1zll4cvYtBltZIWF1HcbpFzjgrzz+VTCjh+V8sbJmE6KVmke1eEvH9nMIodT8uMuA2G6MD39q7rUPsbmC6sdjqcBlVchh2r5e1Oynh1jTYJvlXyFZT0z15+ldN4T8XX2laulqbpZ7D0By0ZB9D2rhr5en79J/ITpp6rc94S1juZHtLm1CxBd8THv6iufuNPmstWjv7dSZIWB2q2BInP7tv6GmXl5daw+nanps6vFC22SMfw89a0tZvrW50mW9sJVmMDFZFB6H0P0rz0pRa8yFeOnciu/D9jrWjXv9nlLeOSRZ3gYYKkA5DDtXnHw78JaVP49vfEGji4tV2GOS1chl8w9Sp9O+D0r0a3FprFtHdWzSW8kq+WWjJ4bHQnuPY1FaWVtomkvBbPm4L/vHVduAfStIVZQjKKe+htzqUHGer6eXcq3z3EBmaGTdcS5XeQB0OK4nUdQvbaG9E0qjaCWK5yB3Arp9UvzAW8ohs52MecGvOI9YtLy5vtOeTdcqSpyMbuMHHrXVhqbavYumktzJfxJcf2MGs38xw+zLrllHXoavWN5JrNsGWQLeRcOo4z6HH58Vx0Y/s+8lhmiZ4l+UqvVl7Mv0/pXSeGrN4rhdRtmSSydSPMUjr9OxzXrzhGMbonmbaMLxhYzajfWWoQqfOR/s8rj1U8N/SrdnpDwT38tyxa0nK4IPIwfvexrW8TWskenX81ujFS4lIHTk54rd+HKJqemMJU3MyYIPf3odXlp83RGsYxWsjndQ0IXXiOyli/dARiKRW6P8uAf1q5a6O93q9rKqFWUGIK33Xxx19RzXceLrQW0FnMBjYQH2jrjjOaxYriWCy3wwNLaxSGdWA5APUEfXNYwxDlBNGkVG2hy2seGnmuUWNjBIjbJN4OOeR+hrnbO6ln0p9NuFxPZylUDHopP+IrvYNdM7XBuMPHJtBb+8oGMfXGOfasHxX4cW31O71OykU2skIkKKeWII5BreFVpqNT5CnTs7mq/iRbkTpADDLa+UDkj5wB1H45rPjnEVrcW7yAJkzIc4475rn40WTV7vyT9+PzQPbgj8K3pLCe6tbZzC3lzAkuBx3yKajGGhlzO68jOtdckttft5WlPlRYSQbiQUJPNZ/iS1le5voLiRpXVjJGxOcqemPwrISZo9ZtScIsn7hieACOlb8aObmTTrz5Jwu1ZG5+gz3FbySg1JDfvSOc1KV4YrNrhWWXbhXPcehqlq0cl/ZQ3SJmaBtki+q9j9K7HxF4WuLjw6kStG1wso8tgflOTjGe3Wls/CeqQaQSY4zdQZSUIeXwO394D2oVeCV2xuN5cr2MWyW+0iAQSKzQyR+bEx5IzyPpU14H122gvYQDIG8qWMHkH1FXtVjuJ9PinjT99Dw2OtXZI410G3lSOOOWYZZQu1sj+dRKptLqbRpqPu9DpfBmoR6Dqlu915sdvtVJCnVT6kHqK9T1S0S+uFuo4TcRSoGSSNdwK9q8Ltbp5IcSqC2MZY9frXpvg2HxLHoMH9kSmWzYll2jO09x7c142Npa897MzxFFO0r2PNtP8AEpvNJin1ZYy43iNQNodQOpHsc1e0LV7W5szdzf6xHCrJgAKMdx/Ksbxl8PfEWnSLb2mn3U0a5iMirlQo6Yx61gS22owRRaWLeRHlkBYMpUKRxgk13xjCa9xnDGUoo79bvT7WOGS9fDMrM5JyM9hVPUNRsrPSF1QzBfPkCpGgydvqD9e1ec6pa6xfLOEtJdsP7rA5AUd637zRoroWkFpKRb28CpCP7z4yzN+OfwodNRauyvaTekTof7Rk+2eda26SW7Rffl655xgdu1Z2ra7Hc+GryGwtf9JfaHVjkgjg4+tbXhzwjr+pJZ2MMFwJHbmV4iFC+uT2r2/wN8J9H8PMbq9jS+v2O7LjKJ9B3/GuWtiqVDWWr7Ic6iitWfPfgfwbr3ijTYrSPTbhCGyJ2yipz3J7D0r6U+H/AMONI8I20MiRJcakF+e5ccg99vpXboiooVFCqOAAMCormXyzEvd3C/of8K8jE4+piPdWiOaVVyXKiV2CKSxwB3phkAiMhBwBnpzSeSrHMg3c5AJyBXlfxa8bX32qPwl4Nha61y5OLmUA+Xaxdyzdjj8q5aVGVaXLH/hkZpXN7QdQSzn1rULqNjOVM6xj7xXnCj3ryHw7D8QPEnxNXXfE9rPZaZFv8i1kO2MKRhQq9z3ya7y18Q6Z4B0aXVPElzvnMaxxR53OQOuPqa0fhbqlz4w09/EbmWO1mnYxI6bSdpxwD2rvi3SjOoo6PS7/AENppc1+xPr0z+HtEkuRua8m+RNx4UnvWt8OdPjt9KW4LGSaT7zH171g+IrO68QeMIrEP+4iQMzZ4UGu78pdL0lYbbA2AKCePxrnqO1NR6sqbtBR6sfez/6FcY7EqecY9a+PdNsZJPiHqG9N80c8r7G5zySB/KvpzUrn7VBNEk54+cgcFif6V5Fq3hS4l8SyalaSCCJAXMiqSxOfumu7LZKkpqT3Q6ULanksEsfinWnttZ0qRicq0sA2vAB/MD0NdN4Lugb6Pw3aos9hDFkTXkYbYxYH5M9OelYer33irUdVnigU26s5B8mIKSOmWbHNdLZGy0vw3cajdzxT3FnH5TsYwzSSHp7HnivaqfDZrfZb2ZpBWbbNaW1EM0kb5ZlbaXBDBj35FdBoHh9dRkZBI4cgcDnj8K5bw/NNrXh+31H7PHbSTyBfs6HC4A5ZR6Gujt7TU9OWK5t3MTE5BB5Fc1TmS5b2Z2Kd46M61/h1K1sfsd+q3HVY5D97+tZqaDrOmLKl9p/mhRnMZzkfStnSvHVpNbrB4is8uuAJ4ucj19q6ex1zSpkU2GuhV7RTgOBnt615kq1eGk1f+u6Od1KsfiVzyK5R/tPmBXtyhyoZCCDQbo2tlKZ2Z5J2ZnI5ZiRgCvWvENnpOpWTm5urJXA4eIgfpXkmpQR2900UdxHJjBV+1dNCsqy2NYSVREGqpZXIsp3t5FvIU8mSRjlVGMgAfga5DS/DGoNqkl7M6mwtsvuTkspB4ruNJje9AtLpIJj8wh2nlpO249e5wKr6Rr1noGtTaXdw7opUHKDgNzkHP410KcopqGrIqJFX4d+PYX8US6Xbobe3KFgsjcEjqfrXYaHFPYeOr22O99H1aAzK2PkWTHK/XNeM32mDS9eu9VXy2hgb92V/jLHjj8a948ITjVvCUF7KFD5AU9x2rHGU40/fitGrGMlf4jofD1mtn4ZeYLuWOYsVHbpk1y8fiiLWJ7uCON4ryBiAjjliOldVpNzNp+j3NqF82WfcIyeADjBz7VzdroltPqjaj5Kx3ceNxVsZIHUjvXnRcW5OfyEr3bZ5j4R1zUNTvNXgvAWMbeYikY2HPIrivFE0dxrz6hpSyxsr/MvTkcbvpXuOrW1lbXN89lBEhyC8iD7xPJrxrxLCLXxCJIRtSXnjpknqPavbwtSM5uUVbQ0s3E0tMeQ63pxlRcSqHcOBwG+taXg7wxfQ6pdrZ3scVhNdsgjn7d8+3FUrvSbwRWV4rKZEfA56DgjNeh+DtRtYNaAu4s205GWz/q36ZxRWquMG4ammqTkVhbJGlz9oAmjifyZVQZX2b6HpWTd6lDoGqR/YVMUYABAGM/h7V6T4p0+0mjuJ9MUcR4KgH94O4rymK2jvPEFlHdfNF5irkjOQTXLhpxqXctjSjJT1ZpeJfFR1XSgm1U2MMYHJ9zXefDq0S7022M8ETpdIoUeoA5P4VH41+H0Fvb3d3psAEQh37R2I61a+FN/ENJ02FhjZugDgdGB7/WuetVhPD/ue5nVnCVK9M5/U/Cmn2vxD/s9oVWwvVJjVf4T3/WsFbCOCXVtMnAdI4XVHb+DknIr0PxZCoXT9RTHnW9/w2OxHIryjU7+SfVrmQOFMsm12/wBkmtcPUnVirvp+KNKUnUhqVvCuiiSB5fs/+k+SbXeTnAPTj+tacUc1pN9jYA4Xs3ANdl8OYrUWl3cTRNMWkG1APlYH0PSrHxLsbSG2g1G0iWF8/Mgxk461U8XeryNEe0SnyHk2g+FU1m71CLBlnik3xQAdW9SewFbviXwLqWmWlnqN9LvEJXdJEp+72DZ/nXUfBy1hk8S6g2VbzUBznHH+TXqOu2scIRHwbR0YSmTlefWpxOYVKdbkWxNWu4T5eh8+2bmZZ9jZK/vI0PQ7TnFeq+CPDVpqmmpfzuZpWZjjoIz7Y/nXCeKNKk0fXZLOHaI0w9s4H3lI+6fwOKseCfG7eGtWa1v8izk6eimpr81anekyqt5wvAl+J/hJdHe5vtPBFtKQsqgYCk9Dj615hPJbJo7C9u1j8psqjDqfUGvoD4ga3puteGGFvOSzjGMZB+tfOGr6BDquqDMkpjVcKi8ZPvWuAqylC1TSxWHnNw13LUEQlRPI3EsBtxznNfVPw70NdH8I6fbEMsrIJJAWIO5uTXn/AMEvAt1YPNf67ZJHHtVbWOTkjH8Ve1gADjgVw5lilN+zi9Ec+MxHNaC6CIVdAy4KsMiqWpaPp2pxGO/sredOvzoD+tcvaP4rsykl/wDZZUjOGWP5Q6+uOxHtVbX/AIhzaMjt/wAI9f3ypjP2Uhjg98da4o0ZuVqbv6M4eVrVHTS+FtDltY7d9KtPKjG1AIwNo+tOtfDOiWk4mttKs45QMB1iGa8/0T41aXrOrQ6bbaNrUN3KdoE1thQfQnPFdxoGparcyTjVNLltYwf3bFw+78qdSnWp6TuvmJSb6m6hXJVSPl4wO1OZgq5PQVVjhkN207MVRgB5eOvualuYjKgUSFATzx19q5xFZtThW4eJg+EXcWAyKjsRJe3IvZQyRKCIIyMH3Y+57e1NT7JYRzzyv8mSXeQjH4Vz83ja2vF8rRsyOc7pCh2xgevHNaxg5fCi1G+xr+Ltaj0bTJJpJFjCq0juzYCIvLHP6CvK/AGqDxa93qWlRy2ugpI3nzPxJePjhf8AdGTW3418La74zurGyWUR6JvVryaU4eZQc7FUfwmutkttP0LSns7GKK3hQfdjTHzewHvXTHkpU7LWT/D/AIJcLxdkeMal4Eu/G3i/7NeyRzWUMglkfBHlxDouO5Ne2ozw2iaVoFnHDDbxiMbvlSMAYAGKzfhnpk1rpVxf3astzfSs5DdQg4Uf1/Gt7QbqOZZY0BJViXOO5J4pYms5vl6RLrT5n6CaPpi6astxdMjXEuDI/b6fSuV17xNNqGuppOkweaOjO3TOeo9qn8c69eWemz3cLvBZQMRK0UfmOcY4UeprzjRPiDdCaSaz0G2srTpJJeXGLyQ/7o4HXOKdGhKadS1yYrW8tWd9No1nocRu9X1eJWBBkVmwvBzjPWoNWvtO1GwklsrpFjl5HlHqOzV4xceM9F1DWLhdc+0EFtnlEEiQ/X3960zqujQ20Ukb2WjQbMRQsTlmBOSV5rt+qzVnNu/pobq27Z2NzZR3ujPDbW0JmhzvmBwzBhjd71wt/oem6X4b/wCEc1Jpftt6xkjOMB8f3T6jFa0Pia00kNeS30TRKu1/KGVfPQY9/StKy13SNdsEN2kNzZrMJIyy4eF+uR6Ct4OpS1afLf8AE0ep5hqOvajo9lpU8FmyabZqqqw/5aY65Pp7V6l4f8SWniXR4rxE8sgYdG/hbHH1p+v+A9O8U2izabqhtrqJSRCQCj568dCDXGXOh654Zs/s0dlHLb9fMiUgbh3IBrZyo4iKUdJfcT9o62az0/T9PaXUr61jkf7gEpyfas6O0luIGaC18wqchl6ba53xLoOq22ir4g1VLe006RVTe8oBDdOnWs3Q/Ej3Hh97XQrlmu7dsPkYAQ5xjPWqjSbjzRlf8kXGbvbc73TNLe+I+QiLb1AI57iszW9PktLv7P8A8syC2VHKjvVTS/HFzBpkEcu2ORHIkHbcBj+VO8U+J47rSvtcP/H0r+UNnX1NSo1Yz1Whaqu+pHMx03T4mnvI4bqJiUcDaThuBu7nuKj8VxWeo+IRG0y/2hIqs0gXCygrnPHRv51zGtW00XhnTnvEZ0lyxB55JOM/hTbtnsLC01C9LnCL5ZHXK8Y/LFdCp68yeupE5XdzRS7S9vJbeYbrYHy1HfA4Fe7eFrH7N4es4YwQsxU4PQCuH8BeDLSbWbXUZow9nfRbogezHkH616lqANlHHbx/N9lVS3HXJry8dWjJqnAic1ZJCWJikgvLggrDDGY1LdSfYV4n451/UtM+KXhuG3upUsZ0AaFOj5YgnHc9K7z4lavrGk6Qr6DZi6umnAMe3IAPAOBTbzypY9MN/awLqIQSPnBaHcOdtZYdez/eSV07q3yMuW+hj35ZkdQPlnDZKnjrXAfEa30qxs9LXUDNE75DTxc5IOeld3rMotrp53/d2rNiNh91R7jtXAX9m2r3lrpmp7ZLNblZllPIxnB59CDmu/C6NSb0R0ON7WNRL5b6LydMIktwPMQE5bpz9a9P8F6DpPiGzjEyMvlp8yjKlX/vVn/2JY2WkXENjBE72uGiubdQA646Eevar3wn1xbbXLrSpxsW6AlgDdfcVzV6nPTbpaWCpJuD5ehc1+wvfC4MzTvc6eRtEmBlO2G/xryy6mL6uGthzv8AMGB6ehr6H8bww3Hhm7S5haaMAHYo5JzXL/DHw1pX9jtcT2kcl4sjROX56GufD4pQpuclrsRRrqMHOR3OmEX2iWxnAYywLv8AfI5ryODTtT8JeJLyGOBv7NnkLJKfuKccc/pXs6AIqqoAVRgAdqSSNJEKSoroeqsMg1w0q3s7q10zlp1eS+mjPNLS5/tzQ9WtPL8y7AE0KDqxAxx7141c2d1aiSW6hlic5ADqRg19IweFrOy1oanpuYJTkNCP9WwPXA7GtfVNJsdVt2hv7aOZGGDuHP511UsbGi/dV0zeniY09EtGeI/CrUHu9Ln0iSaOHZIJllY8jHOMV0fxMuLD/hHnle3YXDrtSUc4APJ/GuV8S+B9a8J6rJe6HDJdWLHIMYyyj0YVzWraxqesRC0ktLgYPKiNq6nSVaoq1N6HR7NVJe0i9B3gjXz4e8R2d0+Wt5CEkI9DxmvonVEj1vRriCGVSzKGUj1HIr5dubC+hhImsLgREdWjOK6nwZdeLw8Z0uyubqJflUyZUAeme4+tPGYdVbVItJoeIo8/vpnXfEiT/QLaaeBY5oFAd+hJ5GP5V5Vr9zBdGM8K46Hua9c8Szpr9vHp2vyxaZqMZAuIS23zRkcox4Nbfg3wh4T0wvcW6RXU4O0y3DiTb7Dt+NY0q8aEPfWvl/mZ060aUfe3PA9Og1O6/wBH063ubhm6LGpIzXrPw3+FUkTx6l4oBEoIaO0B4X3b/CvYIEtYY91usKIe8YAH6VMZowpO9ePesa2YSmrQVvzMqmMlJWirDlUIoVRgDgCnVm2d+rM8ckqyOr4+UYx9a0c56V55xGXPLLKUildIQ528nlj6U6C3sYZZW8uMSR4V3cfiOTXmmoal4s0WJ/FPjOO2fSrCHcmm2EfmStKSAH3dutXbLxpc+JobaHUPDGpWWn3RVo5mz1zxu44FdX1edrrbrb+tSoXnsdnPf+HtK1jyp7iwttTuQDsZgskn0HU1qJdReYFEoYscjjoKw9Q8M6DqGtW+s32mxXOqWiDyJmUlowPSteFU8kyJEDJg9RWMuVpWvfrcXqOuILmW3lSC78p3+5IEB2fh3rGs5J7C8+xTXBvbgRgox+9uOevoO9Up38RX0saac0Gnwlz5jSKS5xz8q9OelaEdpqbXJlDQxXBQK0hXI/L+lVy8qs2i0rbnmPxDfxPd+K9L8PaVhoRta4bHyvnnn2rv7j7PoNlo+ni1dnlnEZePrkDlj6jNb+naYltKZ5X825YYaQjr/hVTVOL5LyZkFvbK2zHXce+a1lWU1GCWi/FlKV3boQT6ncvuljkCIrFQgXJJzjFVrG3N3q32a4WQSwgTsT2J6dO/tXAa3rd9q/jTSdN0XeuktcMl1tXDFwM5z6e4r2DTLNbKARgs7nlpG6k+5pVafsYpvdhJ8qKHiW+fStFupIRGfLiG1c8gZwT+ANVrnVdO8O+F/t11KkEAi81nY9eOvvVzxPZRX2nGKZ2jQsoJT7xGelfOH7UGu3FnJo+iI4a3t4zM0K55PRdx749KrCUFiJKn56+hC1ia2v8AifXPHVkmmeDopbSzMhaWcp8zH1LdAfavNbLw1r2heK4LnVYFltmb5iXJAcdM+5xX0R4NtbW08IaVJYwpEkttG52DgkqCfxzWX8Qoo5NFEm4CQSKPrXpUcUoSdKEbR28zoppSaR5F4n8MaXqE76xd3o0yNJR5kKoX3c9VPaucvdIi8U6zLJY3rCNTjDRnCqOhzXo1xpsusQrDHAbmNVw3BK9eKzTZzaeDCIlhTkEL8uf8a9GnUsrX1OpUE35EOjWmg3HhW68O31lPcup8+O6iYCWNhxuA78dq5ux8MX+qaolppdy8ejQR+bKS+HPrkevHSuhhdLK/ur83Yt8Qszg9OBwo9M9K4zSPFmoabeyatcxBoS+wQ4wrA9R+VaQjP3nD8e5Eoxi9dz0XwxqMcES3Wj6m1yIfka1fhoxnhvxxXqFv4nttStQlxBvQqBLHtztY+tfP+h6UbbWLvVdMkZdOuLZnQE8ruI+U/Q9K7HwrrVzb65LayzZtHjeMRgAncBwSfeuTE4dTvJboHrG8kdH42t/DuoT6bpWo2+o3lusjSQwwOxiV+hLDp0rW/sDw3b2ax2djp1pD1YBtpb0yc15rqPiye11eS3cKkcZCvkndnA+YU/xvptxq1hp17Z6oGV1O+2OQPY8VCoTtGLk0vUmyi7x3J/iHCmnXkFtp2k20tpcLl5ZJwiq/THPOak8M6Al34aF5qht41gnIVIJvMVcjjcR3rD1jW/sWg2dp4q0oa3pRO1mViksB6Kyv64454NdT4UuvC0XhB7Tw3Y38K3z7y9ywduODyPpW0ueFNJXvff8Ap/oTzyc9RfDOv+Gta1KfTXW7dLcb90iYjIBx3qTxj4d0rxDeWksdxLHpsafLbxgbSerEnvXA2dvf29xrGmxI4jZNySY4GDkc+4OK67QdI1ZvA2uO0XlOrR7Ys/MvByR7HjI9qU6fs3zxlb/g9R8zfxanoHhy6fTDF5UsUlvhVhIYYUDp9DR4o8R30cjT6dLp93OW+aGa42HA7DAxmvENA1O9WOeCJnVQPlLKcB/QH+laWoXY1PRLS7UFDEWSbY2MN2NZPBJTvLUb5XqdF4s1Dx1rkdtNol3YadEV2SW0dwryq2fvA4yRXVDW9DNkLXxVJG3mKI3nH7uQPgDIbt0PFeVWWr6hBYwX1icTA43Bc9Kz9d1qfXIftF/KZrGcf6tiP3bjrtP6/jVvCXtGySXbchxS2N3xLpOreBriO7t7ltd8JXrbcSONzA9jgn5gOhFSQNCnh/UjpF6bsxp9ptrSZMTKuOn+1j2rH8NNe6a6aNqwa48O6lxE4+YW8n8Mg/u+47itLQvBbah4gurC/mms5IY/Os7yBsYYnjae4I7Vq9E+d/PuvTv3sTFyibnwi8b3M+g3a6omQz7Y8HGD3GKu6pr1mL5mjuBaXynzI5CQCpHINLP4R1fQbLz7uFNYtYWLTjaEkC5+8QO+OcisufStHvLuI3UUf2WdfMSdhlkHpn2rntSlNzjs+x000nG61Z6Nb/GVF0YHULBvtRTAmhOY3PrjtWb4D8S3UJP2e5jVZZPNMbHAJJ5H61x728GkAJbW8NxaD/lmDlHX+hrQ8C+HptXDS2Er20sRLoSMquDnBrF0KEISaVky1Tpxi9Nz6RtJJJYVaaPy5O4zkfUGpjXmGi+O9Q0m7jsfF8KjzhmC6hHyv7Edq9Div459PS8gDNG67gDwa8WrRlTeu34HmVKcoPUnlnSFGaU7QoyfpUWm6hb6jB59o5ePOMmpiUkRW4PcGufv7Ge2ka80eb7PIBl4CP3cn0HY1EUnoQkmdL3zmk2JkkquT3xWdo2pHULcyNGI2Bwyg5we9aIIPI5HtSas7BsLsRl2lVI9CKcqhVwoAA7AU3PPFKWpCKOqaNpuqqBqNlBcgDA8xAcVhxeDrW1u3+zXEkNkwyIBzt+hPQe1dWDmqt8rSJiM/NggrnqKuM5LRMpSa0uchdeHNO+yta6K07XSHa0qXLYTnJ3jOCfbGa2H8OYt4hZ3csUiqRvf58/hUaaXe2jGDT1t4YJ/nkJGCrdzx1NdBbReRCse4tjuTVSnLuNvszl4dD1eK6mnW4tHDLgJsK5OMZyOlb+iWc9jpkMF1cNcTqCXlPck/wCRV8YoyKhyb3Jbuc1Z+K9Pvpvs+nxTThSVZtnyDHvXBw/F+Sfx3faFHp0awWxZfMYncdvWofhTrmq2cmp6Pq2iyJFYzMBehSBKpPcY9Mciuwh8GaFca3J4jtoAbqVcSbej4rtdOlQnKNRX00LaVzc1Gd4dFa4snVr/AMppIEcj94cbtuO9cr8NPiH/AMJNoktxqFk1nLE5jYkbVdx1Az3rzK9tfHOs/Gaz1PyLm10eznAjABCJFnHT1Peu68d/DS78WeILa+t/EE1np9uVkOnQoFQuOScjufUim8PTppQqSV2r37eWhDTXQ9P02aW5soZriA28rjJjJyV/Gp9qrIzE8njk1g2mrLYRm2vN6CMbY5JDwwHYmvNvF3xisNN1qawW1kneElHOcYPt61zU8PUqytBDcbbnpni3XLbRdIuJ5p0iKIXJJ+6vrXPW6T6hoUEktys1pKVkMiNnIPK49RWV4zsJPFfgq7gBMNxfWqxrv/hJ+YA/yrO0KO903w9pem3gRZ7ULFtjbKnA4NbQpJU7p+9c2hHsekw6dZWElmLWJFkd+owCeOTW4K878JWN7d+KVvrl5jb20LKu5vlLnjgfnXoMriONmIJwM4Fc1WLjK17mdRWdr3OQ+IOsT2a29lYMiXcx3Kz/AHVweprxq/8Ah/L4gvLnUPEmqSXOqOgliA2rGuD90r3Fdt8U71ZNRt5Y32CNDuO7HXtUJuoR4YNxbAfapEVAxOcc8/pXpYbmpU04aNnRGnaKMjwxqFxBqEeghUWNf9Uqy7159Pb27V1HiHQorttOW4uPMtWuAJki6/Ssi18H2b6TZyW/mJqbkus6EjyyO9anh7Wrban9uGFZLU7fMXjcw7kU6klfnpdN/wDM0d73ibjwPdWItdMtV02wikCNcKw3/KfT0NeV/Ei90tNU+zWU4lMYJd+vzVoeL/G8moyXNtprGCzaTLMD97AxXnV6q25e7ljYoPmIb+v+NdODw8ovnnp5f5m1GDjrIRJdOv7y60iWCU3QQSSSlvlKjk4H0/lUF5omma9bW4spRJbIxIdPlK+u4GmeGtc8Nal4k3XRmtWjRgkoPyumPunv9K9C8GfDdb3Q9WGm3GwXMe2KWQbQu7j+RruqVlR1k2tvQzdR3beqKUuhW2l6bbWlqm4XMIZWz/Bjr+PasfU7zTdL1GGV4t975YyqHA6Y3H3r2268JWtnpdkkQLLY2y26D12jr/OvB/Fnh6W41C4urbZEd+zy5DgMOxB7fSuXDV41pNNhz86M7W7nR9R1A3clpcvLtCu6SBVIHQnPftXTanqtla+HdKu47UxW+doOQXx35/DrXMLaWumQKZgLi5ZdxiL/ACgdP1rrNFuNG1fS0bUtNV4opvKFuX+XbgH5fzrpqWSTs2kZ7SJ4obHW9KnLYmWZAXt0TcXQHG7juO9S+GbWz8PF1VE+zPiKEZB8v5gxJ9O9WtJtbTTxdJosElujkFyj5ESgk7QzV0dj4e1DVrUy+RbxmQBU88bmZeuTgcfjXLOqoppv3WarlW5zUt28l0y2oi+xRyyHDLjCsf1708ajcQ2UttBMfs5yBz16jPvxWxaaCiXLwXKbJVOCp6H6eta1j4Z0WKbztYJSNslI16MR7j+VZSq01uU3BLU4y4TztJktIxB5YRWG1QDu3DFVdIg0+CJhJCpiExaSMr98npkema9hh8EeHdSto5oonCYIUh+RXnfi/wAKXnhm9+0Rq0+mFwfMHJX2alSxMKj5E7MUKkJuy3IH0Wyh3LtEdoYmyqjHznoPoDXMXfhO0PhvUY5Il2RgygISehxkfWvQbm6sLjSvOgcZG07c8+tctqsirbugfCsPmGcZ74P5itKVSe1wSvozP06zRrRbdJgkbxq0SP14GAf0xWz8N1dtd08XEu64jLxRxydANu5T+hFcfNZzOkbqJgiKAHIOAfaren3NygBWQrdwJ5lvIOCGU7gD+tb1INxavuayp+7Y9+uIipkkUNiVgHzxx7V4d8Q7AaV4pmtrXK2zJ9ojjHITdkED2zmvT9A8e2et2UUU8Mv9obdzw7Cc4HUH61RTwFc+KdWn1XV71IFfCJAi5ZEHQV5mHbw826uiOaj+6k3U0RwvhHwJqutaJLd2zmQqRsTIAOeoH4c1a8Jaxc+DfEb2urRyQW8p2ShlwAezHNe7+GdDtvD2lJY2e4oCWLN1JNUfG3hWy8Vaa0Fwqx3Kg+VOByp9D6j2pPHxqScai91h9bjKTjJe6eb/ABBla+Qx/u23ASQEDgY+6R7dq7v4YeIINc8NwoFEdxbKEliJz+NcSvgHxPZaOtpHPBdhSQEZgdq9tpPI+mcV0PgPwVe6BqtvdyShUMBE0YIOWI6cVFX2XsuXmWmxNT2fs+Xm9D0KUEwsq4HHGKwYLiV5fslw+LtQWAbgOM9R7j0roDnBx196p3dmJ0Vgf3yHcjHsa4ItLc407FewtWtBcSspDyNuYjpyOlOsJWjjkijG4DJUH+HPOKs27XPSdYz7qap6gjW5E8FlNcSM2CsUgUgeoyf0p3u9R3vuPEt9bwb2U3G0EkDAJqxbXkr24kmg8tjzt3cj61Qt9Wt4n2Xkzwsf4LldhX8ehHvWh5EE0IaBklXtltymhq26EH2lvL8xpoY4yD3yc/57VU0l3mlN7c7w7gJGMEfL9KkNhYXKfNDH1wQDypq20kdsigsxUDaABkmlp0EPjjzcvIWOegGeMVO7bRwpY+gqC0DAfvNwYknB7D0qSRQMsOG9akRUIuvmADYYk7s9Pb6VE1w1sdkkM7t13IMg1YS7MZK3CsT2KLkN/wDXqaKfzF3BJE9mABpjMbS55rpgwtHWANs3E4BX+9g1Zg0UWs7NZTvBG7bmRehP0rVkdYlGSq/U1TvdY06xtZLm7vYIbeMZZ3cACq5m9ENyZK8cu4hm3RBc89Sab5i2qAeWxLDPHrXF6T8W/COsay+mWd+7SKD+98siM49Grob/AFa0hjS6FzG8LcLzmqlSnB2mrCi+YZepaapK8TxJKpGGVxkc+led678G7C68Qx6na3e1Nyme3fnIHcGu8sPEGh3vmWtjqVq90AWKxsGYe9WbW4VbjaTuB4Y+3rWtKtUo/A7GiemhDNB5T7FVTbY3MrdSO2KzbywguZpHt8KsRABxwCK27+aKW5iELoT0ZT1wDUlt5G6WHK7mb5sDANQpNK5Sdh3hth9lIOMrkE/jVPxbPcR6XPJanMiZZFz947TgfnVy2txBcboGwjH5hnrXNeP9RGm6Lc3LY2Qnuc4B7kUU481RCUbyPnPxT4lk1C80+38QGezvnOZ2XBUHPcVWj1pfDstqLvVri4tXckr5Zwgz0rG+JOvfbvsF7ZxxJIzurMFGXAxjNeqeHrDR9c8KRXF7b2klsYQZnUgOjEdT6YNfTTcaNOPMtH0OmMrK1zr7L4j+HrvQR5V4YnUKdu0qx45wa8n1e+udV1O8ktlZIJGLgHjis64aygsbm50i5jkjtG2FuNhGehH51j6/4ldLu3n0tC+nSxBTySQ46/T6VOHwsabbh17msHGlruel+DYIoZY9P1dIxczEvBvYDBPHIrlNR0fxLa+PJf7STyxLK2G3boXhz27Yx2rkfDtjqOq3aTXjXGVbMdwrkOv09RX0P4E8BX2twQSeKLu4n06IB4oX+UyH1YjrU15LDNzk1r/WhnUk378tEZPw3+GGhTXM2syWapbg/JvYlMDknHpXsvhxo7mDdb26wWCHEY243Ad6p+JbAfYbDSNOK2tmX2MU4CqO361t+VFpmmRQo2yKFRz6gdTXhYivKvrJ77ehzznzLTqUpLqFrq6jm4VQGO48c8Yrifih4aUWTXlpCDH8qMqrkgkcEetbFtKLjUpchS9zGcRlsYGc1saNe/2tYz6dqcPlXKExMCeHA6MP0pQbotTXTcE3DVHzrqfgPWr0LcxtbW0KgbnknVFYY+9zWb4tN34W0jTUtEtLhZVYpPEwlib+8cjq2a9k8deBZbzQp7a4torq2b721nDcdCMdK8ebw5b+H9Fk0+0iudzSeYyXL5G7oNo7V7VDEe2s2726W/W5prN3jsdp8PorzUdM0WXVIEWK+mG/K457kD3xivYopdztGvyEkgAduteB23iG4spbNLYszWpUhN2VDj09u1ezaV4l0q9gbZdJbySLzbH78b9x/n1rgxkJ35raCnrYz/GUAjsWuUAE0Lcn+8OmKp6F4ksliFvqiKIzwCRxmm+J9SN/ZywWS/uCMtIeC5HGOemK43TbaW5vY7by3diC2GHQA9adOmpU7TNqcbxtI9TsHurfUXGjEvb7d2yc8SD/AGT6j1q/L4k0y4L2GrW81u7Lh45oyUx9RXn2oz6toMMEmmXDqcj5CMgexB7V6Z4c1W08Q6THP+5eXaFmj4JRu4I7Vy1qfKlN6rutzCpDl944+5+HGiX0v2jStUe3ifnYjBh/OtG2+GWgpsaf7RcSLyWZ8bjXQXnh60nfdGWhPX5OP1psen6nZKTaX6zoOkVwnH4MORUvFVGrKf8AXqJ15taSLMmh6a9k1r9jhWEjA2qAR7g+teA+N9GPhnxC8UYJgb5kJHUEf/Xr3yx1mCaVra7xaXyffgkYZPup6MPcVm+K9AsPE0kFvckgxqW81Bnjjj0qsLiJUZ+/sx0KzhL39jyX4OQS3HjKGdIyY4om3tjgDBA/pXr19MkGptHal/NyMKqnG4jOM9OnapdC8O22iWv2ewldE/iICgt9TirGsarYaJaRy6lOqR7sKzckmliK/t6t4LyCtV9rO8UWob1CmLj9zKByjcH6j1FPmu7aGSJJZ40eXhFZgC30rl9U1rQtatAVuN0iAtE44IOK4iWeRrxSPKuGBXDsdxAyOmazhQ5t9CFRb30PZqjMuF5Rgc4xUUF5HJFC0hEckg4RiM5qzwR61z7GNrbkBkkfcIk2lTjLjg1QN3N55hudqsg58vJVj256irN/aTXBRra7kt2HDYGQw9Pb61PbW8dumI0UE/eI6sfeqVkGxIgAQbaibcZiHBxnIK9vrUGpx3piUae6q5dd249Fzzj8KVbSfzmZ7ouhXG3bjH4ilYC0QCNjrvVuu4ZFVG0u0ZiREEPX5Pl/lTINPnhQqL2ZwTyXYkj6GrsIcR4kOWHf1p7bMNjOXQrVA+xpkZ2yWVzmp003awYTyFgMAljmrZ3KxZSSCMbewpFlZATImAOcg5o5mwuyGQXcfKoJMf3Tj9KrW+o+Z5kd7C9syN8vmn749RWnb3EcwJQnPcEYqSWKOVCkqK6nswyKXqFyh54t3yyM+9gB5Yzj60ssl0zkxIqp2z1NSMjW3FugKAYCnoKqXGrfZ5Sk0W1uo75HrQhnzDffGnWtV163htRFIJZhGqbfkXJxxnrUHxD8QanFYrbFobwy3ptJYtuFDAA9PfP6VLrOm6Ta6AmpRW8QvtPKnzF4+YngDFV5Y/tGo3VzdQl83SXacfKWK8j+dfVwo0k1KnGyRs4SvyoyovGerQ6Wh05yiyTG3gCqowQBk9OgrPufGWt3MmoWtxdyTLaIWf5cGRsgce3NdDoXhu21TXLGz03eq23mOME7Vyc7ifXNdT4n8AS6Jp1/qFpcWuoXUkQleF49jHaM5Ug4I9qtzw9OSi0rsrla3Z5JpF1qFjD/AGhpEQttVZ9qxJnfsbvjvXfad8RtR0CBbLWriSTWmAkD+b8ka/3XA71xWjTS6mNS8RWaM2oghfs/X5uOV9vapBbaNFaXOqa7HIbuf5HiR8srH27VrVowqP31f8/+GJUeqPV7P4ox3YmnS4g8xV3Nt7H3rf0n4mWtzZyTQyKVU4lZgRg4r56T+yoNC1KbR0urgkpG6XOBgEk5G3nsKm0O51ZFtIIrXyLGcHzhsIVge5PXiuaeXUmtNDRPmdrH1Ho3jq1urUfZnRgh6gkke/NZHjXU4tW0u5gYj5RkjqHBrzdZbbTIoxp96ILaMDz5ZujE9l9T7VNFdm/szNp1wlxDuKOSGBBx7iuOOEjCXPE2jTgnbqcLLfWV1JLZXsENtbp8sTKOATxknse+a53RBdeHtYkAngliAYSxF8hlxngdyR0rtdV0WG1uTPebUtUXckSAszNnuK5z+ztOTUhc6tNPL537wfu8Z+v/ANavZTjJWWxNWN/kQaVNbwadqF3okc1ss3yPDcOGQ8dB69e9XvBOianqQSK1s3jilO1guWD+4Hb0r1LwX8KrfxLp63ouomsi+4AKVHvmva/BGhWOjxeVZQRiJPuSgDJFedicyp0rqGrM1KNNJp7HP/Db4Y2nh+0SS/TzbphuIY5257fhXpEMK2tqsSH5UGBmo9Q1G2061lub2VILaMZaR2AH0rgbf4jWeoaVe6rtNtZQTG2gMhAM0nfHrxXgydXEtzepzyk5u7NvUbgXuoXFqu0xJCHA7lgc1T8QtdPahvN82S5ysUatwqjnNYugQT6x4gg1qRmitiCwXOC5+6Fx/npXQ6jbS3OtwwwMEW1jCuDgA7u36VbioNLsaRVjB0yCOa/uZpI5Y5LQCRm35DsegA7VZ1TRpNRvtOmtZDHFEzTDBKuG4zz071bu30/w5Y6lrGsymK3VvNct0AHb35q5pGqW3iLwrb6pocw8m5LNCzD7wzyP0puo/ijtt5DlJN2L7WuowyRPBqiuDx5Mqgq3HTP9aw/Eejx+JNLvI/7PgN9EjFELYYSAcKD6GuM0fT9YuPiV/asdzK9gkXkyQrkKjDgk9hzXd2d5Jb3EV2QGeZwkwX5gcHGRjr2onB0mmmm7X/4AkmjwXSbO+lS5e98K6taXVvJtkLISqsO+e4965KO7199YaQm6hfzTuPRcf0FfYrXlre3ElqXJwCrITgMK40fC3wxBr02o21pK14fnaKS5cQtnP8PSu2nmMLt1I2/H8wU9PePGbrxn/ZlvHBh7tzjKhsbR9a6n4dXU+qX8+rOJlEyJGqseg9Mj6dazvil8PtWl8RBvDfhWKa1MayPIt6Iwh7oVJ6e9ctey+Lvh94oj1CGyaawuIQhtQSY9uMfLjuPWulKFanala781/mae1vflR9BX+k/aLN/tDFFjzkLyW715qby80XWLiexuHhukfDbeknPAI+lSan49jutOhuS89la7Q8izMPNc46DHbNLoes6fr2oWL2yF4mQ72dArMynnr7/zrlpU5wi+daF05W3O7tPG+oRaX9p1TSnCKMvLEeAO2RWTqfxSuJ4mGj6dj0klOf0rpNYktY7K8icqYGiOdvAA29DXlq6VPZadE7hY45Iw+1vvfN04rGjTozvJxCnGnLVoyb3X9Wub0y3Fw0ku4NhuQO4+le7+A9aGueG7e5KhJVPlyL/tDvXz/dWj21yA7b5AuHGfuHoBXoPwz8TWujGfTrvcIpH3I/oe+a6MZRU6XuLY2xFNSh7q1R7BnNeF/GnUWu/EKWYkzFbIFCg8bu5/Wuu8ZfESG0hEOhus0pzvkx936f4143eyz3Fy91cMXkky3JzmscvwslL2ktDPCUXCXPIzft89oWQuylehqaPXbiGZJVlPmDBBzUs2mALdPckSEIkg5wFyM8/SsuOJUCsV3SvyB2Ar2VGMj0b3Ohj8RarqBKvcyKi8hg3OfavbPhT4l/tjQ7ezmLyXdrFtkk7EA4GfevFvC/hPVdduESygdIc5aQjCj8a998N6Ta+D/DrLcTKEjG+WQ9B9PWvKzD2SjyLc4cY4cvKtzpgeDTZZUiiaSRgqKMk+1eL638WrptZjGjRIunRMA/mLlpfX6Vc+JGvzzeH9LRLpf9OXzD5RwNp/ziuFYOpeKlpc5FhZ3XNpc9BuvElm6JFpk9vc38pxFAZACfUn2rZt1kSP984aQ8tjoD6D2r5Cvp30u+O0yR3EeGVlJ3c9K9F8Naj8QbaxW5t7pZI3+YQXWHP056fSuirl/LFOMl8zapg0knGX3nvtFeI6H8Y762vza+J7CMRg7WlgBVkPupr2eyu4L60hurSRZYJVDo69CDXFWw9Sj8aOWpRnS+JE9O2hhyB+VNpQTWJkII0H3VCn1Xiq0Ud7FKWknSWIZ+Xbg47VcNOXpQBALiN0XcQpJxhu5omtLedg8qBmxjOTS3Vsk8RXaN3VTjoajVWAxIzBhxwaBnyjrN3b6jo7QH5JjtJx0LA9DVl9XitraGGzLCaNxM0svQ4AA4rr/hV4f0u6kebWIvPIA8qPGefWun+JfhzSh4RnLQRxyRBpEdVwx5zivp54qlGqqNmenKcYzt1OK8EaxZ6dqUdyy+XJMrJLtHBHXOPrmuw8Y67Z3GlTixlinlkgKIOmwnrXlWi+GvEV6v2rR7ZpIEAYS5AP4VZjt3Eey/jubbUB8spmjJBbPBB9MZ4pVcPTlU51LVf1qKcYuV0yp4m+GV8mhWt7YXsMM6ATvFCD8mRnn1rzfVoJLG6M8kMVxbOFaaV5DtZ+/HUfSvcNY8YtZ+G7uwhsEa62BBMr4Vtw64PIPtXj2dJ023u/t8czyXuSltMpCq47k9vrXZhalWUW6nyMZLdsTQdanF6kGnWdkbCRgrAIQye+6pRHYQ+IFebUNS8xnIMckfyfTOelU9M1a30yNyukLDGTlnimLZ9ODVe0trrUbwvp9xPdoW+dHG1lHv8A41023ewlrZLc6PRtHttRtLrSde1FrfEnnWzq25s9MbT1GOa9A0W2isdLg0zR4pZ0Q7vNZMeYe7GuYvdBs7e4tr4TATxxgRJndl+nX1r2LwD4SuLdLe71OWXM3zRxsf4ccZFebi60VHmvp28y/dpybPK/Efh3xdrHiSOx0S0mWAkFZiPkGRzlvavU1+E9jdwaRaaxKGkhhImeMYEhz0r0y1s1TCQkJ/ujpV+CIL5iS5Ydcn0ryK2Y1JJKGluxhUqNnnfxH0i88P8Aw1msvBkTReSMuqHLGP8AiI96yf2drrV7vS7z+0BIbGLCRM4+83fFeoXvlooaMBlYEEZzmsq4j8m1azR3tI0TfMLZQFjB7DvnFYrEc1F0mtW736mVrnnHxz0jV/Gdzpuk2AMOlxuXmlJwp7ZPr3wK5b4zeBtTm0/wvpGhKiaNpyhp3LAFZGIAcjqTjP51Y8f+NtY/4TLQdB8O288ME1wPMLKS0mGAwT2GMmvXPE1lD5+nTpOds93GlwM5VwgPb2wa641J4dU00ratL9WP3W+UdJBHoWnaHiCWY2u0PsGWwRgnH41kNCNcbVHmleNJ3Z43U9EU4BH5ZrR8Xy3v9lrPbxuLi5bYig42KeAPqawY7f7DYpYQTEiIN5sjH3yVXPbtXLBe7zdTWCKPj3QZtb+HX/COWlzNLLdMGSRyCwVTn8uK1/C2gf8ACL/DzT9H3TXBs4fNfyhhmYnOAO2Sa0LWGSa7hNtAGtogsRZjhlLc8eo6V5X4/wDiJq1t8U7Dw94cDNDBMqllG5p5D1P0AyPzramqlb91H/ETOydzt7/V7iXwn4jhLNZX62+ETd8yBuAxPXP1rhf2dxrVnDqGj61IZI45UmtvMbfgnKvg+h4NexW3huxF7cxyxCSG7QvdGQ5MrNxj6CvPfAHiTT5viTrPh7R9Bawh02N0ed5SzysjAAsD09qcJKVKpGEb7P0BuF79T0nW7IWR+3Ru0e0AO2cj0/D61PBepd2kc6LLIQmSUIDZz0/Src2p28VsXu2UR/dbPp7isNUtrBJHs51+zFflUHp1IFcS95We4JX3Nm1eC9Vb+G3jW+MflhpB8wHXBNcj8QdBuvFOjRpp968F9bT482CJWUN3DKeo6dOaqSahc6zZSW8KzQIH+cBsFsdAD1FafhSae3naVZA9jcHkkbQHA5Iz2461rGEqT51uiuRrU8M1Hwtq9v5tr4g8PmaSEki8sZjsnySeVPKn2rH8Ma34m0zxDE1loRS2QNb/AGZ0IUAnk789c85r6gl1Czu7WdoyjTDPztHyB/h9a8l8WaP4wbxFc3Ph2Swk0qQKRFersKcc4YDBzXo0cX7W8KkUvVuwJ6dTnNb8aTzQzho4riV5MBR8scWPx+b+VZieLJNQWCC9n3XW0s0iD5Bj7o/AVseJ/h/ImkRTfuogrb5TCOVyP/Qc1wmpaBNpyRra7DbP/rJmfkk+w7V2UYUZL3DZRkveR2mhi1urNPLmNzPcuQ208E5yWJ/pVlrYmSVQCEiIDHuO1ZPhj7JpenhPNijdPuTSttHviuisdato9JeaxlW9Ms215EXmRgBhRnkAdambabtqbKqVWgAsS6RnEjcOw5A7UzVLy3stPlSJENw6bFJ/h/zz+lP8XancaLoC3OpRrErcRQgYZ29cVytszXcMLXrL5m4GZEPzKDzj8qqlDnXM9jSE1KVjUs2luLAIkbXF3dPsjU5Ix0Jx3P16V2OnfDq8W2EtzdxLergm3eMgf7oaqvhi9sW8SW0pjMNkse1FAzt7frXr90VtJCXO5ZYN0M0hyMjtnsa5MXiZ02ox0uRXrSg0oi+C77TX0uO3tVS3uIgVlgbhww6k+oryj4qeKZtX1lrKxnb+z4RtIBxuPeu+8MeGEu9OutUmDQahqDF0kBOY4jwFx7gc/WvKvGmjnTtavbeAhhF0YHOMYyf1rDCQpuu3e7M8OoOq3uzmdNtnYyBedvA56k12ni7ykutH0+FwfstqkZP+0Tk/zrkrCTy7p3JAji53e9PsmvNQ1iJolLuzbyxPGO30r1KlNylzPZHdKN9WavhPT01r4j2CXABSNeQedxQEivTBcXFzqj72dts2wKQRkdMkEdOK850W3fSxa6zGwW7hmkIXOdxHAGPpmu+k+IjPaW72+lMl265bzmwie/TJFefioynJciukrHFXTbVjiPi/aW8HiqJYkCNNAryKPXJH9Km8GfE658L6TFpz2CXltGxO7zCrBSeg7VieKVvdVvp7+5WSaZxgPjCk+3tXIFZFYg/KORtPtXRChGdJQqa2N4U1OCjPU+u/DXiHTfElhFd6dNuyAxjbh0PoRWyK+VPAXiafw/cvJDIB6A/yr0XTfjC4vkXUII2t2OGMYww968utgJxk/Z6o4quDkn7mqPah0oBxVXSr631Kwhu7N98EoyrVaPSuBq2jOJq2jHqc1mamzLcDDY+X1rQXqPSobqwguZd8ybmxj8KAPm34e+LY9C1NzeKvkn+M8gevFbnxI8aWviHSoNL0Ft/myDzpQMAZPSvO7GDZdtb3TBYySdx6qwrTW0gijnurKQusBGyXZyxOOw9DnnvX1VTD0va+16/gerUgnLmPffDOmfYNHMabDGsQjKDgcdvrzXCfG7w9JcfD68uLMyJfRYljeNiGbByUxVfwz8UdNsdPOl67dRxXLDcs8+VQ/p1rkPiT8R11PSv7O0DVYJWeQNw2OnTmvNw9CusQnbqcTWrTZ5bqOrpcWVsbpX+1mMffX7rgYyRWZJqN7eqqX8SXcacgAcgexFbup67qurm1sdd0+zu5gfLjuI1Cyn6lev413/hb4L3lw8d5CZYd/WOQdBXvyrQoxTqaGiblueYWNk00n2awcoJf+WEwP6GvZ/hd8NLiQmW4ieKOdVEnzY9+Pauo8NfD7UbfxJAjafAmn277pJ5xkyH/AGR6V7bHGka4VQOMcCvIx2Z6clLqTKtGPwnHXPw/0B0he7t8pAucbsD3rlPBPidvFPjbV47DcujWMSQW6dsg9fxr1a5ZyB5e0j+IHuKzNG0TTtFjlextYrczOZJNigbmNeTGv7kvaavp5dzDmb1ZfskAI5+ZR8wz0+tUdav7dN0c85hhTHmMPftmobvUo9JnZG/e3V1JkL0AGOMn8K8L8bazrWu+PbddLufJ0m2c+fFG+BK+RncPyFGHw7rS3styoxcnc7qfx5YD4h2/hS2aWNo4/OaUgYI27to/Cszw94o1fxB4j1bS0uU+zTQGSFVUEphgeT7rkfjWF4VtvCWq/Eqeeae6k8VW9rIzRr/qBGF28n+8FPSut8J+FYPBcWo6neSp50sJRGD5Pl56+3YV2SjSppq2tlv37jT6CXOh6jd+Ln1K3eJYbqQbJEfPlqoA6ep6V1viS1Mmt+HbKHiOEySv6AbcZP5msb4carLqes3EO1fscMYMaf3OeD9TXTteRmW61WX5bSFH3OwxiNMk9fU5/KuarKSkk+iCe9uxmNd/2x4lj023bNvZkTzN6t/CPwFU7rRh4n1zUS88kFnZoIY/KwNzkZJJ744/Ouf+EmpS6x4b17xRe/unvbpvL2jpGDgAV1WjXp/4R64W2VTd3dzIidsAnAJ+ij9KdSMqUnFbrT59RxbtdDvCEENz4altrZ5FnEZiknweXPceuOK4u+8MaF8PLxdd1bU1aV3VYRIMMCWG4r+FesaTCIbWONcBI1EaqB2HHNfP3xt0zUPGfxk0bwzA7pZrboXcDIjDElmP4AVeFcqlSUea0dW/REym7ux7A09zqE149nI6RNtNqRjB28nH1/lVfQprAXWotJBHHqiMFuCIsOzEZG49x6Vw2vfGHwz4T1qHw5DDqF3PpoFsXijDgEAAgc8niu+8L+IdN1uBZ4FaC+ukDnzotkhx0yD6VnKnOEOZxaT2Y4yT0RJq1zZW/hxE1SVYGlYQ7mBI3Z4xVbTbVrfT/LvoWGXOZMYyOxNa+uaP/a0EEE8UMqROJAZSfvDocCp3sbuWEpc3SOCcbVTaMenesVUio7jUrKxz0mnLDGQXYMW8xnQZOOwpkN5ZyN/Z0cxlkKkqm3AXr0HatebTmurKVAzC4jDIvOATjANcno/h3VrfUzdTSx4hm+eMr8zIRyQf6VrBxkndmkbNO7Ne3t5UAe/SOG2iHEMfQ+pJ7/SobXxL4UuJ1troxo4PlJ54yD6YPatzxCX+xFbdMOeemRn3rw/xz4m8NeHtXjgvdJikvGxKzxAqq8/3c4NXh6ft3bW/kS9Vd6HsN/4Yd7lvsxWS0deEfkp7Z7iuZ1zwza3QihgtVjlXJZWGAB6U2/1XT410mS6vb1xdhHtvs2REu7BA2g9frmu0vN9tFIbl1lRIzIGK4dDjmlzVKVnf9Coza6ngGteAI/t0k9xqU6xjc4iZBn6KehrDtJxFax2mkkxQqzAlDhge+T1z9K7XW/i14Yj1I6fcwyHDlJZdmdh7Ve1PRbO7k8mGWNluoRKqx4WQoe47kV68K80kqya7FR5Z7M8l1O+hOo2kMssuprYrnaZCUjduSSx+8Qeg9q6Lwfos4sHvL0EzXTmTkc47fpWj4i8NaN4RsraW4UjjesedwcnpnHU1z0/ia7snVbVP9MmdZERhuAGPSutS9pD90VTahI7CaGL7TNLblsrHhFAwc98VtW/iS6l0A2wlc2SsBIZRyVUjcAfUg1zF/qEUmNrLtbHyo2fm78jtmuZ1mS7gtwtuHuHYkKg+6nufWslQ9rbmOtpTjd6nvl/8UNJi09E0iGWe5ACJGF+VTjA+teO+NNfWxuB/aB3394wkkVHBwvYH3z2puiaNqdho5uNQvA0o/fBS3CjHr247VlR+DApOsXt39reVy0UKneVPUZx6VGHw1ChJtP8A4JjGm4fBuyWW2ubtFSCMiNl3s2eAPetrU9Wbw7pKTG2yBbgRoThpGOBx6cVBcaxHpehxyTwt5cDfMpYEysein8easC5g8Raf/bWsBIvJQSJE/ChR3x+Va1HzW5lodFSd/dJ4Ndt38Rm2tFYT29sk4iYZUMQAR7kFq6zwVCur3EsuoyFQgGA4+RznHX0HHFeMQaq9t9v1rTx5mo3cwgj3j5QM54/SvRrHV/sVrcW0s8lvbSOsg43CM4yQw9M5PFYV6DUfd/ruc6u4tHrWvaRY2mj3d5eXEPkxJuXaAAHx0H19K8o0/wCH1zq9u1/fTNarL80UaryAe7emfStqDVDr+saZaXM5nsJDlYjhPMYDP64GK723ljWa4tCrqYTghjzxz16V5qnUw0bX1f5GSlOkrdT5z8VaI/hq5Eck4njl+7IowPpWXZyZuFQ8k8jNeifF27s757WzgiC3Aff5YOSB71zGneGZppIXuHW33MF3ScAZ6V6dKpekpz3O+E701KR9MfDWBoPBunKzBsoW49zXUqK88+GOqSWdkND1fbDdQDdCSeJEz6+vtXoamvna6aqO54tb42KoGadSDrS1kZnxd4k1pF1K3szAgh8g7JlBDPu5yfzrJk1BrnwpcWWjXEi34kBaMnDlO4FdFofgrVfFlnBJpNhfQWsZKQvcqckeo9q9R0D4E2wubW91i4DTKuXVBglh344r6ypi6FBJSeqOt1LrV6HzhZaXr+u6nETbTtMihXVx8rY9j616f4B+Cmo6lPLPqVmlpCuSgJPzH057V9I6N4Q0nSpC8NpGW/hLLnFdCqhRhQAPavNr5xJq1JWMnOMfhPJvhp8HbDw1qL6pqnlXV8f9XGBlIvfnvXrKKqKFVQAOwFZGs+ItP0pG8+dDKOPLU5Yn09q5+1OreJ7kXEt3caXpfPkpA22SXHfPpXnVJVMQ/aVX/XkTyt6vY7kkYqjdXa+YkSbW3nbweaqW1pNbgLd30sttGvLTEZf3Y8cVn+HryPV7q51pQVsI829pkY3AH5n/ABPA+lY8m76Im1jT1S/tNIie91K6jtrOGMs5cgAe9YXh3xba+JBJf2LB7GPIiZTnzG7cVm/EnRtO8SeHdUh1S4CcIiokwVoznIz7knvXEfAvT7rTLe9jv7f7NY2TySKGPz8Lgk+tdNOjB0XO/vIdjrfHM1v4dsrzWL5zI1ram5lG7lpDwoA7Dk14H8NPEOp6zBr93eW8C27IxSQJhiSfug9+1ei+AtStvjFpvim11C0ks5XAgE3nMyugOf8AgJAxkD1rz+z1SC28cQ+F9Bnmh8PaKWaQp1vJum5vUZIAFejh6fIpU5L3lv5IanqmemfBrwBFpkmseK9RkM0t7GYI4wD8itgN9T2rqvijot/rej3ljpCM1wVjUhGwSo7f1rqbI2+h+H7KylMa+SitKznCoepJP1rnz4ght5J5/M8+e7m2QpEclh6Yrh9tUqVvarW2xa3bRa8DeHP+EM8Ira+YJdUmG6eQtnafTPoopfiXpmoap4FuNJ0IrHPfBbbfIcBUJG5vyzTrzUp21zTdJ+yBrqSL7ROrHIX0BIroHtbu6lEd4EERODtPbHSsnOaqKrLe9yWurMDw/pVloHg+z0mxQNBbR+XvP8ZHVvfJ5qro9wkGqrbaXa3N9KhPmTEbYo89cHua7l7eOGEeTCmUGEHTFV9Os5bXYodBbqp+QDncTnrUe2vdy1uNTSQ3TndIJDckCQMSVHYViQqIJLi/GlyfbLgczOo8xsn5V+g/Cr3iLxFpuiGP7XOiO7YwDyPrXm/jT4i6idPuZNBuYIY4QXeSWLLMvonb8TTo0p1H7q3FFSeqR22l+GPDnh2SXUJLOxi1G5cyzXboN7O3JwTyPwp+qeJNB00faJb6zY9juBYf1r5d1PxhrWv2txdNdTK4XG3dnA9R+Fc7dSSajoiXgZ2ltJgJ9oPPGVfA+nP0r0lls5vmqz1NfZ2V77n1DdfFfR03SWz+fEp2M6kYBrm7z4tGXz5bViIVbGR/DXhtrZPp+mG6U+Yl9J57DHAGP/r1d8OSm416906blLhWVR6ccH8M5rZZfRgm9zWNOKV2j0/RvHWtandTz2tyJAknC7hgitqT4qnStYj0/WQEmdRudcFF+teQeGo9V8OwaqZbNxOGVBG4zyTjj1ySMV2rfCXUddDX13fww6kq5EDKXUv6Ejp1oqYfDxf7yyiKSjy3ser2/jvSb5fLdigcfeHI/SsjUPD/AIN8VYW9t90wPyy4weO2fevJPEWieIfBOkfb7xIWi8wJOYQTsTpn2NRr4qvLO5uUxzGgaI7vvL1yfzqIYK3vUJfNMFGP2WfRmkaTpun2z+SBLENu2KQAhNowCPSuU8WzSy+L7K7hd0gW3eF0OcbuoP8AKuK0TxxLdWVtPcq4WQ5PzdMV6ZoWs6drtpHCrqrsMAE/MDXJKjUoS556i5HH3mcBrngbQJlm16W0i3RfPKqqOO+QfzqC71zRtctbHUbaQpCp+zwNjBjK+rDpXdXulFdRe1kkiWOeExNayHAk/wB2vH/GtjpvhCfTU06aOC2lZvtFkVIGMjLH0P8A9auuhL21ouTv0/U0pSipKU9jvNTsFSwa5u5FBhbDm5VWI9Me/p65ryTxXpt1LdJNDKbWGXJkkZMmQeox29q9R8V6RZeONJgEF1OsDKmwwPvHAwMjv9ara3osCafb20wdltyArn+JQOp/GtsLWVPd69rbDT5rxsePG5trCSGy0hJLu8kx87nCg9zgdau3viub7fbWiQRyiIiOabG0sR2UCtvX/C15BepqQubLS9K+XbLM/l7z3UDqxqX4ZWtp4g+LEMK2yx2tqjzSBhnzWTgYHYEnNeg6tNxdR62Vyefldrk2p+BvF/ie3g+yWj/YHG4LcT+Tu/PJx9BWfL8P/FFlbpDf2P2KxUMI/sNx8rt/dY9RnFfTsOy4mlZiySBTjBxj6UgiW9hCTKskEi4YEZDfXPevIWbVFpyq39eZn7S8+Znypp2i6611Fa6ppcQ0uA7jbuc4wOx6k57morO61KUaouqxCWxWMqsUTDbnpgEelegeKEmtNV1ax+0vcW6s0SAn5wpGMbvb+lcZpegXPhzQLy8LiS3voXVUYYYr0zj+tepGpzx5nbW1vzOnkas0ZsulWuoR28ukMxt9NbMsAPzF87uCeDnGM+1X7bUrqOK7vvEkYhtXlCxQEjd+Y9qyNDK3GlXdnBZXEjTOFjFrkvMw7fSuyXwB4j1nQVt9T0S4hhix5UaSBpAB3PPXmrqcsNJuy89/zJWmt7Mgu9UtLcW02n3AWVtssBZsZPotPvvilfxQiKe4kjeZjC++Mb1OfXrWZq+hx/YF0+KLyZrX5I1mjKkEc9+a5HTNOvtR1aGfVGUyQyYUykBWNZqjTmryV7Gsot20udraotvqBu7ucS3LfdJ5H612qeJNOaJUKeY5T+6MIfxryzWbkyXEjZ3uDgKBgflVnTmaSPbPIVduyjr+NRWw6qJOR0Soqe50Gs+JJSyx20827JAJbJxXqHw1+Ijj7BpGtSpknYk8hOcdgT65rzvwz4Og1FXvLh5lgjbazKM7fT+dY+pKbHWJ7cE4hYhSeDXHUpUqqdLqjKdOlUTpn2IuCM0tc58P9RGp+E9OnDlmEQRs8nI45ro68CUeWTi+h40o8raGxxpGgWNQqjoFGAKdRTJZEijZ5GCIoyWY4ApElTXL9dL0m7vmTeIIy+3OM+1c0lt4l1qNXuLqLT7WQBxHEMuAe2as+LGbXNC+yaZhvtUgUStkKApBJ+nFXdNvSths+0QztaqVkMbBixA6cVtH3Y3W5ovdV1uZNt4L0+2lWe9la5KnP704yev41u6VbSpEZZWIDH91Fgfuk/u8dfrXj2i3V/8AEHxxrFlqNjdLa2EzItw2UjiweFXH3jXrVnHcwXVtayTNMqD5mx1wOPxrWvCUPdm9SpO63PKfi8fHeueO9N8PaCklr4cl8v7RdKoAck/MCT6AdK7rx9rMHg7wrbxWcAYrtigjHqOmf51Le/Z7bxfda9qN6sOnWFuIArnCiQ8kj1ODiuI13VLL4kSKNLdGS2k4O/tzycdPpWsLVORNWit/XzJhFcx5BfWWoa54yl1SK8aVLvhbfLfeIwQ3bGcmvo7w1p8sPgpfOjie6u4vKJfjchGBn19arWeiWkWkW7wKiSpb52Iu3czAjLHv1710dvr+jNcQ6RBewyXcYVDGh3Fce9XisS6qUYLRfoVOy2Oe0vR9H8GaFZaVDJbabdXBlkKrj96dvzk/hivN/DHh22l8YRmNESKS4WU7FBZokO75iOvIArK0/QvFOofHLVbnxN9qXRtOM0kLyA7DFn5NnrnIr2rw9o9vZXAeBwk9xGTuA+6mckDPTqKuU3QTvK7krsUJXTZw/wAXdC8VeKrnRtK0OIJpl1OTqE28AqAQcEen074Fdpp2kW+nanDfXoTy0ZLa0YgEj5cbj6HIqz9rns9H1a9QMsrSGK039NpwqkD6kmuC8Vte6v8AFvwx4Qgnc6fZWrXd96nIwMn69PrWMHKpFU1pFX/zf6IUny/M9W0y2hm1G41KNBhwIkYjG4Dq34n+Vac7BIWY8ADNPRRGiqowqjAHpXlfxf8AHUOk2L2FrIgmlyrOG5T3rkpwlWmoxFGLm7I2vFHjiyiEVjp1wj3kz7TgjCAdQffivI9Y+KurW2qT2l3LcwzR5QeWBgcdSK8v0yDVZ/EsEpciOR9zTucow6813Ou6Za63fxTqNl0E2uQcgEevrXt08FSo6S1OuFLTRGRrk0/iSBmS4muZt24b25Ygcim+ELSS/kvNDlaRoJYGkGWxsYAZA9v61r6Vb2mlFra3VbqUESLcD5dr55+o7VqRMvmmXai3DcHYnzN+VdEpWXKtuhtKnfU53w/okGj2l5E07z3HRdyD8v1rR09FtIJDpdlb2qlf3pC/f4xzn61px6HdykXU1pJFCc4BBBNRSolsxQkl+m3rg1LnzGkYK1jL+yK1kls0UbDePu8AAdAPanaXZ20GqLfbVSQHyy4HzFecgfhxW3Lp876bHcxwEq7FTgYAwK5u4RRIdzE4PAzxn2pxfNdJlcqsdlosVvf6k1vLEu83MWE+8AqkbeO5yTXrZSW1gCwIvnKfmOMZ55/GvELO4ghaO/slZZbVTIFV/mYqAfm+pNejXXxJ0uLw+uoXFje/aDtHkLHyZGHC56c15+KpTk1yq5yVk7l34lwwT+Db6yuZUX7eohXzOcE9wO+MV4NfTaTo+p2WlXIna4a1jgFxPFtEjAYI9s9q920jTLi/iTW/Fag3ki7oLIcx2yemO7epq94x8K6X4q8P3Fnd28fmbCYpgoDxOBwwPUcgUsPiI4d8ktV1t/Wpkpcu25866xHLBd2cNnHKLEY4xkZHJ3VY8O+I1e8fYgtrmEktEDwR7Zrb+DXh+51G61qC/nl2rcZLdmAAz+Ga67xb8LrBbwarp52NjBQHBJ9/UV6c69KE/Y1N+5uqn/DFnR/FsXiCVLW6BWdAjxT45FWfGvhnR/EkKw6rKBexg7biEgH8R3rxjw5qV/Y6jf2FyETUIJCEYjAZe364rrPCPiyLWLaVdSimivIpykiIfvevPasamElSlz0nZIbUW1Y6vwj4e/4R+3it7G7MsAzgt1znPSrfiG4QAq0O1gAR6NXH2PiAm6kbTpxJaFvkJOTtB71fGtvqFlewzQhrq0je5jCn5pQB0Ws5Uqjnzz1L5OVc3Q5/xtZ2PiDxLY3PiFNybVRITKdu3vtXIwTWN4e1i78P+OoL/SJbKeyiZovJRgMRdNuOowKj8QTJ4gsdNlDtFfh8qfRwM4Htil0/w5eajrgbw14bWfUFAnkuJJSsKMeo/wDrV6UYKNPlnta1un5mc4xspJaH0BY+NNDuJAZLtYX4ba3PboCKr6z4+02xWb+zn+2z4A2xRnCseOSf5V4VH4B8R2OtSaj4ggudPcEndAN8R/EdvrXUxalbAJaalcvJe718oiQEOAOOOuffmvOll9FNOMuZeQ4UYSXN0G3MjzTSyY/eiQ5SThsk8tx6ehqzd6haWuirHqEAae3tnit5V+7KD0U+hBqkl9Nc3JkdUWaIEsWjI8wcgbm6bsGopNLg1q0mgu3EQjdZUOcYUdSPXH+FdLilbm0SOmSujufgVpSN4Rh1u5t4Uu7vdt2pgIgJxx6nvXo08kkMJmC5fGWWP0x2rzv4Q69b3GnXOhuQtxZznCE4LKeeP8967bUhDsc4MKKDvYMQF7kmvGxnM68nL+l0OConzWZ5t8YltZrC2uQ3l3mduO8g7ZH1ryp8PIxVY/NjQsFxjBxz+Ndi2uQ+KvGs5jgkn063VirscKAOhrA1TQdXkurya3tbyeMnKqIcBc8/lXs4WPsoKnJ2e/39D0KLtFRZyNjeyXkPmvH5byEg8VtaarW7ebKDtTj6mqqw3SRCadMEPt2lcbT6GtmWY/2aqlFDbjk+tdNR9EdMVoWLDxJcWkr/AGR5IUbIIB61h3E73F+0shYsT1PWnI2PnfhgOnanWlrPPNlEZ3bsozmuZQSd0iHFJnp/wW1LVj4ijt7RnezI/fKfugev1r6Irg/g/ocmkeF42uoFiuZyXPy4bHbNd5XgY2op1XyrbQ8XFTUqjsYqwa1gl7u3J7BUwB+dZupT3EuoQWMp8zzv7oDKMdz6V51c/EO41T4pXvhqxZ2021V45nI4jcY5yDyM8V3uveJI/Dvh23v7XS5Z5psARgEbeOSTgnFN0akHFNavb5ma7kfjDVPDllHFo2ua1HZXlxHuiUy+Vv8AqegBPrVrwvpAghivfLihBiCqqMGDjb94kcc14/4W+HT/ABB8Sal4s8eySC2Fwr21tnCGMA/K2ei9Pyr1aXx14e06OCzt1k+zqPLURx4VAOAPpV1qXs0qVNuT69k/II870SN3TbiFPtMMUP2eYEF/kwMkdfemvqRtVKCMttzl2PfPWq8+/UrdzBITDOvySAYKCqGhaZf2TztfXIuIwcICOSPU1z8qd2x2Rw/xo0y71TwdLHYmYpJcO0sgXJXIADEDtx+tct8DPBN7pEcrSTybJzh3jBRWBGMDPPHXNe7PmzBSKENMPmSPPDZBqJpZoLK7u7uAeYq7mhTkAAfKBXTHFNUvZJD0vcwvGU01h4Y1SbT4pJ5YYcrGOWcCuG+BUU3iHVp9avNOFo8K+WpAwH5649a9J0y+XUFvniXDqmNnfJH6Vq+HNLh0q3CwAqrqCw7Z71KrKnSlBrV9Rydk0ZHxA1OG3tHs4zsu5Y/9YRnC9f51V8ER3dzoa3OrzfvrhdpYnlIwc4z9BVjVVg1eNrrCnMrQxsfQcZ/nVi5aGHSL5ZJVSKGLYo7KcDaP0FRdKmoLcSWlh85Gs6nBDbFHsY13ZHsV6fka5zTrWC0+N99c+WTdXdiIy5P8K4PHp0rqPAscY0kSRyb8na3GMN1b8MmovEmmQ2mrW/iKNX+02w8pguMMh4OfzpQmoSlDyaFpflYvxB15NB0C4ndipKnBHUV8ma3qB8TPMwYLdZDojN/rMdga9T+NHiIXd6mlPvWQttIP3TkdK8s07w/FHqUcqPPOFfaYwuQCPevXy+gqdPme7OilFqNkWvBEV/BBMt5bywHepjDj5W9R/KuogU3U6BWVDwT5fb2JNRXk7RSrbRurKR+681NhXPbn+dR6fM9tP8+S+e5zzXTJt6nXTjZWPRvCPgbT9SlxqF224nf5MXH516bpvhbR9Ni2WdlGmerHlj9TXA+FjHYab/aMjBpg3zlm4C/5Nd5H4hspbT91PH5xBCqTjJrw8XOrKVk3Y467m3o9CzqWkQ3VpJCn7suMDHauG0v4cyjUvP1KeFoFJIRRkn8a6YX0tnG13ezsArDzBjKhc9QK57UvirpVtf8Ak29tPcwg4MqnH5Cope3ScaepNN1do6m34xht9O8KzQW0KohwoVeMe9eA3dsW1D5WjO0/LGzYya9G8aeNLTXbIRWSTRlRk7vX0rzo6fJdsXiUu+DjjoB39q9HBQlTjee7OqjFwhruPl1G80++sm8qJ9OeEhmEX3GGQyP61e8N+INP8QapDb28nmwNdpg7Suxx7HtjvVPV9Ts4n07T7u3ZrrUPmnlVyFjJOB8vf/69cboa3PhUX91GqMY5lKewVuT+VdkaanFu1n+Yr3vbofWcYa4vHferQLjgKcqw/pSMr+XO1ncL8isW3r944P5Vy3hrx/pvibS4Lm0uI43QAXMTHDKfp6e9VfF/i6x021msbK4hlvbkN5gDZaPI6jHt614io1OfktqcqV2Z/wALJ4oLeVANly0zGViM5B5B+ld1Pdo9hdNdCJrdUPzHoB1596+cfAd5qcd1rE0M7wpGvnRFCflfdgD8RnI9qkvtR8da9cQWmr3MVvo/mZZ7YoNw5PzbT6etelWwLqVW+ZL+uhpNOUrmPp+onWPEesXUyK/kniUdk3Y2/wBR9Km8M6uw8XvYzaf9juDLvVpAf3wGcE/UV0PhuG11ZEj02DyoVvkhbJUBx2ckDvz1rrPiPY2Olw2+pNFIklkwX7S0e7cmc4yO1d860VJU7bmsZbK55RYS6Vo4vb6G7lbSLiXCoB+8hbJDKfUDjn0q/wCK9J11fEWn3mjLM0EduPKaLOSB1Jx7YrM1DwrG8NzDb30TQ3dyLuJMnIjPJz68Ht6V7B8M9a0/U4Z5HLvscxwMF5QqMFR9Rg061V0l7SK5iE3ycr2PO9ds9mlW12sXlXqKbkIowXJUggCvavgdYPpXwr0xpkYXM6m4kx987jnnv0ryX42a7a6nqNjBpY8uaO4jQheNwH/169z+Ht/BqHg7T5NOcOsUfllQc7XBwQT9a4cfOcsLFtWuyaqukzaimDnDzLIHPG8fmK8X+KHhbT7fxRZ3dnCI3kYPEucBG/wzzXtpKmfY8aB8fKxx1ryj4t36w+JLSOMiOSGAAqRkgk8VxZfKUa9odUVhX79ilp3hu+1HTo/KcOkeQHK/Mef156Vzl5bPY37C8jMkW8Ap6jPb3r3DwfF5Gj27iMkvGGBPABrgfivbpaQi4+VG3g/KPunGea6qOLc6zps6Kdbmm4s8x0+5nSeO5AaxunDIC/Em5c4IH8WBj3wa0tf8U+I763GlfbC1lKoWWZgA3T88ZqbT/CGoeLvEFncW8vk/ZIWV5XOU3tnkD1x2qn43+HeueEvD0t5p9wb9JZlMkij5oyT1Knt9K7pSoymoya5ui/4ISlG9pl/4a6Xa6ZqYsJLs3CvIPMkX7pHoK9smZZGeND8hHMfAIHrXzoL+PTTDPPOi3KJjYgPLfStqD4kai+mC3eNFdjjzAOcVzYvDVK0lOOoVaLk1ynSePtOt4bG6udqiXIUpnImz0P1968yhkBjWOTjGSatax4hvNSmVrmYuI/udhWdulZzJ8q7hngVvRpypwtNnXSjKEbSHINxbIP5V9E/A7QILfw0mozwKbidiULqMqo9K4T4deAbrWUtrq6j22LnLOe4HYfWvoSzt4rW2jgt0CRRqFVR0AFedmGJTj7KL16nDja6tyR3JxS0g60teOeWebeFfA+leCIitl9pu7rUrkNcXEmCzn1b0HXpW9rniyytL4adHMY7jIHmbAyKc/dNJY3jW9nLLdnbJZyYKk5JBrzHSPDZ8T/EPUr6DUll0yZmdo8kOjew/qK7ox9rKU6z26ltJaHofja7uDDHptmnz3BwAvRv/AK1Ytxomk6BoiTalbC5vs8oWP3j0GPTjGa62exS0ijA8yZ7SNQrtyWx0z71yHi3WrW1ltYr9EhljYJEWYE5J4HPXJx9Kmi27RiawlZJIs6l4wfw/oWmJqNh5Et1naijAVff3rq9Bvn1WwhlEPlKwz97OADxXjut6h4t8V+BtYuYLNbjUdPuUa2TyQeOdwUd8Ad60/AT+KLj4d6iddjni1Ap56xhtjEZ4GOw4/WtKmGShfRO+upDXvcrPUb24jtY5r+U8jMcY/vHPAz7mvI9W+L9o994rtGjdY9KtyCwHLSAgED23HArqLyXVfFHw10+ezt1tLxpd80e7hApOTn8M1xV98NNGvtO1Z7CW4m1PXZUEy7x8qhskr7bueadClSjf2z1vb8f+HFaVz1DwjqNlq/h611xMbrqAOGPB+bqpx710OoZeD7JE22W4QxqccKMcmsnw94UstF0aLSbdn2wwqqMTyMeo6cnNZ3h7WjrPju/tIcm1062EbMDx5rE5H5YrmcVNtw2X9IN9Wa2lafDJP5aj/RrUeUg9SMZP51hpc6dqvhnUoL64jtpZLyW2fJ+7IhwAfyH510SXdl4e0m5utTuEhgicmSZumc4ryKw0+XVtQ8Q6jFLEdOTWZbkb8gSIyoQR+VaUY87bbslbUFJ81ket+CFeDSfs0yhZoXIYDvnoffNQfES7FroSKZAgnuYoMdCxZugrE+HHiyy1zUbvSbTct1pqKJjuB3A5xj1A4FUf2i1mj8AJqFvkyadfQXeAeoVuf51MabeIUZaXZMpWlzHlf7RUX9k65LewRuL0smyQ8qoI6/XtXqPwttbWX4faRKoXzJVLTuVySc96f8VtNsfGPw2kvYIleWWOOWNwPmXODj9a83+FniHUPDNk2kz2014iFnXYMMg/HjFd65q+FSj8UWdEVKcbo3PjLarpVjHd2cMJLHayEZIJ7gV55B5tvbxlkCM6h2x29q6vxHrsWt3Vxfavci3t41CrGhDBAO59T9KzX0SOS6NzBMZLdwskZZgVdW5BBH8q6sO+Smoz3Ouk7Kz3HW/iC9NqLTkKex9K7f4f6c+rA3t05Kb9kUY9uprzt7ZY70xyjyhuCF3bhc8Ag/j1r1r4Ztbw6HHF5wN3GSqqD1GevvWWKajTvHqFaVo6HdTbeEljBVmx+FeMfEzw+IfEVjeWapHE4Lsh+XcVIz+OK9ivIFnsxJvB2OWbtnFeF/GvXi/ifRrKEHy7a2kmfDZ3FiFA/SuPAczqWj5nLSk4yOc8X6quj2k8sYQ3bsYoR6D+9jviobDxje6StskccUlzLComd0/iYZIAH4VJb+HZ/E97CfKUKhLCWQkKo7kjuK9B8OfCsPefb9Qc7Mg4UcEgdQDyK9Oc6NONqhvU0erPNb3SrzU/ElrfiNzZwhHZumCDnGPrXS+G/h9qt7bXk9/FtWWQyKr/AMYOc8ehr3Ow8O6dbIg8ne/AwQOan1S1nuYnht2VFYYY45H0rilmT+GCsZe1Sd4nhz+A/wCyrS4e0jMRYDeqtksOw+lcPZWL6GJ7y8V/OZthLHJOf89a+oo9Jj8tFEZk2ks248Z9/wDCuN8ZeD7bVUlSOH5l5/djADe+a0oZhd2n1KjUTZ5nocMmqabuijWASI7ERjG48gfjxWL4d0S80+7uZUUiKSHEobgHPf8AU1q6rqF54VuRpcdr5YAVo3kzg4qxD4lfU9JvYAVi1BoiqL2yenNd6c1FuK91ml+bRlH4fzWmjJPEtwl1b3FwuSoxtIB6+9dV4/1mDX/CVxo2mX8Ms1wyq0zONsCejYryzwXbxxXV/p8yt57HfNt5CDBHUd+a1/B3htdAW8M11FO9yRsEeTtRMt3HLH2p1aMPae0k9VZ+pCje11oVdd057TWNDImZLOztxFJclSF2qMZP1rT8Il/CcUuLjeLqUsnlnO8Y+8PQYrK+z6lqnhkiWKbL3ztIJMg7M5yAe1czrOpa39tYx24jt4IWRUQAlExgBj2OOa6PZua5H8xSajqkdDoMFzrXimC38NQC+aaVpJJJhnYAeuewz0r0bwxo3if4XpfXd8ovbC6kLtHESFTPUnHSuv8Ag1odro3hDT7i0jEc9xCs0uBlmyOhP8q9FXy7ywL3CbkZcYlUcqfavJxmYe+6fLeOzvu/8iZTV9VdHnX/AAtbTTpXmy6Xcm5SMtl8bAQPXr+leGLqupeK/Hltf6iWiF/cgqGyFVVHyj6VJr0iWfi7WfmkbS4V3qqk7doPGK67S5rHU9Ts3t7eOOIwrL5JHZgSuR7gGuylQpYVOcI7rfsbxpwWqdj07wV4p8mxWz1IkNDmIrjJDA+vpXL/ABU1ODUDZ6dZoI9zmSYA5GfXP0rC0aANf3UyfJFGhbaDwOeBVdLeS7a6uy2zySMsefmP3R+lcsMPCFX2lzWNKMJc56t8NLSW38IRALiSbLlyMFS3T68YrSu2abSr+K42GKOF2diMZwCG4rK8M+IrSfw3p9ubmG1vIotksTybTwBgj1HesXx54ngexbS9IcSXVyu1pEOQQT0HqScc158oTq1npq2cnLKdQ8Fs7+4vLeH7WivOSyIdvOzPB+tSsjeY6MOjYINeyWPgix0zRw1zbie8YlXkYHKMP7mOgFcR4w0k6RdgIGZJl3hiuN1e5HF06kuWB6FKpF+6mcmkJWQYGR1Ga2dD0m71a7it7eMyyyHaqqM/jU2g6NLr2sWNlbMokkIUnH3R3P5V9Q+GPDOm+HrOKGxt1EijDTFRvbPXmubFYyNBd2ycRiFRXdlrwzpa6RoVlYpwIYwp+vf9a1aQgMuKOmBXzrbk7s8Rtyd2KOtBYA8mgClpCPDNJ8bw+Kftktm582ArJN8vG3OMfSsHTYvE9jqdydOguLOKOXd5kaZV1PJ6de1b3gLwtbaF4jv5dOjV0lt5JJdnKggZCjNTeBNe8SaqNUS+s0sdOFysNsikjdu5OPpj8Oa9huMOb2aTjpub6rRnp2jyXEvhwzTuHuGRmLnjdjoTXj/i3RJvEF6txPbXD20LGffDGCHfspPqfavb44oX0h4lASJo2XjsCCDXyHrXjLxxZeNzoOnyXBtorpUjiC5DgHqaxwEZznKVOyaIUra2PT/E3jx/BEWkW0gSCa+kLzRjnjGCSPxx+Fej2fimw1nSYJLIjfIxgfA6YXP5c1yHxe+Hdr411HStSv51gFvBtfa2DuznArb8M6Ja2VrbWGmxyNb2yn5nHzO7dXP0wB+FTUVGVKM18XUaTerK/wATdU/sD4WXYsC0LSMLdWHBJY/MR+Ga2/hvDAPC2i3roVka2AJb6cn8az/ij4YXWbDTLTfi3E4Lxjq5Ixn8s12GlxQ2unxCRkESII0A4AUcAVlKcfYKK3bbYPYkmeVLK4uEQO8hyBnGF6fy5rM8IaJa6V58touPN++56yMeSTVLxh4itdO02SKOZEZsqoB5HHNXNE1vTLWKy0q51GBNRe3EwgZ/n2kZzWKjJQduv6C1UfU4L4w+F/Eni6a0t9IZf7HMxMqq2CxBAyfbitzTNHbS9GV9NEbrBc7HRhlZQFVCR9CDir2j+Kk1m3v7PTY3j+yyLAs7cqxLYP8AWqPxCuRoWnabZQJKbdQWKxcHjqa6lOpJRoNWt/WpVK8naPUd4c8Hf2b8TtR8T21xEtpe6fHDJbxrjEgIyx7dq6nxho8HiHw5c6ZcZ8q6AQnHTPesf4fam+seHtsqyqUl2qW4YpnI5rrLiVY5Id7AIWIOfpx+tc9Wc1UTe8dPu2InFwk4s5nwTZNp+nf2PeuJREixBWXGQoxj8hmuX8f+Aby6t7mbRZAjsp3BFwWX+6K7S/jk/wCEgDxyRpKE3RLg5fjnPbFaVhem4t1Z1w/Qj3qlWnCXtI9SlJx1R8f+MPD2pxaatrplvPJGDunLLg5x0xVW8ku9J0mwsbK4aHagDhTyTjJ5+pNfZF9pNtcRuUhjEjDqV61gav8ADzQNV+a8tA0hILMPlyR9K9GGaQaSnE1VWD6Hyt5t7q1iv2lnbYMFzwWweM16N4bN9bQxmy/eB4QGXdjGOuCOlexJ4A8Pw2D239no9ueSi5BP+JqpqXhW3Gjtb+HfJt5iNsfnLlVHfjrmlUx9OouVIr2sGrHKyaje2sKya1PHFA77VjExY4C8kjvx9KxtD+HV34k1W417W18mC4I8uL+Ixg/Lx247V0vhz4WhNcg1bxHq82oXVuxaKBU2QqcY6fxV6XJPDCPLwMqMhV7fhXPUxKpaUXdvr/l/mQqrT91GZpWgWGnWSRpbRoqD5RjpVrUrswWclwTmFF+4B8znsK4nxfqt9YLLqOo3qWWi2xEkjNksw/ugfUVQ8K6x4g8fpFejS10zQHdtk0rnzJkB+Vsds1h7Ccl7ST07/wBdSHdv3jsNV1XfHDbpMltNKQdn8ZXH6GrNvA8NvbrGS8rMTgnnpzVI6Tpel6hNcKzS6lIoAaRi3ljpkDtWnYyuGRkR5EXKl8Y/HnrWcrJe4PpoY9p4q0+bR769heaSO2leF1Vfm3r1H096XT9Wku7BLtY42imUMg5B6cA+tC+EoIdCv9P05Vt2uWaQyNzuZmyzECor/U4dIlsrKKAPAGMMqhMfdHGPxrS0JXVPX/IqNnsZmr+D49WWWXUoPtZfkMG/1Y9APSuQ1j4eQpY3kOgKbe7lVY1uH6qD1xnvivT4dZF/aC608M0inmErhmHsDUtyhuJI5f8AVTZwF98d61hiasNL6FOUlozwceD5PCpisYMrHJzK5yWlPcsawn8J6hF4mbXvEd/Hp9rFNut7aFt8kqAZG3so9SfevffECySuoXY84HORwa8016PT4kvbzxNdSwxwH7yIGJix0VfrxXoUcZOe+7+/5Gt4ziubRI81n8VXvinXJray2x2sSsPNPbn7xY8DmsSXTtQtrO7S0u4b65mfY7QSbsbuuTXodvYaR4w0eODw7YPpthM535wnCdSW7jv7VljSP7B0y4g8Fzrqt1I2yO5hw218jcBnuBgZr0YVYL3YK3k/1Y4yulr/AJnuPwluIl8LWFkzM01lEqOSOQQOh/CpfGviqH7JNpOgPJc6rcr5Y8lc+UD1JPrXgunf21aeIBaT6hOqWdqJr9o3OJZTwEyOpycfhXuvg3So/Dtha/ca9uADLMw4GcEqM9K8jEYeFKftZO99UjNRiryZ51q3gPUl0uS4vrRJbHyQskYkG8J64Fc7pGi3Ebalq8tyFR2jSEKMBVXgLX0pfW6NAjQKn2d1YS4OcptrwGOO41fVWsrMN9n83gKOM/4V0YXFzrRlfSx0UZe1d2tiXTMJoeoSx5w0qRn6Gorm+GnaRLORttwpWZ8ZwQew7nBNa9/pjaZoUsbIRL5oaUHIxzxWXqWbjR5bGFfNW7DRKduVDHgfj3q+ZTd+lzabvsOtbiSOSGW1jtjCYPNjleXnDMSOg457VDpE9vD4r029u1Y3DXSJO5YeXx91VHYZqlDpa+Hbeztpbl5YniO8o2XOxug9MmqcqoSG2jceVU87ff61SSd7PcmKutdz6Mvbi3srd55SGLDcqAdyeenvXj/xX1GzuIbOKCQNc7mduR8qntxXN3finXotNNkdSuPsw+UKCOnpnrVLwnoN54o1qO0gDuZGBkk6hF7kmuShhPZPnnLYVGh7N88nseh/A/w9PdaqmrsCtrADhv77V70Ko6JptvpOmW9laIqRRIFG0Yz71eHWvMxNf29Tm6HnYit7Wd+hIOmaj2Yk35PTGKf+FIQD1rnMBy0tItLQB554W12HXdJ+3yQrbz3lsYnVB92UDDD+VXdYt5NI0Bn0tUm1BVJgErkI8uPk3Dp1xzT9I0PSvA3hfF5dbvLy0lzKMF2PoP6VLpuqR6zFHcaddaff2nHmKvJC+v19jXTJrmbh8NzW6exc0K4a90GCz1aaB9QWMRXq252qJMfMBjpXNaj8PdKttfj1uG2lllZwnk7+ASfvnPXFXfAmjTabLqdzPJu+13TyDtsGTj+da3irWLrSraGK1tTcXMx2qQMhfc0KUoVHGk9/kJXTsjA8V3scNwlpCuJM5Cj73Pf61qeBBMttcSXKmNs8oeoNZGj6aYVn1C9Zpr+RhtD8lCe1dBpGnTRW87s2+eYhHbOB+A/GidlHlRpOyVjl/F2pXX9r7YnOUHyj0zWe1/rU8K2yoQqEHcoJ/Kuo1Xw+lxqXmrL+9QbjnkdOhFU/iLr6+CfBbXsVj9omQKSFUkKT3PtmtINPlhGN2xupGMVocfb+H7jWPEBF5IZIt25mC+n8JrroPhnpsutPrd1ubUn2gEsSEUDAAH0rnPgr8Q5vH91Nbz6KLYWibpLqFsRsc8DGOv416R4j8SW2hy2tsyNNdXBxHEnXHqfarrTr0p+ztyu23kROs5pFPxNdeHfCHhqe51cw2tgvBwMFm7BQOprmtB8SDx9b2+p+H7aRGtJSI3ujt3rjBOO4rm/iNaWPi7xRbS+JLkR+HtPhbEKPjfMTjOaj0DxrY+GoX062ijhtoEaVGRhjYB29feqjQ/dqSu5/gl+rCNOd7nsekaebC2ImmEtxJIZXYDaMnqAPSub+Iuq6lptpaT6Np8t/ILtEliRC37rGWxjoenNeB6X48urvxe+p2us6ndW0ch3/AGlvkKnoFUfdHavRdD+NEd7fS2clssIgOJHLctzjCj+tEsFUpyU2ubv0Dkk9e56jdx3OoabaXIgkt7gDcVbAkTPGO4qXTbae2hXLSzyKSx8xlySfcDFY2lePtJvriWETBTGMlmYYP0NSp4u8NC5kuE1a2Mo+RwJOuPauNxmvdcROMlo0Q+Pta1nTPCd7caFp1xNqYwFjxvKg9WAHXHpXnHwy0v4gajqzalr8l/DaEqy/a5CHYhucJ2XGe1d34r+JXh/QrD+0ZbuGfyiVEcT7nOR2H5V49bfH7VLv7R9ntp5hnKCOHc/4ADoPeu3DUqsqbjTprXqybWZ9FvpsrStI11Ptx/qUbarfWi5up7S0eYafNLgcRRYZ/wCdeD2Pxd8VXAid4VtInfbuu7QoN3oTnvXE+LPiP43uHeTUNZOn2iyYWO1QKzY7Uo5bWbtKxXJK17XR9Q2uqXOoNsewubGPHMszIpz7LnNRyatplreLYte263mDIEaQE49Sa8G8MeHNW8eaUl7favqNvZ7BmRMeZLnk5PTA9hXYWXwh8JW1wgki1Ga4BGZJLtzvP54/CpnhqVN2nP5JX/Njas9Dav57LxJDLH4xsbOLSY7gNbxLPvaUgHJfbxitDUPid4W0iKGNbkCFRsVY14UDgACvGPiz8Mb/AEfULW88LTzsJWKtayzcEjoFJ9j0NZt54fkubBI7qeC0vLcDdGfmGCBnkeldUcJSqxTcvd7f8DU1jT57nuVt8TvB06m4+3oHcbmZojk4/hz6+1UZvjJ4b+aG1a5MzcAFMZz6ZrxiDw7bLp0TJfo0mS7R7OCc9BUWqeEGurlLzTriPczDzY5m2gH+8hH8qpYDD31b/r5FSoWVz029+MdxGZ2trcLaRry8q/MPfitCz+Kuj3KxzXoeOMqG86Vcpnv9Oa8x8UaPdz2d5b2uxwdrAK33wOcZ9aw00WWbww2nX0brJIxfA+8o960WCoSjpoU6Otoo+krLxnoF3PDDDhjJ8yzYAUn29q2zdxzSrmIJHtOJQefyr5a+HXhbVtWklsVWW28hcKXzkAHr+eK7vW/BPjbQrFtQ8N67PcyKN0lnK+SQBztNctXA04S5VNX8zKceVJnoM+neJotWJiuba+0XcRNGx2zR91ZTjke1Y3jXw5HqMRjdRNHKuHjIzuGOcVieGPiVepYx3Wp2TypFGDPcIMeWPRvSuh0nxZoXiW783TNQwSButH6g9mX0NLkrUZczja3VFK8XqeU65bWkWk/2Fp9wbRPKZIvMmIyd2Tnvis7U9XsvA2habpumgXM0atJ5zcCSQn5nx6dgK9j8UeGdM1G1mubuBHli4RwApJ6ivI9Zu7KztDcXthbX0ls4WEXCZaMk8YIPTOODXo4erGsktXrr6mqipK8d0W4rqRfCMusraEz3VxEBDglUB++fx7V7vp19a6/ZWj2E2J4I8SQsAShHGGH4V8/p4j1WLSpme2kYZysUY+82OoHbHFV/Ad/faaZ765vJrW6eQuVQ4kbPY57UsRhXVi3s09P8i5UnPqfQnjbW/wCzNAmjWQxzzxeXFFgZXsx/KuU+DVkBYT6iV8xmkaJT12kAHmuB1BtS1Rmmu52nv7tgkMYfcQn4V6posOn+CfB1tFqlyYp9/nOiclm9K4p0lQo8id3Jg6fs6fKt2QfFSFYNH3qHElxckjJznC849s9q4y7K28FlawyQmWMrgu42x47Ef3iTWb4m8VXfiPVUZYpTax5WGJT90dySe5o1TSbm/wBHs3jsbpLOGVZsquNxHr3NbUqLpwipstQlCKT3OY8c32qXHiewtlSKK0tso5t1+T1OT3Ndj8PNC/tUXdxIpa3tkLsx9ewrkLi4jlieOOULLE58xSSN5J6j6dK9s+Cdm48C6pIy5SZ22ccnC1piKnsqGmg5P2UG0eWW+g3PiHxGmnWgwZJCC2OFHcmvpPwr4dsPDelxWenwom1QHkA+aQ+privhlpyrrdzdBMGNCPxJr0+vMxuIc2qa2OXGVm3yLYKO9FOUY+tcBwi0UUUAKtLSAU12waAPAvjlFe3Gqy2l9LMlk0TC1cMdqs2Mk+/atP8AZ38OTeGvAWo3V0+ZLmUlCwIARRwRnsSa9SvbKG+uZobuETQlRjKKwX86rare20NsLRCi4AXyxjj2xXc8U5UFQS7XNN7WOak8VxWccVlGd0ZYbpe+e/15q94t1ZxqdlFEw8hod75H3snjHvXnviS4m0e/srOJI5oxMTKQMkjrx6VS1rxNc/8ACU6fHwYpDghhkBc8AVrHDXalHzNLJe8z1XwrbsltcSld8asflzyD61v6YfJtp5pDhd5OB0wB1H1rE8MzSxv9m4H7lpWA5yD0NdBDPEbSMbcZwdp61w1L3ZE97Fa0mhRru6k6F8DPcVzF1rxvPE0WnKhkiMvTghwFOQR0xmtvxLD5EH2pp0hgDDcHGRg8H8a5zwzFDd+PzNaYNvBabsk9S3AIrSnFWcmVC2rO2htbHRLGVrO1t7ZTl2WGMIGb1wK8T8Y+JZZdbCLKPOfPz/3E6kj8K9f8YSCPSpiykkqdhBxg4r5N1bV/LOoXEhIa3JOO9deX0faNzZph0tZMo6v4pbxMt9aWUjicODEM48xVPJPvWTqtlqiW2mSWsE009uHEoUEggnOPcYruPgnpEWq6umpx6bbbWV2m+YqMg8cfXrjFeqfEXwVaap4enl05Wt7iNN48k4AI9PY16UsRTpVFSBNP4tzxbw5ZW1rAZIYpYhenIgcfcx/CD9aq6PbNfJc30e6G6Z2QLtwOB1H8q67w8gtfD0baogkvY2EibpANp7nHc5AqxHrP+nBWiRLUq7JEFAC7lIOPxJNaObu7I6Yx0Vjz21uro6HqF1cTOxt8bB6Gt34YeDtR1TTp7llYXNwp8oScbcnr7V0Ni+lWk0zxWZCbCxyN3z5BBx6da9d8AzWl5opnTcsrcgqcA/554rLE4l04NxRFRNWl2PF/EvgG70LTktr5luXnlCxyHkMD2z7Gvd/C3hzTfDOi20FjbwQlIgHkjUbmOOST1rI+J32f+xIGuCf3dwj7l56V10Twz2dtLCyuroGxnqMCvOxGInVpR5u7MpSvFFVbaPV7V/tlvFIh4dHTOfT8q8G8a+HNMuby4sdQlkgkhl2BlGSVz/hX0BBBLHDMRIQiE5GeGHr+VeD+Nb2DUvEd7Mj5Uv8AIQOoAx/SrwLlztJ6F0FzNx6HqvwshgHhCKz02Qm0tneEkn5sdifwrdfd5kZgAcjuf4q8W8Ha7c6BcSHTEaaGXAlhcEq2O/sa9Mh8RNJbZsrRkvSAVjbopPXn0rPEUJxqN9GTUoyi9tDP+KV066Jbpwt284ePBywwDk/qK4rwx4K1rXLgzbGhhfhppR1rudM8MX2r68LrUz5kanqTwB7CvUIYY7S3CRgIiCk8V9XhyQ1ZTqqjHlWrPJdU+HkWjaS0hvnkY8FQgwa88u45LTc0cgZAee2K9/1XUbK+j+xTxO0M+FWVexOcH2rxrxXoc+nyXCMjZUnGe4rXCV5zdqj1NMPUc9JbnOQXs1v5UqyK6pJnBHINF7rE894zQbYiz/PtHXjrWSxKOSwbaeKsvZ3EFvHc+VIsZ+6xU4NelyR3Z18mp6Z8KtSS51q+inEaz/Z1CsP4wG5/nXpF/J9lsriaTAhjQuzk9gOteeaN4ae7i0vxB4elWGbZtni6fOOp+ho+It34hFg0F1CsVicK7RZw/Pf0FeTVpxq1fdf/AADhqQ55+6zZ8F6Ra2Hh61tLm3WUagzTylwCCW5AP4dqp+O/h9pur6W93o0cWm6zbnME8SbASOobHUEV1ls8M0Vo1uiPG8QdWDYxxxirl9Pbx26IFM8kxxtVsjPfPtWPt6kanPF6mEndnzVrXiXV9POpaXfS/aHs4lnGG5bpnn25qvqsmlXPgttWkiAuEkjP3CwcN3bngAjBP0rc8YaTZah401R1Yq7rNbbYgPm4wTj6mskaHc6LoVvpsuycSQMrYGQ6tkH8jj8q9qEoWi46PQ6Vz9Oph+Jdevm0Wzj0u5ezmlGcxHDSDHTNO8S63dahqWlWMK7ZBEr3EiIMhVHT8cVyOvadqenSadbXW77SkZaNQ2QCrZGPwrr/AA5DctFc3Nw4jkVdrBhyUPPB/pXVyQilIqC55N7PQ9C8CfY9J0+51m4w9yPkgQ9sjqa5XW9Zk1XUGku5Hfk4HYV1+m+FJ9R8DyajbTNmP5RFjh8d68xmEkU5SQYOcEehrkp8spyle7/I6o8rba3O8+G11YTa/jVMCzthuiUrwzg8Fvzr2BrtIL5En2taKXdCB94sM8e3NeA/Du/+x+JoprtN0EwMRz93JGBn2r0XxhqsiFLaKUtPB8kUartL7uBge1ceLpOVVLucteDc0jzDxOIJvFt61r8sMs2FAHQE19W+E9Lh0nw1Y2EKBUSEbh6kjJrwTw78PtWfxRpw1OymjQyrJKxGRtBzX0mAAAAOBWOYVE4wpxdzPGzVowi7mdo+kW+lCUW+T5rbmJ/lWljnigClArzG29WcDberACloopCCgdcUUooAUU0rk06igDjvEXiWz0LzBvU3LD7u/gfX0ryW28XJqusvHC73d0W+by/uqewHqa8+8YeILnV7/wCxWckjXN0wLufvAmvcPhB4Es/C2kLd3iiS+dQ+5xypP9TXruhTw1Lnnq3sjr92mWtP8PNDbfbtZt/MmkDGVAN3lrg8D0PTmuc/sS38VeJdIurKWLyoTslVD07g16Wt8LHw/c3+on92VdnHXA54rm/h/Jp7pdvpljHZmOTICtu3KTkEmueFWSUp/LyM5SctzctWaw8VT28xEkUtr+7KLjbtYZUn15rCn8ZQWfxDt/D8ssaSyxb/ACyPm56AGrV94usIvEr6XYvBe6tOhaC2L7ASOoLeuBXkNvpF7qn7Q1xfzwyQ22nosp387Rtwq5+p/SnRoKfNKppaNxX1PpHV7SHUNPWC4QOjspwfWuJ8K7tN+IN7YybSJoSyeoHXFdlcTqljHJM+1IyCSOorEu7fHjC2vo4t7CJlR/Y9RXNTlo4vqhR0ujo9atBfabNAQCWHAPrXyD42sbDTtflg1FZEt7ttkyoedoPJX3r7IjkEiA4we4PUV8m/tKw+b44itYEUTbQwIPBz29jXblUn7Rw7lUpWujf+E1xpHh6ARrMDosxIjnm4O7PIY9q67x3400+w02aK0dLu4umFvDHbtnGe5NeM2llqNz8PINPtYkcrctNJuYKIxjqSe1dD8MtL/tq3MOmsLgwPs85x8isDy368V2VKEHJ1ZvZmqir2ehoXDPDHawWqSEPMRLGFyWGAcZI6ZrIuQQyxMB97jaOhH/669Pv/AAHPaaVK0NxLNcnD8rhWx1APvXE+F7OG+1cJcMoiUkMp6j2z3NOnVg4uSex0wmnqZclq6FZGDEyfw9Mj611Hge81nTC4tbTzrN85Rlzg1u+K9Mto7m3jt1G4BQMdj6fWvS/DukwabbxzFiGdB8rdFrCvio+z1V7k1a0eXVbnkviuz8RauUaTTZFtl4VV6H8K6LwSdettO+y6tYmKygGIrh/lZM9vcV6Zc6hbW2fNkAI7Dmqcd3Jqfyx2m6xkBBeQ7Tn6d64pYlyhy8qsczr3jbl0OeuLSfWok0wXpgglUs7w8lhjpn0qXSvA/hzQ4C88MUrD70k+DW39jsNLjLtOlqD/ALQUfhWDq+o+G7XNxd3T3I64EhK5/Cs41Jv3YN28iYym9IXsTz3ej2b7bXT7cJjJJjxkewqzYJE5WeHSYUVudzNgn8K801j4lzSKbfRNPgtYy2Edhuc//XrU09dTuYLefUZJobmcfImckf7R9PpW0sPOMby0+Zq6UkrydjvrjWksrmK2NuiPJkj5uBjr2qSx1VrqfFxE8KZKDcuAffNeV+Ida8S6VfxWRKSH+B8ZMwPt6+tb9rJ4hltIJb+OJcEu0StncPQ++KiWGtG91r5kyo2Vzq9U0V2lJtjiIDIUD7pHSs3xJpB1LwzHNPlbqJcHzON1Z03xMSzvRa3ek3EIQhZHZh8vv7iuwubzT9S0hpRMJLd1yNh+as2qtJpyRFp02m0fOcVtGupqhTID8qfr0r1/ULSOfS1tZYY5LaRBtTGHH0HY1Dc+DrHWpxLp9xFGQcktxIp9wOtd1Y2Cw2NtBcFZ5IUC+Yw5NdGIxMXytbo3r107W3Keg6ZBYaPHbWiNGh+b5uoNW7/ToL+wls71BJDIMMKu4xwBjFV98iMxl2hS+Fye1ee5SlLmvqcnM27nJ6To76DG9k05uLRXP2csPmjB6r9KxfEV9q+n2Ui6TppKorAT9oh6gdSe9ehX1n9phdVYKx6H0qrptpJFG0V18+4EH0IreNZX5pamimr80tT5dtopTqCvHM4nYMrOTySWzmta9gNg6iKeRwVH3jyvOcV3viX4eyRXd3dWrpBBuyrtyBmsm/8AA2qwafd3M6fu4ofNV/WvZWJpzSaZ6CqQlazPPNTks729gn1bOYE2RFBypPf3qtqF209uR5P7slQrfQYzT7e0l1HUUgt42klfjavNe0eFPhfaXOiyxa7bvHMWBjdWww4rarWp0EnI0nOFJXkQfBG7u57DULOU77EQ7kB6K/Q/nXm3i3SJGuZNQSJRE7sAPcd/pX0f4X8M2Xhuxa2sQzBvvM3U1BP4M0aazW2e2PlBt2Nxry44yEa0ppaM41iYqo5LZnj3wq8Ff2/pl41y3kqrhQSM898V65oPguw0qWKeaWe+uIQBE9wc+X/ujtW7pGl2mk2i21hEIoh26kn3NXawxGLnVk7OyMa2JlUej0AL3NH0p+aK5DlExjnmloooAKKKKAFx3pRSCloAKKKKAPmf9n/4ftqN3J4p19G8hDut4m43n+8fYeld/wDG3U9SsfA98dGEg1KYqYhGOVUEZI967vV9QsvDejpHEkaqgEcMAHX0GBXnvxS8YtoHgybWpLRJ5GItmgJ/1Mh5wfbFeiqs8TXU3G6vojR6pt7Gb8GtUv8AWvCC6f4qDXMhDCbj5iCTgH3r0Hwx4dstCsp4LJneMkOzPgtjrtri/gR4qsfEGjuILCK1kTDu6Jjdk4IPqQe/oa9Os4lUXVuSd8hLkj34rHEScZyilZdgTstDxdvCTXPxZsNTjimAimOJFB25BOc46CvYItMinsZJbmLbPvkbd3I5xn14pLaMyNN9nIW4hfcVYcE45x9ajvtdWytbeBYftF/cuUjtg2CR1LH0AFKrWnV5V2Vhyd3oR3asdEuFfDHyx7c4qDSr3MVq/VkyoyOTxircyb7aKOQEKkg3rnOf8azriJbyWd9HkRri1l2NHn7pA6Ee/FQtUVpszsYgCgOBzzXkvxg+Hcuv6xp2taeitLCwW4Q/xJ6j3Feo6PcG506GR1KSYw6HqpHarhwwx1FTRqyoT547mV7M+IfFujazp2sahYNO0dtcKer7QMHofavbfgTpVroHg21VVM09wWmmkQ/KCGxjPsK0vjv4ShufD97rEI2yW8RZwoyWAryL4T+JdR0exlMMsSWIbzWE5whHQjP+Fe3KbxeGvD5nRdT2PpfUruZDKZtn2dcFTnjHr+FeGasG0vWGNorbJnZ1I9Cc5/Kun0zx9Br+pxWP2qzhiOQsETlnlJ6jJGBUHi/N7er9jRFa0j8tycEuTzj8hXNhoOlLlktzWhaLsUdI1aWTWLcXpAQODuY16vr3iTS7REkfUI3QrgRxfMQfWvF5LKRzDPkupXHA/iNXYYord/nSMIF+8Rzn/GtK2HhUaZrOnGbTOqm+JlrbZW20szPn/WTP1/SsvUfiXrd3C32dYbOIcbo+SK5O/CXEiRr9+TgKO9JDpc7abKGXADKpBPQsT/StVhKEVdr7y/Y01rY2NL0zWPFl0JZriSRBzmRieParXinwvPpNlHNEJJIMDK579K67wFKsOkxKNoaPKlgemOM1b8VvFp/h+e8vbo+UeQG9z2rneIlGpyrYxdVxlbocN8KdIF54rubm8gISyjHlqw/iJ5OPbFelahcxPdBo1ICNjJFea/DDxdpx1+/tb+7WC4cqELcK+45xn1r1KzgdLmWZtpjdwwzzwOmKxxjftfe7GVWV5FHW4orjxX4fLBNwWVwT7AVsXCFmALbjkngcCvO/FvjfTbL4lWNq0kTLawsJZDwodsYXPQcDrW+3jjRxEWhuEmYEqI4zubPqccY/GspUqnLGy6EayskZPibTzeeJJUtoTJFFb75ccbMZ5J9h2riNPivJWKWyvyflVSQCD0PWtFfHM+n6X4nvtUcJLfv5NlbdGC4ILfjn9K85tfE+oTalb2tgjBYgA7J8xJ/u16NGlUs4tbG9OTWjPQoJtVs3Fxp9w8U8TbWBbdnn0r0Dwl8S7K8kFlrpWzvVIUSD/Vv+PY18+R6xqkfiu9j3PClm4jkycDcf5kd6vWetW15q6WKI8j3BIeQ4wW5wcelFTCRqL3l80KXJUV5H1wrLIgeNgynoQc0kiLIu1wCK8Z+HXiWHQdUbT7u4kksLjCxyMdwV+h/DOa9qUqyhlIIIyCK8WtQdKVjkqU3TdiuhwADuYdiKkpWURJ8o4oAHBBHNZNE3ExkHIyPQ1W1OzXUNOuLN3aNJkKEr1Aq2aAueeKEraiv1OZ8KeC9K8NhmtIvMnYkmaQAtz2rphTtpoxVznKb5pO7HKbm7yY2k4p+0Um361JImaTrTtv1pGUjBU9Oo9aAHZGcUtJkcUAj1oAWiikFAC0opKKAHZFJmkpQKAF60U0jnilwfWgDz1vB+q6v4kk1HVL/yLGM4gtVG5jg/eY+tS+J/BenX/ha90i/kWWG6lErl/vFgR+tFFbrET5lZ2t2NFNvQg+G/gjSvB2nSjSp5pYpjuDO2QMdgK62KR3tjeIF3NGcDHINFFKrOVSTlJ3YMxzrltpOm3mq3rFo4YgZGJ6/MB/WvJ/iNqM+j/GCyBuJfs1zpkv2Vgf4jkjB+uKKK7MJBObv1UvwSIqOzPRfh1r0WvR3NuLWS3ESKcs2QzHriuc1m+m8P/EiC2gDbr3BlkA5b3/LH5UUVUacVXlBbWNZ6PQ7y21Iw6gFkbypHPKt92T6V00EiyIGXjPUHsaKK8+okrE1ElqJcwRXMEkE6LJFIpVkYZBB7V5jrvwl0T+w76z0yGSBZN0qKpyAfQelFFOlWnSfuOxEXZ3R4pplno/hG4mv3unu7q0JVEUco3Tt3rN0vWNU1XVru/uGkt7SQeXHE3Qknr/8AX96KK+rhBSj7SWrOylrJHZRapcaHpUhKLM1tGDGrjIMh6EjuKz7fxXPc6HfXOq28aC2AcmJdofPsehoorKNKMlzNa3LqPlndFbw9rJ1e1+3Wto0bRPlSxyMgfyrP1fXtQk1bT7GC68p7hx56qMDBbAB/WiitvZx52rbDqSfImT2vj/U9M1l9OtY98UZEapjJb3q/4yk8Q+JxBEkVyLYPuK7GOQPSiioqUoU3GcVqKnFSvc5HStEh1LW7q0+2faZ58xLbwoxYN2JIHBGK9J8OfCrxNaae9zJqWqOqKTHZmfaW9sHiiiuXMa86DSj17nLz8120rnU+C/htLcE3viHTYrV5c5tmcSP7byOPwFdKvw/0B7ieLTo/s08A2yGPIGSPSiivHni6s5N3sP2su5nr8HPD9xqP2u6nvJioAEckhCg+1Y/i74f6nHepZ+DLq10u0YH7ROyZcD24z+VFFEcXVvdu/rsLnk7ps53xxY6T4MuNF0m6tJNa1i/j2zXEh2BE6b8Dv/hXmHiS21Lw/wCJbvTtPs0jkUALcIC29SOoJ7UUV7GGblGLbvdNv7zSm3Lc7ZIp5tJivJI9jFVQhPuoQOvsO9eteE/iJYWnh6yg1JyLiNdjZz26UUVjVpRrK0ujOx01UXLI7jRfEGna1GfsU6uSMlc1PbxyR3GGk3xDn6GiivGqwUJOKPOqwUJNIvkg45FLlR3FFFZGQm4HuKXIoooAryykSKseM96ekyucDqOtFFA7aD3JYYU4+lJhsd6KKBDTheW/Wk3quMnGelFFMB4YM2A2fan0UUgCkwTRRQAZx1NOBGOKKKAKGpapb2CbrgsABn5VzWdB4ga6TzLayuXi6BtuM0UVqoLluWkrXP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The glands and foveolar epithelium are replaced by eosinophilic enterocytes with a \"brush border\". At regular intervals, mucus filled goblet cells are seen among the enterocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34277=[""].join("\n");
var outline_f33_30_34277=null;
var title_f33_30_34278="Emphysematous urinary tract infections";
var content_f33_30_34278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emphysematous urinary tract infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Amy C Weintrob, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34278/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/30/34278/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysematous urinary tract infections (UTIs) are infections of the lower or upper urinary tract associated with gas formation. They may manifest as cystitis, pyelitis, or pyelonephritis.",
"   </p>",
"   <p>",
"    Issues related to emphysematous UTIs will be reviewed here. Diabetes mellitus is a major risk factor for these infections and is also associated with an increased risk of asymptomatic bacteriuria and certain symptomatic UTIs such as cystitis, renal and perinephric abscess, and Candida infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12868?source=see_link\">",
"     \"Asymptomatic bacteriuria in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32502?source=see_link\">",
"     \"Susceptibility to infections in persons with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of emphysematous UTIs is poorly understood. Elevated tissue glucose levels in diabetic patients may provide a more favorable microenvironment for gas-forming microbes. However, bacterial gas production does not fully explain the pathologic and clinical manifestations of emphysematous UTIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus and urinary tract obstruction are the major risk factors for emphysematous urinary tract infections (UTIs). In different series, diabetes was present in more than 80 percent of patients with emphysematous pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,6-9\">",
"     4,6-9",
"    </a>",
"    ], at least 50 percent of patients with emphysematous pyelitis, and 60 to 70 percent of patients with emphysematous cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. In addition, most patients were women, similar to the predominance of women in acute uncomplicated cystitis and pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ], and most patients were over age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest published experiences comes from a retrospective study of 48 patients in Taiwan who were diagnosed with either emphysematous pyelonephritis or emphysematous pyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ]. Diabetes was present in 96 percent and urinary tract obstruction in 22 percent. The mean patient age was 60 years (range 37 to 83 years) and women outnumbered men 6:1. Similar findings were noted in a literature review of 135 patients with emphysematous cystitis: diabetes was present in 67 percent, the mean age was 66 years, and women accounted for 64 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other smaller series of patients with emphysematous pyelonephritis, urinary tract obstruction was present in 0 to 50 percent of patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In contrast, obstruction was present in all six patients without diabetes in two reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. The main causes of urinary tract obstruction were papillary necrosis and, less often, ureteral calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a gas-forming UTI is usually made by plain films of the abdomen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT). Such radiographs reveal air in the renal parenchyma, bladder, or surrounding tissue in 50 to 85 percent of cases. CT scanning is more sensitive than plain films and may show the extent of gas formation and any obstructing lesions in the urinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging, particularly CT scanning, has also been used to classify emphysematous pyelonephritis, which in turn can help make estimates of prognosis and guide therapy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prognostic classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EMPHYSEMATOUS PYELONEPHRITIS AND PYELITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysematous pyelonephritis is a gas-producing, necrotizing infection involving the renal parenchyma and, in some cases, perirenal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,6,7,11-13\">",
"     4,6,7,11-13",
"    </a>",
"    ]. Emphysematous pyelitis (ie, gas in the renal pelvis) or cystitis can occur with or without associated emphysematous pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ]. These infections are usually due to Escherichia coli or Klebsiella pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,5,7,14,15\">",
"     4,5,7,14,15",
"    </a>",
"    ]; Candida is a rare cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of emphysematous pyelonephritis and emphysematous pyelitis are indistinguishable from those seen in severe, acute pyelonephritis. Most patients complain of fevers, chills, flank or abdominal pain, nausea, and vomiting. The onset of symptoms may be abrupt or evolve slowly over two to three weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory testing usually reveals hyperglycemia, leukocytosis, elevated serum creatinine, and pyuria. Acute anuric renal failure is an uncommon complication of emphysematous pyelonephritis that can be seen in patients with bilateral infection or unilateral disease in a solitary functioning kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the series of 48 patients cited above, bacteremia was present in 54 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ]. All organisms isolated from blood cultures were simultaneously found in cultures of the urine or renal pus. E. coli (69 percent) and K. pneumoniae (29 percent) were the predominant pathogens. Two patients had a polymicrobial infection with E. coli plus group B Streptococcus or Proteus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, treatment of emphysematous pyelonephritis or pyelitis usually involved nephrectomy or open drainage along with systemic antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/7-9,19,20\">",
"     7-9,19,20",
"    </a>",
"    ]. In more recent reports, successful management with systemic antibiotics together with percutaneous catheter drainage of gas and purulent material, as well as relief of urinary tract obstruction (if present), has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4,7,21-23\">",
"     4,7,21-23",
"    </a>",
"    ]. A systematic review of 10 retrospective studies including 210 patients with emphysematous pyelonephritis noted that mortality associated with medical management plus percutaneous catheter drainage was significantly lower than medical management plus emergent nephrectomy (13.5 versus 25 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/23\">",
"     23",
"    </a>",
"    ]. Regardless of the type of drainage or surgery used, all patients require treatment with parenteral antibiotics; antibiotic selection is as outlined elsewhere for the management of acute complicated pyelonephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prognostic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the findings seen on CT scan, two classification systems have been proposed to estimate prognosis and guide therapy. One classification system divided emphysematous pyelonephritis into two types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &mdash; Renal parenchymal necrosis with either absence of fluid collection or the presence of a streaky or mottled gas pattern",
"     </li>",
"     <li>",
"      Type II &mdash; Renal or perirenal fluid accompanied by a bubbly gas pattern or gas in the collecting system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differences between the imaging results seen in types I and II may reflect the fact that vascular thrombosis is also present in type I. Patients with type I patterns had a more fulminant course characterized by a significantly shorter duration from symptom onset to diagnosis (4 versus 11 days) and a significantly higher mortality rate (69 versus 18 percent with type II). Also, type I was associated with necrosis and hemorrhagic infarction on pathologic examination compared with diffuse infiltration of inflammatory cells and abscess formation in type II. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors for adverse outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Emphysematous pyelonephritis or pyelitis may be alternatively categorized into four prognostic classes based upon CT scan findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class 1: Gas in the collecting system only (ie, emphysematous pyelitis); this finding may be associated with severe obstruction at the site of the pyelitis in some patients",
"     </li>",
"     <li>",
"      Class 2: Gas in the renal parenchyma without extension to the extrarenal space",
"     </li>",
"     <li>",
"      Class 3A: Extension of gas or abscess to the perinephric space (defined as the area between the fibrous renal capsule and the renal fascia)",
"     </li>",
"     <li>",
"      Class 3B: Extension of gas or abscess to the pararenal space (defined as the space beyond the renal fascia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extension to adjacent tissues such as the psoas muscle)",
"     </li>",
"     <li>",
"      Class 4: Bilateral emphysematous pyelonephritis or a solitary functioning kidney with emphysematous pyelonephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors for adverse outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient outcomes with emphysematous pyelonephritis or pyelitis vary with the classification system type and other factors. We prefer the classification system using four categories over the one using two, as the latter links the type of class to specific therapeutic approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ]. Adverse outcomes and mortality were with one exception limited to class 3 or 4 disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 16 patients with class 1 to 2 disease, there was one death (in a patient treated with antibiotics alone) and PCD was effective in all patients in whom it was attempted.",
"     </li>",
"     <li>",
"      Among the 28 patients with class 3 disease, six died (21 percent) and 11 (39 percent) had PCD procedures that were considered unsuccessful due to progressive or persistent lesions. Of the 11 who had unsuccessful PCD procedures, seven underwent subsequent nephrectomy and six (86 percent) of those survived.",
"     </li>",
"     <li>",
"      Among the four patients with class 4 (bilateral) disease, two died and three PCD procedures were considered unsuccessful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse outcomes in the patients with class 3 or 4 disease were closely linked to the presence or absence of four risk factors: thrombocytopenia, acute renal failure, impaired consciousness, and shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ]. The success rate with PCD and antibiotics was 85 percent in patients with no or one risk factor compared with 8 percent in patients with two or more risk factors.",
"   </p>",
"   <p>",
"    Subsequently a meta-analysis of seven retrospective cohort studies examined 23 risk factors in 175 patients with emphysematous pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall mortality rate was 25 percent. Four major risk factors were significantly associated with an increased risk of mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral emphysematous pyelonephritis (class 4 in the above classification)",
"     </li>",
"     <li>",
"      On imaging, renal parenchymal necrosis with either no fluid content or a",
"      <span class=\"nowrap\">",
"       streaky/mottled",
"      </span>",
"      gas pattern (type I in the initial classification system cited above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/14\">",
"       14",
"      </a>",
"      ]. Type I was associated with a significantly higher mortality than type II in both the report of this classification system (69 versus 18 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/14\">",
"       14",
"      </a>",
"      ] and in the series of 48 cases (36 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conservative therapy, defined as fluid resuscitation and antimicrobials without PCD",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were noted in a prospective study of 39 patients with emphysematous pyelonephritis in India. In this study patients were treated with medical management plus percutaneous catheter drainage (PCD). Repeat imaging was performed after three days and additional drainage tubes were placed if needed. If there was no clinical improvement, early nephrectomy was performed. Patients who improved with medical management plus PCD underwent delayed nephrectomy if they developed recurrent pyelonephritis or had a poorly functioning kidney on nuclear imaging. The overall mortality rate was 13 percent. Thrombocytopenia, renal failure, altered mental status, and severe hyponatremia were significantly associated with mortality. Renal parenchymal destruction of &gt;50 percent based on CT significantly predicted the need for nephrectomy and predicted death. The early nephrectomy group had a higher mortality rate (three of seven) whereas the PCD-treated patients had a lower mortality rate (2 of 24). There were no deaths among patients who had initial PCD followed by delayed nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published data are limited on the management of emphysematous pyelitis and pyelonephritis. Based upon the observations in the preceding section, we suggest the following approach to the treatment of emphysematous pyelitis or pyelonephritis according to disease class; it is generally similar to that advocated by the authors of the above cited review of 48 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients are treated with parenteral antibiotics. Antibiotic selection is as outlined elsewhere for the management of acute complicated pyelonephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"       \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with class 1 disease (pyelitis) who do not have abscess formation or obstruction can be treated with antibiotics alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/21\">",
"       21",
"      </a>",
"      ]. Other patients with class I disease and patients with class II disease should be treated with antibiotics plus percutaneous catheter drainage (PCD) and, if present, relief of urinary tract obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with class 3A or 3B disease at low risk (defined as none or one of the following risk factors: thrombocytopenia, acute renal failure, impaired consciousness, or shock) can initially be treated with antibiotics plus PCD and, if present, relief of urinary tract obstruction. However, given the lack of confirmatory evidence beyond the one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"       4",
"      </a>",
"      ], some urologists feel that early nephrectomy is warranted in all patients with class 3 disease.",
"     </li>",
"     <li>",
"      Nephrectomy is indicated in all patients in whom PCD is unsuccessful.",
"     </li>",
"     <li>",
"      Patients with class 3A or 3B disease with two or more of the above risk factors should be treated with antibiotics plus immediate nephrectomy.",
"     </li>",
"     <li>",
"      Patients with class 4 disease (bilateral involvement or infection is a solitary functioning kidney) should initially be treated with antibiotics plus bilateral percutaneous catheter drainage and, if present, relief of urinary tract obstruction. Nephrectomy is a last option.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EMPHYSEMATOUS CYSTITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reviews of published cases of emphysematous cystitis revealed the following clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with emphysematous pyelonephritis and pyelitis, there was a predominance of older women with diabetes.",
"     </li>",
"     <li>",
"      Abdominal pain was the most common symptom of emphysematous cystitis, occurring in up to 80 percent of cases. By comparison, the classic symptoms of acute cystitis (dysuria, urinary frequency, and urinary urgency) occurred in only about one-half of patients.",
"     </li>",
"     <li>",
"      Pneumaturia after bladder catheterization occurred in 7 of 10 patients in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laboratory testing usually revealed pyuria and hematuria with positive urine cultures. The two most common pathogens were E. coli and K. pneumoniae, which accounted for 75 to 80 percent of cases. Other isolates have included Enterococcus and Candida and some infections are polymicrobial.",
"     </li>",
"     <li>",
"      Bacteremia was present in approximately one-half of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysematous cystitis can usually be treated with medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. However, bladder irrigation may be needed if blood clots are present or the patient cannot adequately void. Surgical procedures that may be performed include debridement and rarely partial or total cystectomy. In a review of 135 published cases, 10 percent required combined medical and surgical therapy and the overall mortality rate was 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parenteral antibiotic selection is as outlined elsewhere for the management of pyelonephritis. The duration of antimicrobial therapy depends upon the clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emphysematous urinary tract infections (UTIs) are infections of the lower or upper urinary tract associated with gas formation. They can manifest as cystitis, pyelitis (gas in the renal pelvis), or pyelonephritis.",
"     </li>",
"     <li>",
"      The clinical features of emphysematous pyelonephritis are indistinguishable from those seen in severe acute pyelonephritis. E. coli and K. pneumoniae account for most cases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain is the major clinical manifestation of emphysematous cystitis, while classic symptoms of cystitis (dysuria, urinary frequency, and urinary urgency) occur in about one-half of cases. Pneumaturia may be seen after bladder catheterization. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factors for emphysematous UTIs are diabetes and urinary tract obstruction. The infections primarily occur in women at a mean age of about 60 years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors for adverse outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of emphysematous UTIs is made by abdominal imaging; computed tomography is more sensitive than plain films and can detect obstructing lesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse outcomes and mortality are highest when there is extension of gas or abscess to the perinephric or pararenal space (class 3 disease) or involvement of both kidneys or a solitary functioning kidney (class 4 disease). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognostic classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8160536\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend parenteral antibiotic therapy for the treatment of all emphysematous urinary tract infections (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In certain cases, other interventions may be warranted, as below. Antibiotic selection is as outlined elsewhere for the management of acute complicated pyelonephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"       \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with class 1 disease (pyelitis) who do not have abscess formation or obstruction, we suggest treatment with antibiotics alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For other patients with class 1 disease and all patients with class 2 disease (gas limited to the renal parenchyma), we suggest treatment with percutaneous catheter drainage (PCD) and, if present, relief of urinary tract obstruction in addition to antibiotics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of patients with class 3A or 3B disease (extension of gas or abscess into the perinephric or perirenal space) depends on the presence of the following risk factors: thrombocytopenia, acute renal failure, impaired consciousness, or shock (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Suggested approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For such patients who have none or only one risk factor, we suggest treatment with PCD and, if present, relief of urinary tract obstruction in addition to antibiotics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Nephrectomy should be performed if PCD is unsuccessful. However, some urologists feel that early nephrectomy is warranted in all patients with class 3 disease.",
"     </li>",
"     <li>",
"      For such patients with two or more of the above risk factors, we suggest immediate nephrectomy in addition to antibiotics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with class 4 disease (bilateral involvement or infection in a solitary functioning kidney) we suggest treatment with bilateral PCD and, if present, relief of urinary tract obstruction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with emphysematous cystitis who have intravesicular blood clots or cannot adequately void, bladder irrigation may be needed in addition to parenteral antibiotics. Otherwise, antibiotic therapy alone is usually sufficient. Approximately 10 percent of patients require surgery for debridement, or rarely, partial or total cystectomy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Emphysematous cystitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/1\">",
"      Ronald A, Ludwig E. Urinary tract infections in adults with diabetes. Int J Antimicrob Agents 2001; 17:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/2\">",
"      Geerlings SE, Stolk RP, Camps MJ, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/3\">",
"      Boyko EJ, Fihn SD, Scholes D, et al. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care 2002; 25:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/4\">",
"      Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000; 160:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/5\">",
"      Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore) 2007; 86:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/6\">",
"      Evanoff GV, Thompson CS, Foley R, Weinman EJ. Spectrum of gas within the kidney. Emphysematous pyelonephritis and emphysematous pyelitis. Am J Med 1987; 83:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/7\">",
"      Chen MT, Huang CN, Chou YH, et al. Percutaneous drainage in the treatment of emphysematous pyelonephritis: 10-year experience. J Urol 1997; 157:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/8\">",
"      Pontin AR, Barnes RD, Joffe J, Kahn D. Emphysematous pyelonephritis in diabetic patients. Br J Urol 1995; 75:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/9\">",
"      Shokeir AA, El-Azab M, Mohsen T, El-Diasty T. Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology 1997; 49:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/10\">",
"      Thomas AA, Lane BR, Thomas AZ, et al. Emphysematous cystitis: a review of 135 cases. BJU Int 2007; 100:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/11\">",
"      Kumar A, Turney JH, Brownjohn AM, McMahon MJ. Unusual bacterial infections of the urinary tract in diabetic patients--rare but frequently lethal. Nephrol Dial Transplant 2001; 16:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/12\">",
"      Mokabberi R, Ravakhah K. Emphysematous urinary tract infections: diagnosis, treatment and survival (case review series). Am J Med Sci 2007; 333:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/13\">",
"      Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int 2011; 107:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/14\">",
"      Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology 1996; 198:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/15\">",
"      Chang SW, Yen DH, Fung CP, et al. Klebsiella pneumoniae renal abscess. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/16\">",
"      Johnson JR, Ireton RC, Lipsky BA. Emphysematous pyelonephritis caused by Candida albicans. J Urol 1986; 136:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/17\">",
"      Hildebrand TS, Nibbe L, Frei U, Schindler R. Bilateral emphysematous pyelonephritis caused by Candida infection. Am J Kidney Dis 1999; 33:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/18\">",
"      Yao J, Gutierrez OM, Reiser J. Emphysematous pyelonephritis. Kidney Int 2007; 71:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/19\">",
"      Ahlering TE, Boyd SD, Hamilton CL, et al. Emphysematous pyelonephritis: a 5-year experience with 13 patients. J Urol 1985; 134:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/20\">",
"      Soo Park B, Lee SJ, Wha Kim Y, et al. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol 2006; 40:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/21\">",
"      Roy C, Pfleger DD, Tuchmann CM, et al. Emphysematous pyelitis: findings in five patients. Radiology 2001; 218:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/22\">",
"      Mydlo JH, Maybee GJ, Ali-Khan MM. Percutaneous drainage and/or nephrectomy in the treatment of emphysematous pyelonephritis. Urol Int 2003; 70:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/23\">",
"      Somani BK, Nabi G, Thorpe P, et al. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol 2008; 179:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/24\">",
"      Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II. Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol 2007; 178:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/25\">",
"      Kapoor R, Muruganandham K, Gulia AK, et al. Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis. BJU Int 2010; 105:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34278/abstract/26\">",
"      Aswathaman K, Gopalakrishnan G, Gnanaraj L, et al. Emphysematous pyelonephritis: outcome of conservative management. Urology 2008; 71:1007.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8066 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34278=[""].join("\n");
var outline_f33_30_34278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EMPHYSEMATOUS PYELONEPHRITIS AND PYELITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prognostic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors for adverse outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EMPHYSEMATOUS CYSTITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8160536\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12868?source=related_link\">",
"      Asymptomatic bacteriuria in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32502?source=related_link\">",
"      Susceptibility to infections in persons with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34279="Insulin glargine: Drug information";
var content_f33_30_34279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin glargine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/34/5669?source=see_link\">",
"    see \"Insulin glargine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"    see \"Insulin glargine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2114346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lantus&reg;;",
"     </li>",
"     <li>",
"      Lantus&reg; Solostar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lantus&reg;;",
"     </li>",
"     <li>",
"      Lantus&reg; OptiSet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2114349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2110691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin glargine is a long-acting insulin administered by SubQ injection. Insulin glargine is approximately equipotent to human insulin, but has a slower onset, no pronounced peak, and a longer duration of activity. Changing the basal insulin component from another insulin to insulin glargine can be done on a unit-to-unit basis. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the total units/kg/day of all insulin formulations used. Insulin glargine must be used in combination with a rapid- or short-acting insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting or a long-acting form of insulin (eg, insulin glargine) (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate-acting or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Insulin glargine-specific dosing:",
"     </b>",
"     Manufacturer recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ: Initial dose: Approximately one-third of the total daily insulin requirement administered once daily. A rapid-acting or short-acting insulin should also be used to complete the balance (~2/3) of the total daily insulin requirement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Initial basal insulin dose: 10 units (or 0.2 units/kg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Conversion to insulin glargine from other insulin therapies:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Converting from once-daily NPH insulin: May be substituted on an equivalent unit-per-unit basis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Converting from twice-daily NPH insulin: Initial dose: Use 80% of the total daily dose of NPH (eg, 20% reduction); administer once daily; adjust dosage according to patient response",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2307975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"      see \"Insulin glargine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ: Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2110692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2114395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5498540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lantus&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lantus&reg;: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lantus&reg; Solostar&reg;: 100 units/mL (3 mL) [prefilled pen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2114347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2110693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. Insulin glargine should be administered once daily, at any time of day; however, administer at the same time each day. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. Do not dilute or mix insulin glargine with any other insulin formulation or solution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2110688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glulisine, insulin lispro, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2114351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2114344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Insulin glargine may be confused with insulin glulisine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lantus&reg; may be confused with latanoprost, Latuda&reg;, Xalatan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Insulin glargine is a clear solution, but it is NOT intended for I.V. or I.M. administration.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lantus [U.S., Canada, and multiple international markets] may be confused with Lanvis brand name for thioguanine [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2110685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2110683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin glargine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2114356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin glargine is a clear solution, but it is",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin [eg, insulin glargine] via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2114383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2114382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2114385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2114352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2114353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been shown in some animal studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. When compared to NPH insulin, insulin glargine has not been found to increase the risk of adverse events during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2114355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2110682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if significant amounts of insulin glargine distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8103878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lantus SoloStar Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $54.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lantus Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $158.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2114396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2114390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Basalin (TH);",
"     </li>",
"     <li>",
"      Lantus (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IN, IT, JM, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SE, SG, SK, SR, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Optisulin (AT, BE, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, MT, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Podevta (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2114388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glargine is a long-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2114391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: No pronounced peak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Generally 24 hours or longer; reported range: 10.8 to &gt;24 hours (up to 32 hours documented in some studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow; upon injection into the subcutaneous tissue, microprecipitates form which allow small amounts of insulin glargine to release over time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Partially metabolized in the skin to form two active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: No pronounced peak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamann A, Matthaei S, Rosack C, et al, &ldquo;A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(6):1738-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/12766103/pubmed\" id=\"12766103\" target=\"_blank\">",
"        12766103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heinemann L, Hompesch B, Linkeschova R, et al, &ldquo;Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH and Placebo,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(5):644-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/10834424/pubmed\" id=\"10834424\" target=\"_blank\">",
"        10834424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holman RR, Thorne KI, Farmer AJ, et al, &ldquo;Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1716-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/17890232/pubmed\" id=\"17890232\" target=\"_blank\">",
"        17890232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lepore M, Pampanelli S, Fanelli C, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 2000, 49(12):2142-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/11118018/pubmed\" id=\"11118018\" target=\"_blank\">",
"        11118018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owens DR, Coates PA, Luzio SD, et al, &ldquo;Pharmacokinetics of 125I-Labeled Insulin Glargine (HOE 901) in Healthy Men,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(6):813-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/10841002/pubmed\" id=\"10841002\" target=\"_blank\">",
"        10841002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porcellati F, Rossetti P, Ricci NB, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(5):1261-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/17303785/pubmed\" id=\"17303785\" target=\"_blank\">",
"        17303785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskin P, Klaff L, Bergenstal R, et al, &ldquo;A 16-Week Comparison of the Novel Insulin Analog Insulin Glargine (HOE901) and NPH Human Insulin Used With Insulin Lispro in Patients With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(11):1666-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/11092290/pubmed\" id=\"11092290\" target=\"_blank\">",
"        11092290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ratner RE, Hirsch IB, Neifing JL, et al, &ldquo;Less Hypoglycemia With Insulin Glargine in Intensive Insulin Therapy for Type 1 Diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(5):639-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/10834423/pubmed\" id=\"10834423\" target=\"_blank\">",
"        10834423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, and Gerich J, &ldquo;The Treat-To-Target Trial,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenstock J, Schwartz SL, Clark CM Jr, et al, &ldquo;Basal Insulin Therapy in Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2001, 24(4):631-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/11315821/pubmed\" id=\"11315821\" target=\"_blank\">",
"        11315821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schober E, Schoenle E, Van Dyk J, et al, &ldquo;Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2001, 24(11):2005-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/11679478/pubmed\" id=\"11679478\" target=\"_blank\">",
"        11679478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scholtz HE, Pretorius SG, Wessels DH, et al, &ldquo;Pharmacokinetic and Glucodynamic Variability: Assessment of Insulin Glargine, NPH Insulin, and Insulin Ultralente in Healthy Volunteers Using a Euglycaemic Clamp Technique,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2005, 48(10):1988-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/16160867/pubmed\" id=\"16160867\" target=\"_blank\">",
"        16160867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yki-Jarvinen H, Dressler A, and Ziemen M, &ldquo;Less Nocturnal Hypoglycemia and Better Post-Dinner Glucose Control With Bedtime Insulin Glargine Compared With Bedtime NPH Insulin During Insulin Combination Therapy in Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(8):1130-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/30/34279/abstract-text/10937510/pubmed\" id=\"10937510\" target=\"_blank\">",
"        10937510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9023 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34279=[""].join("\n");
var outline_f33_30_34279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186124\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114349\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110691\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307975\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110692\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114395\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498540\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104245\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114347\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110693\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110688\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114351\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114344\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110685\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110683\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114356\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114383\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114382\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114385\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114352\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114353\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114355\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110682\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103878\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422169\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114396\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114390\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869463\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114388\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114391\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/34/5669?source=related_link\">",
"      Insulin glargine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=related_link\">",
"      Insulin glargine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34280="The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes";
var content_f33_30_34280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34280/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/30/34280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the back, extremities, nervous system, skin, and lymph nodes in children will be reviewed here. Other aspects of the pediatric physical examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=see_link\">",
"     \"The pediatric physical examination: General principles and standard measurements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=see_link\">",
"     \"The pediatric physical examination: HEENT\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=see_link\">",
"     \"The pediatric physical examination: The perineum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=see_link\">",
"     \"The pediatric physical examination: Chest and abdomen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The back examination is relatively standard for all ages. Spinal alignment, structural asymmetry, soft tissue masses, skin lesions, and points of tenderness should be noted. The vertebral column should be straight, with alignment along an imaginary vertical line from the midpoint of the occiput to the gluteal cleft. The level of the shoulders, scapulae, and pelvic rims should be symmetrical. Any midline soft tissue lesion overlying the spine should raise suspicion of an underlying neurologic defect.",
"   </p>",
"   <p>",
"    Defects of the bony spine or of the overlying skin or soft tissue in an infant may indicate the presence of a meningocele, myelomeningocele, lipomeningocele, diastematomyelia, abscess, or tumor. With many of these lesions, the neurologic deficits may be sufficiently severe to lead to genitourinary tract, gastrointestinal tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower-extremity impairment.",
"   </p>",
"   <p>",
"    Scoliosis in the neonate has great significance because it produces cosmetic problems and potential visceral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic dysfunction. Almost 33 percent of children with congenital scoliosis have associated urinary tract anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flattened buttocks and shortening of the cephalad extent of the gluteal cleft is the classic sign of sacral agenesis. The clinician should ask the caregiver about maternal type 1 diabetes and must order a lateral radiologic image of the lower spine to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Darkly pigmented neonates and infants may have bluish macular skin lesions over the back termed Mongolian spots. These lesions are benign accumulations of elliptical melanocytes that regress spontaneously after one to two years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=see_link&amp;anchor=H16#H16\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Congenital dermal melanocytosis (Mongolian spot)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Midline dimples in the skin overlying the coccyx generally have a visible intact base and are of no significance. Dimples above that level require further examination, including imaging, to rule out underlying neural tube involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link&amp;anchor=H44#H44\">",
"     \"Assessment of the newborn infant\", section on 'Trunk and spine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients, particularly children in the preadolescent years, should undergo examination of the spine for scoliosis. Acquired scoliosis in preadolescents may herald important pathology (eg, spinal cord or vertebral bone tumors). On the other hand, idiopathic scoliosis, which is most common in adolescent girls, can usually be followed with observation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proper examination requires unobstructed visualization of the back. The patient should be standing straight, but not rigid, with feet together and arms at the sides. Asymmetry of the back structures should be noted. For the second phase of the examination, the patient should be asked to bend over at the waist with legs straight, feet together, arms in a dependent position with the tips of the thumbs apposed, and head directed toward the floor in a relaxed position. The presence of a rib hump or abnormal curvature should be noted.",
"   </p>",
"   <p>",
"    In addition to inspection for scoliosis, the spine should be examined for kyphosis and lordosis. A normal lumbar lordotic curvature, giving rise to a pot-bellied appearance, is found in most toddlers. Spontaneous resolution of the curvature occurs in almost all as they advance into early childhood. Mild lumbar lordosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracic kyphosis require no intervention; more prominent forms of either deformity warrant thorough evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXTREMITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview of examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to examination of the extremities in the older child and adolescent is similar to that of the adult; examination of infants and younger children requires an understanding of anatomical limitations and acceptable variations in normal alignment. Examination should begin with careful visualization of the upper and lower extremities, looking for appropriate alignment, unusual masses or protuberances, joint deformities, missing or fused digits,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    integument abnormalities. Attention should be paid to muscle mass. Adverse effects from maternal drugs, congenital defects, and",
"    <span class=\"nowrap\">",
"     chromosomal/genetic",
"    </span>",
"    abnormalities may cause limb deformities and limb-length discrepancies.",
"   </p>",
"   <p>",
"    Physical examination of the extremities includes determining the range of motion of all joints. Normal, full-term, newborn infants have significant flexion contractures of the upper and lower extremities, limiting the range of motion. Flexion, extension, abduction, adduction, supination, pronation, eversion, and inversion should be demonstrated within the normal anatomical limits of the particular joint. Variation from normal between paired joints and extremities also should be noted. For older children, the clinician should evaluate gait, as well as the sitting and standing postures.",
"   </p>",
"   <p>",
"    Palpation of the extremities should be done to determine areas of tenderness, swelling, and increased or decreased temperature. Any one or all of these findings may be noted at sites of fracture, bone or joint disease, infection, and sprain. Clavicular fractures in the newborn may be undetected in the immediate neonatal period; on subsequent examination of the clavicles, they may have unilateral or bilateral swelling (callous formation) and tenderness.",
"   </p>",
"   <p>",
"    The tone and strength of the muscles should be examined. Patients with Duchenne muscular dystrophy, who have pseudohypertrophy of muscle groups, will (deceptively) appear to have adequate muscle mass, despite having decreased muscle tone and strength. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Femoral anteversion, tibial torsion, and metatarsus adductus commonly are found in infants and toddlers. The vast majority of these anatomical variations is present as a result of in utero positioning and tends to correct spontaneously. Minimal intervention, consisting of passive range of motion exercises, may help enhance the correction. Prolonged malalignment of the feet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    legs may occur as a result of poor postural positioning, for example, if the child habitually sits in the reversed tailor position or sleeps in the prone knee-chest position with the feet crossed beneath the pelvis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=see_link\">",
"     \"Lower extremity positional deformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early months of walking, infants have a normal, wide-based gait; the legs often are rotated externally, and the feet are flat. The more normal gait of childhood develops with anatomical and neurologic maturity. Toe walking, found in patients with cerebral palsy, may be a transient finding in some normal infants. Passive range of motion of the foot will help distinguish a tight heel cord that is limiting normal dorsiflexion from the full range of motion seen in the otherwise normal toe walker. Toeing in and toeing out, seen frequently in early childhood, generally correct over time. In the majority of cases, corrective shoes, splints, and braces provide little if any benefit and are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Developmental dysplasia of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough examination of the hips for evidence of joint laxity or dislocation should be performed on every infant from shortly after birth until several months after independent walking. Findings compatible with developmental dysplasia of the hip (DDH) may be detected in the newborn period; abnormal signs present at that time may disappear. The clinical features of DDH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27113?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Child with a limp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible causes of a limp in children include infection; neuromuscular or neurologic problems; primary bone, cartilage, ligament,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint abnormalities; allergic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory processes; cancer; mass lesions; and foreign bodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23706?source=see_link\">",
"     \"Overview of the causes of limp in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16729?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hip pain in childhood\", section on 'Specific causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NEUROLOGIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete discussion of the neurologic examination is presented elsewhere. Except in an unusual situation, a thorough neurologic examination of every patient is not necessary. Patients who present with or who are found to have neurologic or neuromuscular abnormalities on examination should undergo a complete neurologic assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=see_link\">",
"     \"Detailed neurologic assessment of infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aside from the sequence in which it is performed, the neurologic examination of a child varies little from that of an adult. Neurologic assessment of older children and adolescents begins with determining mental status, followed by the cranial nerves, muscle tone and strength, deep tendon reflexes, cerebellar function, and sensory responses.",
"   </p>",
"   <p>",
"    Adequate examination of the infant and younger child usually requires the protective security provided by the caregiver's lap and the use of toys and bright objects to provide diversion or visual attention. The method of determining mental status depends upon the child's age. For the infant and younger child, mental status is based upon language and motor skills, as well as social interaction.",
"   </p>",
"   <p>",
"    The sensory, motor, and cerebellar examinations might begin with the lower extremities in infants and young children; for school-aged children, the examinations begin with the head, neck,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper extremities. With the exception of the first cranial nerve (not often or easily tested in infants and small children), cranial nerve function can be tested in much the same way as in adults.",
"   </p>",
"   <p>",
"    Assessing cerebellar and motor function and strength in the infant or toddler requires close observation. While the patient is engaged in normal activity, the examiner should look for appropriate alternate or symmetric movement of the trunk, head, and extremities. Upper-extremity muscle tone and strength can be assessed in various ways. For the infant as young as four months, an examiner can make the determination based upon the ability of the patient to pull to a sitting position while holding onto the examiner's fingers. Alternatively, assessment can be judged by noting an infant's upper-trunk resistance against the examiner's hands held under the patient's axillae as he or she is being lifted into the air. Lower-extremity tone and strength can be assessed by noting an infant's ability to bear weight while standing supported.",
"   </p>",
"   <p>",
"    Deep tendon reflexes can be elicited at any age, but in infants younger than 33 weeks' gestation, reflex responses are diminished. In preterm and late-preterm infants, an examiner's finger placed over the tendon to be tested can be lightly struck with a percussion hammer to elicit a reflex. Complete absence of deep tendon reflexes may be attributable to anterior horn cell disease or peripheral neuropathy. Deep tendon reflexes with an exaggerated response can occur as a result of upper motor neuron pathology.",
"   </p>",
"   <p>",
"    Many developmental reflexes present in the newborn disappear within the first year of life. The rooting, palmar grasp, and Moro reflexes are gone by two to four months of age; the tonic neck response disappears by three to six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Plantar flexion of the toes, elicited by firm finger pressure at the plantar metatarsalphalangeal joint area, may be present for the first several months of life. Dorsiflexion of the great toe and fanning of the smaller toes (Babinski reflex), elicited by stroking the lateral aspect of the plantar surface of the foot in a posterior to anterior direction, is a normal finding up to about 18 months of age. For older patients, the normal Babinski reflex is characterized by plantar flexion of the great toe with no movement of the other toes.",
"   </p>",
"   <p>",
"    In males, the cremasteric reflex can be demonstrated by stroking the inner thigh area in an anterior to posterior direction and noting ipsilateral scrotal retraction and testicular rise. The lack of response or an asymmetric response is compatible with a corticospinal tract abnormality. Occasionally, the response will be absent in otherwise normal boys younger than six months and older than 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SKIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the skin requires careful inspection and palpation. When describing individual skin abnormalities, the examiner should describe color and size and whether the lesions, tumors, rashes, or defects are raised or flat, coalescent or isolated, well localized or diffuse, pruritic or nonpruritic. Terms such as papule, macule, pustule, vesicle, bullae, and nodule describe the appearance of",
"    <span class=\"nowrap\">",
"     rashes/lesions",
"    </span>",
"    and have meaning for most health professionals. Because skin lesions from different causes can have the same appearance, however, the clinician must be careful to make the correct diagnosis and recommend the correct treatment. The history and physical examination are of significant benefit in helping to differentiate among various disorders.",
"   </p>",
"   <p>",
"    Essentially all lesions originating in the skin of children are benign. Lesions without an altered appearance of the epidermis, however, may not be easy to categorize. A mass that moves freely over the underlying fascia most likely is present in the subcutaneous tissue and should be considered benign. Malignancy is a possibility when the lesion is fixed to the underlying fascia or the examiner is unsure of what is being felt; an appropriate referral should be made in this circumstance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palpation of the skin may reveal rough, coarse, or dry areas in the region of the neck, knee, or elbow, which often are found in patients with atopic dermatitis. Large patches of coarse papular lesions palpable over the dorsal surfaces of the upper arms and thighs of an older child or adolescent may be compatible with hyperkeratosis pilaris. An elongated or patchy area of moist, erythematous, denuded, pruritic skin may be seen in patients with contact dermatitis caused by poison ivy. Pink, raised, pruritic lesions of various sizes and shapes, diffusely scattered over the body, are found in patients with urticaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Skin color",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations from normal skin color could indicate a previously undiagnosed disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Carotenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A yellow tint to the skin may be compatible with carotenemia or jaundice (hyperbilirubinemia). Carotenemia can be found in infants and toddlers whose diets consist of large amounts of strained yellow vegetables, particularly carrots and other carotenoid-containing fruits and vegetables. Carotenoids include alpha- and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , and lycopene&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/5\">",
"     5",
"    </a>",
"    ]. They are contained in carrots, sweet potatoes, mangoes, apricots, melons, tomatoes, peppers, and green leafy vegetables. In addition, beta-carotene is frequently used as a food-coloring agent.",
"   </p>",
"   <p>",
"    Unlike jaundice, the skin color characteristically is more yellow-orange and more noticeable in areas with increased sweat glands (eg, the palms, soles, and nasolabial folds), sparing mucosal tissue and the sclerae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/5\">",
"     5",
"    </a>",
"    ]. Although diet is a major cause of carotenemia in childhood, some diseases, such as nephrosis, diabetes mellitus, anorexia nervosa, liver disease, and hypothyroidism, also can produce the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice (",
"    <a class=\"graphic graphic_picture graphicRef73199 \" href=\"mobipreview.htm?0/41/663\">",
"     picture 1",
"    </a>",
"    ) can be differentiated from carotenemia by the yellow-green skin color, yellow sclerae and mucous membranes, and the darkly colored urine and lightly colored stools. Collection of bile pigment accounts for the change in tissue color. Disorders giving rise to hyperbilirubinemia include neonatal (physiologic) jaundice, hemolytic anemias, hepatitis, enzyme defects, and biliary tree obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17975?source=see_link\">",
"     \"Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Blue-gray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bluish-gray discoloration of the skin may be a side effect of a drug or caused by the ingestion of a toxic substance. The parts of the body most often involved are the face, neck, and extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopigmented or hyperpigmented skin lesions may have clinical significance. Hypopigmented areas often are benign but can be compatible with various disease states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/9\">",
"     9",
"    </a>",
"    ]. Small hypopigmented or depigmented areas may be the result of postinflammatory lesions, pityriasis alba, or tinea versicolor. Patients with neuroectodermal disorders, such as tuberous sclerosis complex, often have hypopigmented ash leaf spots. Streaked areas of hypopigmentation characteristically are seen in hypomelanosis of Ito. Vitiligo, an autosomal trait of variable penetrance, is a patterned loss of pigmentation secondary to the destruction of melanocytes. Albinism is an entity with total or nearly complete absence of pigmentation. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Chediak-Higashi syndrome is a rare autosomal recessive immunologic disorder with diffuse oculocutaneous hypopigmentation, leukocyte dysfunction, and recurrent infections. Patients with this disorder have fair skin, light blond hair, translucent irises, and renal, hematologic, and neurologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=see_link\">",
"     \"Chediak-Higashi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased skin pigmentation owing to an excess of melanin may be localized or diffuse. Between one and four light brown macular lesions (cafe-au-lait spots) no greater than 0.5 to 1.0 cm at their largest diameter (depending on the patient's age) is a normal finding in many patients. Larger and more numerous cafe-au-lait spots can be seen in neurofibromatosis, Bloom syndrome, ataxia telangiectasia, and several other syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35493?source=see_link\">",
"     \"Bloom syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More darkly pigmented cutaneous tumors that appear anywhere on the body may be present at birth or appear years later. Large congenital and atypical nevi (usually developing during the second decade of life) may become melanoma. Melanomas are found rarely in infants and children; they have an irregular border with deeply pigmented or varied colored areas, may have ulcerations or satellite lesions, and have a tendency to grow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=see_link\">",
"     \"Congenital melanocytic nevi and speckled lentiginous nevi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link&amp;anchor=H11#H11\">",
"     \"Acquired melanocytic nevi (moles)\", section on 'Atypical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired nevi (not present at birth) are less than 1 cm in diameter, may be flat or slightly raised, are light brown to black in color, and have discrete regular borders. They develop during the first several decades of life and often eventually disappear. Though the vast majority of acquired nevi are harmless, certain changes, including rapid darkening, changes in size or borders, ulceration, itching, pain, or bleeding, indicate a need for biopsy and histologic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link\">",
"     \"Acquired melanocytic nevi (moles)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vascular lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular lesions commonly seen in children may have clinical significance. The most common vascular lesion seen in infants is a pink macular stain (often called salmon patch, stork bite, or angel kiss (",
"    <a class=\"graphic graphic_picture graphicRef70234 \" href=\"mobipreview.htm?18/38/19040\">",
"     picture 2",
"    </a>",
"    )) most often found on the nape of the neck, glabella, upper eyelids, forehead, and nasolabial folds. They require no treatment, and the vast majority fades within the first year of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30038?source=see_link&amp;anchor=H4#H4\">",
"     \"Vascular lesions in the newborn\", section on 'Nevus simplex (macular stain)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infantile hemangiomas are benign vascular tumors composed of proliferating vascular endothelium (",
"    <a class=\"graphic graphic_picture graphicRef60004 \" href=\"mobipreview.htm?11/7/11390\">",
"     picture 3",
"    </a>",
"    ). Approximately 90 percent of these lesions undergo spontaneous involution by the time the child is nine years old. Hemangiomas of the face",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lumbosacral region may be associated with extracutaneous manifestations and require additional evaluation. The clinical features, evaluation, and management of hemangiomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular lesions that neither proliferate nor involute and are caused by inborn errors of vascular morphogenesis are termed venous malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/14\">",
"     14",
"    </a>",
"    ]. They grow in proportion to the growth of the child and may require treatment. The facial port-wine stain (",
"    <a class=\"graphic graphic_picture graphicRef59124 graphicRef73978 \" href=\"mobipreview.htm?21/27/21943\">",
"     picture 4A-B",
"    </a>",
"    ), the most frequently occurring example of this condition, often is associated with a neurocutaneous disorder (Sturge-Weber syndrome) (",
"    <a class=\"graphic graphic_picture graphicRef73343 graphicRef60560 \" href=\"mobipreview.htm?9/1/9239\">",
"     picture 5A-B",
"    </a>",
"    ). Port-wine staining of one of the extremities may be associated with soft tissue hypertrophy and overgrowth of the underlying bone (Klippel-Trenaunay syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4727?source=see_link\">",
"     \"Sturge-Weber syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30038?source=see_link&amp;anchor=H7#H7\">",
"     \"Vascular lesions in the newborn\", section on 'Klippel-Trenaunay syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spider nevus, the best-known type of telangiectasia (also known as spider angioma, vascular spider, or nevus aranei), is a central vascular papule surrounded by symmetrically radiating branches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/15\">",
"     15",
"    </a>",
"    ]. Spider nevi appear most commonly on exposed areas of the face, upper trunk, arms, hands, and fingers. They are associated with liver disease, pregnancy, and estrogen therapy, but also may occur in individuals without these conditions. In an observational study, 38 percent of 426 children (aged 1 to 15 years) without liver disease had &ge;1 spider nevus; most had between one and four; only 7 children (1.6 percent) had &ge;5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/16\">",
"     16",
"    </a>",
"    ]. Among children with chronic liver disease, 16 of 34 (47 percent) had no spider nevi and four (12 percent) had &ge;5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/16\">",
"     16",
"    </a>",
"    ]. Most spider nevi persist indefinitely, although some may regress spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/15\">",
"     15",
"    </a>",
"    ]. When treatment is desired, treatment options include electrocoagulation and pulsed dye laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Striae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Striae, or \"stretch marks\", also known as striae distensae, are linear depressions of the skin with epidermal atrophy. They are typically several centimeters long and 1 to 10 mm wide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/18\">",
"     18",
"    </a>",
"    ]. Initially pink or purple in color, striae later become white, translucent, and atrophic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/12\">",
"     12",
"    </a>",
"    ]. Striae occasionally may mimic physical abuse or nonaccidental injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Striae tend to occur in areas of excessive stretching of the skin, eg, the abdomen, lower back, breasts, buttocks, and thighs. Individuals who have gained an exceptional amount of weight in a short period of time, people who have become pregnant, and pubescent adolescents experiencing rapid overall growth frequently exhibit such skin changes. Striae also may occur in patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/20\">",
"     20",
"    </a>",
"    ]. Adolescents engaged in weight-lifting programs may develop striae of the shoulder and chest areas. Excessive adrenocortical activity (Cushing's disease), as well as prolonged use of oral and potent topical corticosteroids, can lead to striae formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise etiology accounting for striae formation is not clearly understood. A possible explanation is that stress-related rupture of the connective tissue framework occurs along with destruction of collagen and elastin. Corticosteroids produce striae by suppressing fibroblastic activity, allowing for newly synthesized collagen to fill the gap between ruptured collagen fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Striae appearing during adolescence tend to regress spontaneously over time. Among various treatments used for persistent or cosmetically unacceptable striae, topical retinoids, flash-lamp pulsed dye laser, and chemical peels may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the more common skin lesions seen in childhood are warts, pyogenic granulomata, and sebaceous (epidermal) cysts. The examiner should be suspicious of a potential underlying neurologic defect whenever a pigmented lesion (with or without a tuft of hair), a vascular lesion, a soft tissue mass, or a skin defect is found over the midline of the head, neck, or back.",
"   </p>",
"   <p>",
"    Though cosmetically unattractive, warts on the hands and feet (",
"    <a class=\"graphic graphic_picture graphicRef72268 graphicRef62168 graphicRef56924 \" href=\"mobipreview.htm?8/30/8680\">",
"     picture 6A-C",
"    </a>",
"    ) do not always require treatment, and most regress spontaneously. Warts in the genital or perianal areas should alert the examiner to the possibility of sexual abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26249?source=see_link\">",
"     \"Cutaneous warts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pyogenic granulomata are benign, generally small, raised papules appearing anywhere on the skin (",
"    <a class=\"graphic graphic_picture graphicRef52128 \" href=\"mobipreview.htm?38/2/38958\">",
"     picture 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/4\">",
"     4",
"    </a>",
"    ]. They bleed easily and are best treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    or electrocautery.",
"   </p>",
"   <p>",
"    Sebaceous cysts occur at anatomical sites where hair is present. They should be surgically removed if unsightly or bothersome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LYMPH NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph node examination requires careful inspection and palpation. The approach should be symmetric and sequential (eg, beginning with simultaneous palpation of the occipital and posterior cervical nodes, followed by palpation of the anterior cervical nodes, preauricular and postauricular nodes, submental nodes, supraclavicular nodes, axillary nodes, and inguinal nodes).",
"   </p>",
"   <p>",
"    Routine examination of the lymph nodes includes attention to size, mobility, tenderness, adhesion to adjacent tissues, and the temperature and condition of the overlying skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/26\">",
"     26",
"    </a>",
"    ]. Nodes that grow slowly generally are benign; those that grow rapidly and are rubbery, hard, nontender, and matted tend to be malignant. Enlarged, tender nodes with increased warmth to the overlying skin usually are infected.",
"   </p>",
"   <p>",
"    In normal children between two years of age and early adolescence, superficial, enlarged, freely movable, nontender lymph nodes are easily palpable, particularly in the anterior cervical chain. Cervical and inguinal nodes 1 to 1.5 cm in diameter are found frequently but generally remain enlarged only for a short period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/27\">",
"     27",
"    </a>",
"    ]. Nodes up to 3 mm in diameter in the axilla and submandibular areas often are found in the otherwise normal child. Palpable posterior auricular, occipital, submental, supraclavicular, epitrochlear, and popliteal nodes are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/28\">",
"     28",
"    </a>",
"    ]. Any node larger than 3 mm in the neonate and in children older than 12 years should be considered as possibly abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34280/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of and approach to the child with enlarged lymph nodes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30744?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The back examination should include assessment of spinal alignment, structural asymmetry, soft tissue masses, skin lesions, and points of tenderness. Important findings may include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Back'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Soft tissue lesions overlying the spine (possible neurologic defect)",
"     </li>",
"     <li>",
"      Flattened buttocks, shortened gluteal cleft (possible sacral agenesis)",
"     </li>",
"     <li>",
"      Scoliosis in preadolescents (possible pathology of the spine or spinal cord)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the extremities should include assessment of alignment, symmetry, masses, joint deformities, missing or fused digits, skin abnormalities, muscle mass, tone, strength, range of motion, tenderness, and temperature. For older children, gait, sitting, and standing postures also should be evaluated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who present with or who are found to have neurologic or neuromuscular abnormalities on examination should undergo a complete neurologic assessment, including mental status, cranial nerves, muscle tone and strength, deep tendon reflexes, cerebellar function, and sensory responses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=see_link\">",
"       \"Detailed neurologic assessment of infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the skin requires careful inspection and palpation. Skin abnormalities should be described in terms of color, size, morphology (eg, papule, macule, pustule, vesicle, bulla, nodule), distribution, pattern (coalescent, isolated), and pruritus. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypopigmented skin lesions may be a sign of a number of disorders, including tuberous sclerosis complex, vitiligo, Chediak-Higashi syndrome. Hyperpigmented skin lesions may be a sign of neurofibromatosis, Bloom syndrome, ataxia telangiectasia, and several other syndromes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pigmentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular lesions may include macular stains (",
"      <a class=\"graphic graphic_picture graphicRef70234 \" href=\"mobipreview.htm?18/38/19040\">",
"       picture 2",
"      </a>",
"      ), infantile hemangiomas (",
"      <a class=\"graphic graphic_picture graphicRef60004 \" href=\"mobipreview.htm?11/7/11390\">",
"       picture 3",
"      </a>",
"      ), venous malformations, port-wine stain (",
"      <a class=\"graphic graphic_picture graphicRef59124 graphicRef73978 \" href=\"mobipreview.htm?21/27/21943\">",
"       picture 4A-B",
"      </a>",
"      ), and spider nevi. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vascular lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Striae (\"stretch marks\") are linear depressions of the skin with epidermal atrophy. They tend to occur in areas of excessive stretching (eg, the abdomen, lower back, breasts, buttocks, and thighs). Striae appearing during adolescence tend to regress spontaneously over time. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Striae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the lymph nodes requires symmetric and sequential inspection and palpation, with assessment of size, mobility, tenderness, adhesion to adjacent tissues, and condition of the overlying skin. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/1\">",
"      Keim HA, Hensinger RN. Spinal deformities. Scoliosis and kyphosis. Clin Symp 1989; 41:3.",
"     </a>",
"    </li>",
"    <li>",
"     Barness LA. Manual of pediatric physical diagnosis, 6th ed, Mosby Year Book, St. Louis 1991.",
"    </li>",
"    <li>",
"     Fishman MA. Pediatric Neurology, Grune and Stratton, Orlando, FL 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/4\">",
"      Putnam TC. Lumps and bumps in children. Pediatr Rev 1992; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/5\">",
"      Karthik SV, Campbell-Davidson D, Isherwood D. Carotenemia in infancy and its association with prevalent feeding practices. Pediatr Dermatol 2006; 23:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/6\">",
"      Leung AK. Carotenemia. Adv Pediatr 1987; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/7\">",
"      Gollan JL, Knapp AB. Bilirubin metabolism and congenital jaundice. Hosp Pract (Off Ed) 1985; 20:83.",
"     </a>",
"    </li>",
"    <li>",
"     Disorders of pigmentation. In: urwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd, Paller AS, Mancini AJ (Eds), WB Saunders, Philadelphia 2006. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/9\">",
"      Vanderhooft SL, Francis JS, Pagon RA, et al. Prevalence of hypopigmented macules in a healthy population. J Pediatr 1996; 129:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/10\">",
"      Amichai B, Zeharia A, Mimouni M, et al. Picture of the month. Ch&eacute;diak-Higashi syndrome. Arch Pediatr Adolesc Med 1997; 151:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/11\">",
"      Korf BR. Diagnostic outcome in children with multiple caf&eacute; au lait spots. Pediatrics 1992; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     Endocrine disorders and the skin. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd, Paller AS, Mancini AJ (Eds), WB Saunders, Philadelphia 2006. p.615.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/13\">",
"      Burns AJ, Kaplan LC, Mulliken JB. Is there an association between hemangioma and syndromes with dysmorphic features? Pediatrics 1991; 88:1257.",
"     </a>",
"    </li>",
"    <li>",
"     Muliken JB, Young AK. Vascular birthmarks: Hemangiomas and malformations, WB Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     Vascular disorders of infancy and childhood. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd, Paller AS, Mancini AJ (Eds), WB Saunders, Philadelphia 2006. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/16\">",
"      Finn SM, Rowland M, Lawlor F, et al. The significance of cutaneous spider naevi in children. Arch Dis Child 2006; 91:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/17\">",
"      Scheepers JH, Quaba AA. Treatment of nevi aranei with the pulsed tunable dye laser at 585 nm. J Pediatr Surg 1995; 30:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/18\">",
"      Burk CJ, Pandrangi B, Connelly EA. Picture of the month. Striae. Arch Pediatr Adolesc Med 2008; 162:277, 278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/19\">",
"      Cohen HA, Matalon A, Mezger A, et al. Striae in adolescents mistaken for physical abuse. J Fam Pract 1997; 45:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/20\">",
"      Strum&igrave;a R, Varotti E, Manzato E, Gualandi M. Skin signs in anorexia nervosa. Dermatology 2001; 203:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/21\">",
"      Shuster S. The cause of striae distensae. Acta Derm Venereol Suppl (Stockh) 1979; 59:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/22\">",
"      Fox JL. Pulsed dye laser eliminates stretch marks. Cosmetic Dermatol 1997; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/23\">",
"      Kang S, Kim KJ, Griffiths CE, et al. Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol 1996; 132:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/24\">",
"      McDaniel DH. Laser therapy of stretch marks. Dermatol Clin 2002; 20:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/25\">",
"      Obagi ZE, Obagi S, Alaiti S, Stevens MB. TCA-based blue peel: a standardized procedure with depth control. Dermatol Surg 1999; 25:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/26\">",
"      Carpentieri U, Smith LR Jr, Daeschner CW 3rd. Approach to a child with enlarged lymph nodes. Tex Med 1983; 79:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/27\">",
"      Margileth AM. Cervical adenitis. Pediatr Rev 1985; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34280/abstract/28\">",
"      Chesney PJ. Cervical adenopathy. Pediatr Rev 1994; 15:276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2868 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34280=[""].join("\n");
var outline_f33_30_34280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXTREMITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview of examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NEUROLOGIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SKIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Skin color",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Carotenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Blue-gray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2868\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2868|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/41/663\" title=\"picture 1\">",
"      Jaundice newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/38/19040\" title=\"picture 2\">",
"      Salmon patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/7/11390\" title=\"picture 3\">",
"      Superficial hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/32/18946\" title=\"picture 4A\">",
"      Port wine stain - V2 infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/45/722\" title=\"picture 4B\">",
"      Port wine stain - V2 child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/61/2002\" title=\"picture 5A\">",
"      Bilateral port wine stains in SWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/21/33105\" title=\"picture 5B\">",
"      Sturge-Weber syndrome - bilateral PWS infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/51/27454\" title=\"picture 6A\">",
"      Periungual warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/40/16003\" title=\"picture 6B\">",
"      Plantar verrucae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/7/11376\" title=\"picture 6C\">",
"      Verruca vulgaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/2/38958\" title=\"picture 7\">",
"      Pyogenic granuloma 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35493?source=related_link\">",
"      Bloom syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=related_link\">",
"      Congenital melanocytic nevi and speckled lentiginous nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26249?source=related_link\">",
"      Cutaneous warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17975?source=related_link\">",
"      Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=related_link\">",
"      Lower extremity positional deformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34281="Contact dermatitis histology";
var content_f33_30_34281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histopathology of allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epidermal spongiosis and spongiotic vesicles (arrows) are present in this biopsy of allergic contact dermatitis from poison ivy. Infiltrating lymphocytes are apparent in the epidermis, where they effect the cell-mediated delayed hypersensitivity reaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34281=[""].join("\n");
var outline_f33_30_34281=null;
var title_f33_30_34282="Surgical oncologic principles for management of resectable esophageal cancer";
var content_f33_30_34282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical oncologic principles for management of resectable esophageal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Scott Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/30/34282/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/30/34282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal cancer presents as localized disease, defined as adenocarcinoma or squamous cell carcinoma confined to the esophagus, in approximately 22 percent of all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/1\">",
"     1",
"    </a>",
"    ]. Regional disease, which includes spread to regional lymph nodes, accounts for another 30 percent of patients with esophageal cancer. The goal of surgical management is curative, and a surgical resection is the traditional mainstay of multidisciplinary therapy for patients with localized disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical spectrum of esophageal cancer has changed over the last few decades, with an increase in incidence of adenocarcinoma and a decrease of squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Surgical management is independent of histology.",
"   </p>",
"   <p>",
"    The selection criteria and surgical management of patients with esophageal cancer are discussed in this topic. Neoadjuvant and adjuvant chemotherapy and radiation therapy, and management of patients with unresectable esophageal cancer are reviewed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32960253\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The esophagus, approximately 25 to 30 cm in length, is located in the posterior mediastinum and extends from the level of the 7th cervical vertebra to the 11th thoracic vertebra (",
"    <a class=\"graphic graphic_figure graphicRef61563 \" href=\"mobipreview.htm?30/60/31684\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70566 \" href=\"mobipreview.htm?2/21/2390\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55061 \" href=\"mobipreview.htm?25/63/26610\">",
"     figure 3",
"    </a>",
"    ). It is divided into four anatomic areas including cervical, thoracic, lower",
"    <span class=\"nowrap\">",
"     thoracic/esophagogastric",
"    </span>",
"    junction, and the abdominal esophagus (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"mobipreview.htm?4/36/4678\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67045 \" href=\"mobipreview.htm?9/2/9253\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54654 \" href=\"mobipreview.htm?24/16/24838\">",
"     figure 6",
"    </a>",
"    ). The esophagus is composed of the mucosa, submucosa, muscularis externa, and adventitia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73301 \" href=\"mobipreview.htm?37/9/38035\">",
"     image 1",
"    </a>",
"    ). There are three critical anatomic points of narrowing: the cricopharyngeus muscle, the broncho-aortic constriction, and the esophagogastric junction, which are also the most common sites of iatrogenic and mechanical perforation (",
"    <a class=\"graphic graphic_figure graphicRef54206 \" href=\"mobipreview.htm?15/16/15620\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75732 \" href=\"mobipreview.htm?35/53/36689\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arterial supply includes the inferior thyroid artery (cervical esophagus), bronchial arteries and the aorta (thoracic esophagus), and branches of the left gastric artery and inferior phrenic artery (abdominal esophagus) (",
"    <a class=\"graphic graphic_figure graphicRef83473 \" href=\"mobipreview.htm?38/13/39124\">",
"     figure 9",
"    </a>",
"    ). The venous drainage is through the inferior thyroid vein (cervical esophagus); the azygous vein, the hemiazygous vein, or the bronchial veins (thoracic esophagus); and the coronary vein (abdominal esophagus) (",
"    <a class=\"graphic graphic_figure graphicRef83472 \" href=\"mobipreview.htm?16/17/16661\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The esophagus has a rich network of lymphatic channels in the submucosa that can facilitate the longitudinal spread of neoplastic cells along the esophageal wall. Lymphatic drainage is to cervical nodes, tracheobronchial and mediastinal nodes, and gastric and celiac nodes (",
"    <a class=\"graphic graphic_figure graphicRef83471 \" href=\"mobipreview.htm?9/35/9780\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7375097\">",
"    <span class=\"h1\">",
"     HISTOLOGY OF ESOPHAGEAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common histologic types of esophageal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma arises from the cells that line the upper part of the esophagus; adenocarcinoma arises from glandular cells that are present at the junction of the esophagus and stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32960261\">",
"    <span class=\"h1\">",
"     TNM STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union against Cancer (UICC) for esophageal cancer is used universally. The 2010 AJCC TNM staging system recognizes the biologic heterogeneity of the disease, and stages adenocarcinoma and squamous cell carcinoma separately (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"mobipreview.htm?4/35/4668\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'TNM staging criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors arising at the esophagogastric junction (EGJ) or in the cardia of the stomach within 5 cm of the EGJ that extend into the EGJ or esophagus are staged as esophageal rather than gastric cancers (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/13\">",
"     13",
"    </a>",
"    ]. All other tumors with an epicenter in the stomach &gt;5 cm from the EGJ, or those within 5 cm of the EGJ without extension into the esophagus are staged as gastric cancers. The AJCC and Siewert classifications are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H7933267#H7933267\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32960269\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise pretreatment staging guides multidisciplinary management decisions, including a surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/7\">",
"     7",
"    </a>",
"    ]. Pretreatment evaluation, including endoscopic biopsy, computed tomography (CT) of the chest and abdomen, endoscopic ultrasound (EUS), and diagnostic laparoscopy and thoracoscopy, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Preoperative staging evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H944333#H944333\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Pretreatment staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7376975\">",
"    <span class=\"h1\">",
"     SELECTION OF OPERATIVE CANDIDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgical resection was the standard treatment approach for patients with an early esophageal cancer, but its utility as a monotherapy has been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The role of neoadjuvant chemotherapy and radiation therapy as components of multimodality management is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7395532\">",
"    <span class=\"h2\">",
"     Criteria for resection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8510484\">",
"    <span class=\"h3\">",
"     Esophagectomy as first line of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for an esophagectomy as the initial therapeutic approach to the patient with an esophageal cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with clinical T1N0M0 lesions (",
"      <a class=\"graphic graphic_table graphicRef58757 \" href=\"mobipreview.htm?4/35/4668\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with T2N0M0 lesions are candidates in many medical centers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8510491\">",
"    <span class=\"h3\">",
"     Esophagectomy post-adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who tolerate their induction well and have a response by radiographic evaluation and endoscopy are generally candidates for a surgical resection four to six weeks following completion of the chemotherapy or chemoradiotherapy.",
"   </p>",
"   <p>",
"    The indications for induction therapy first, followed by an esophagectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with full-thickness (T3 or T4) involvement of the esophagus",
"      <span class=\"nowrap\">",
"       with/without",
"      </span>",
"      nodal disease",
"     </li>",
"     <li>",
"      Patients with esophageal cancer invasion of local structures (pericardium, pleura,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diaphragm only) that can be resected en bloc, without evidence of metastatic disease to other organs (eg, liver, colon). (See",
"      <a class=\"local\" href=\"#H7383708\">",
"       'Indicators of unresectability'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8510535\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative contraindications to an esophagectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced age &ndash; Advanced age is associated with greater morbidity following esophagectomy. However, age alone should not determine operability as selected elderly patients have similar outcomes to younger patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H178444762#H178444762\">",
"       \"Esophagectomy: Complications and management\", section on 'Increasing age'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Comorbid illness &ndash; Comorbid illnesses increase the risk of postoperative complications (eg, cardiorespiratory complications, anastomotic leakage, reoperation rates, wound infection), and death following esophagectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H178444755#H178444755\">",
"       \"Esophagectomy: Complications and management\", section on 'Comorbid illnesses'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7383708\">",
"    <span class=\"h2\">",
"     Indicators of unresectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of peritoneal, lung, bone, adrenal, brain, or liver metastases, or extraregional lymph node spread (eg, paraaortic or mesenteric lymphadenopathy) precludes an attempt at resection. Celiac nodal metastases and",
"    <span class=\"nowrap\">",
"     mediastinal/supraclavicular",
"    </span>",
"    nodes are scored as regional nodal disease in the 2010 edition of the TNM staging system, regardless of the primary tumor location; it is the number of involved nodes rather than location that determines the N stage (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Regional lymph nodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1459411\">",
"    <span class=\"h1\">",
"     PREOPERATIVE RESPIRATORY REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive preoperative respiratory rehabilitation reduces postoperative pulmonary complications after an esophagectomy. A retrospective cohort study of 100 patients undergoing an esophagectomy found that patients managed with preoperative respiratory rehabilitation (n = 63) for seven days had a lower rate of postoperative pulmonary complications compared with patients not receiving preoperative respiratory rehabilitation (6 versus 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32960293\">",
"    <span class=\"h1\">",
"     OPERATIVE PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7377428\">",
"    <span class=\"h2\">",
"     Cervical esophageal cancer resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the cervical esophagus presents a unique management situation. Because most patients present with advanced disease, a surgical resection usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus. This one-stage, three-phase operation requires cervical, abdominal, and thoracic incisions, and a permanent terminal tracheostomy. In addition, bilateral radical neck dissections are generally performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/17-27\">",
"     17-27",
"    </a>",
"    ]. If there is sufficient margin on the upper esophageal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"mobipreview.htm?4/36/4678\">",
"     figure 4",
"    </a>",
"    ), we perform a tri-incisional esophagectomy with a hand-sewn anastomosis to preserve esophageal length. (See",
"    <a class=\"local\" href=\"#H7378101\">",
"     'Tri-incisional esophagectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Restoration of gastrointestinal tract continuity is accomplished with a gastric pull-up and anastomosis to the pharynx. For tumors confined to the proximal portion of the cervical esophagus, with a sufficient distal resection margin, a free jejunal interposition graft, or a deltopectoral or pectoralis major myocutaneous flap are alternative reconstructive options. Free jejunal grafts are advantageous because this approach avoids mediastinal dissection, although expertise in performing microvascular anastomosis is required. Graft necrosis, fistula formation, and later graft strictures are specific problems. When compared with gastric pull-up procedures, graft survival and leakage rates are similar. Complications of esophageal procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141763#H92141763\">",
"     \"Esophagectomy: Complications and management\", section on 'Conduit-related disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7377436\">",
"    <span class=\"h2\">",
"     Thoracic cancer resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with either adenocarcinoma or squamous cell carcinoma involving the middle or lower third of the esophagus, with the exception of gastroesophageal junction cancers, generally require a total esophagectomy because of the risk of submucosal skip lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In selected cases, such as a superficial or early invasive esophageal cancer arising distally in the setting of Barrett's esophagus, a more limited resection can be performed. However, the optimal surgical approach in these clinical settings is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. If a limited resection is performed, intraoperative histologic analysis of the surgical margins must show no evidence of Barrett's changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophagectomy is a technically difficult operation and the complication rate is high due to the anatomic challenges of the procedure. The choice of surgical approach depends upon many factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor location, length, submucosal extension, and adherence to surrounding structures",
"     </li>",
"     <li>",
"      The type or extent of lymphadenectomy desired",
"     </li>",
"     <li>",
"      The conduit to be used to restore gastrointestinal continuity",
"     </li>",
"     <li>",
"      Postoperative bile reflux",
"     </li>",
"     <li>",
"      The preference of the surgeon",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The transhiatal, Ivor-Lewis (transthoracic), and tri-incisional esophagectomy procedures are the most commonly performed esophagectomies in North America while an esophagectomy and an extended (three-field) lymphadenectomy is performed in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although the gastric interposition is most commonly used as a conduit for reconstruction following esophagectomy, the jejunum or the colon can also be used as the conduit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. These conduits are resistant to the effects of gastric acid, and they have a shape similar to the native esophagus. However, their use requires two additional anastomoses; and in the case of the jejunal interposition, the fixed mesenteric length limits transposition to the proximal esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7378087\">",
"    <span class=\"h3\">",
"     Transhiatal esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transhiatal esophagectomy (THE) can be performed to resect cervical, thoracic, and EGJ esophageal cancers; it is performed through an upper midline laparotomy incision and a left neck incision, typically without a thoracotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/47\">",
"     47",
"    </a>",
"    ]. The thoracic esophagus is bluntly dissected through the diaphragmatic hiatus superiorly and via the neck inferiorly. A cervical anastomosis is created most often with a gastric pull-up approach. Disadvantages include the inability to perform a full thoracic lymphadenectomy and lack of visualization of the midthoracic dissection (",
"    <a class=\"graphic graphic_figure graphicRef83471 \" href=\"mobipreview.htm?9/35/9780\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the largest series of 800 patients, the five-year survival rate was 23 percent, the perioperative mortality rate was 4 percent, and the anastomotic leak rate was 13 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/48\">",
"     48",
"    </a>",
"    ]. Other postoperative complications included atelectasis and pneumonia in 2 percent, and intrathoracic hemorrhage, recurrent laryngeal nerve (RLN) paralysis, chylothorax, and tracheal laceration in &lt;1 percent each. Similar results have been noted in other large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/45,49-51\">",
"     45,49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7378094\">",
"    <span class=\"h3\">",
"     Ivor-Lewis transthoracic esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ivor-Lewis transthoracic esophagectomy can be used to resect cancers in the lower third of the esophagus but is not the optimal approach for cancers located in the middle third because of the limited proximal margin that can be achieved. This procedure combines a laparotomy with a right thoracotomy and an intrathoracic esophagogastric anastomosis. This approach permits direct visualization of the thoracic esophagus and allows the surgeon to perform a full thoracic lymphadenectomy. We prefer a minimally invasive Ivor-Lewis approach to a thoracotomy.",
"   </p>",
"   <p>",
"    Disadvantages of the transthoracic esophagectomy include a limitation to the length of proximal esophagus that can be resected to achieve a histologically negative resection margin, an intrathoracic location of the esophagogastric anastomosis, and a 3 to 20 percent risk of severe bile reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/48,52\">",
"     48,52",
"    </a>",
"    ]. A leak occurring at the intrathoracic anastomosis is associated with morbidity and mortality rates as high as 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/53-58\">",
"     53-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many centers report favorable results using the conventional Ivor-Lewis esophagectomy with a right thoracic anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/51,59-65\">",
"     51,59-65",
"    </a>",
"    ]. Prospective comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/66-71\">",
"     66-71",
"    </a>",
"    ], plus at least one meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/72\">",
"     72",
"    </a>",
"    ], suggest similar long-term outcomes compared with THE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/64\">",
"     64",
"    </a>",
"    ]. In one of the largest series of 228 patients undergoing an Ivor-Lewis subtotal esophagectomy, the perioperative mortality rate was 4 percent, and major respiratory, cardiovascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thromboembolic complications occurred in 17 and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/64\">",
"     64",
"    </a>",
"    ]. Nine patients (4 percent) developed a mediastinal leak, which was anastomotic in five, and due to either an ischemic gastric conduit or gastrotomy dehiscence in the remainder. Only one patient developed a chyle leak. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link\">",
"     \"Esophagectomy: Complications and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89042319\">",
"    <span class=\"h3\">",
"     Modified Ivor-Lewis transthoracic esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modification of the Ivor-Lewis transthoracic esophagectomy includes a left thoracoabdominal incision with a gastric pull-up and an esophagogastric anastomosis in the left chest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/73\">",
"     73",
"    </a>",
"    ]. This approach is most useful for tumors involving the gastroesophageal junction. Only one incision is required, but disadvantages include a high incidence of complications such as postoperative reflux and limitation of the proximal esophageal margin by the aortic arch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7378101\">",
"    <span class=\"h3\">",
"     Tri-incisional esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tri-incisional esophagectomy combines the transhiatal and transthoracic approaches into a transthoracic total esophagectomy with a thoracic lymphadenectomy and cervical esophagogastric anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. The three-incisional technique allows the surgeon to perform a complete two-field (mediastinal and upper abdominal) lymphadenectomy under direct vision and a cervical esophagogastric anastomosis. We prefer a thorascopic approach to the chest rather than a thoracotomy to minimize the risk of respiratory complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H89118810#H89118810\">",
"     \"Esophagectomy: Complications and management\", section on 'Pulmonary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following surgical oncology principles are used to perform a tri-incisional esophagectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracotomy &ndash; A right posterolateral thoracotomy or a thoracoscopy is performed first to assess resectability and exclude local invasion of contiguous structures. An en bloc resection is performed that includes the esophagus and mediastinal (",
"      <a class=\"graphic graphic_figure graphicRef69492 \" href=\"mobipreview.htm?14/38/14948\">",
"       figure 12",
"      </a>",
"      ) and upper abdominal lymph nodes (",
"      <a class=\"graphic graphic_figure graphicRef83510 \" href=\"mobipreview.htm?4/47/4853\">",
"       figure 13",
"      </a>",
"      ), including the right paratracheal, subcarinal, periesophageal and celiac axis lymph nodes.",
"     </li>",
"     <li>",
"      Laparotomy &ndash; The abdomen is explored to exclude metastatic disease, and the stomach is mobilized in preparation for the construction of the gastric conduit.",
"     </li>",
"     <li>",
"      Neck incision &ndash; A left neck exposure is preferred for the esophagogastric anastomosis, since this approach reduces the risk of injury to the recurrent laryngeal nerve (RLN) (",
"      <a class=\"graphic graphic_figure graphicRef64619 \" href=\"mobipreview.htm?28/18/28975\">",
"       figure 14",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/48,59,60,74,79\">",
"       48,59,60,74,79",
"      </a>",
"      ]. The left RLN recurs lower (around the aortic arch) than the right RLN, which recurs around the subclavian artery and is therefore more likely to be injured from a right neck approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages of a neck anastomosis include easier management of a possible anastomotic leak, lower incidence of reflux, more extensive proximal resection margin, and location outside of radiation ports if administered preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141763#H92141763\">",
"     \"Esophagectomy: Complications and management\", section on 'Conduit-related disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our reported series of 250 patients treated with the combined approach, there were no intraoperative deaths, and the perioperative mortality rate was 3.6 percent (9 of 250) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/74\">",
"     74",
"    </a>",
"    ]. The cause of death was pneumonia and progressive respiratory failure in three, aspiration and respiratory arrest in one, pulmonary embolism in two, sepsis in the setting of conduit leak and empyema in one, ischemic bowel and multisystem organ failure in one, and cirrhosis in the setting of ischemic necrosis of the conduit in one. Early postoperative complications occurred in 124 of 250 patients (50 percent); they were considered major in 83, and these are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"     table 1",
"    </a>",
"    ). An anastomotic or conduit leak (from either conduit necrosis or leak from the staple line) occurred in 14 and 5 patients (5.6 and 2 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7377444\">",
"    <span class=\"h2\">",
"     Esophagogastric junction cancer resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal cancers at the esophagogastric junction (EGJ) or intra-abdominal esophagus have been traditionally managed surgically with either an esophagectomy with partial gastrectomy or an extended gastrectomy, with or without thoracotomy (",
"    <a class=\"graphic graphic_figure graphicRef55061 \" href=\"mobipreview.htm?25/63/26610\">",
"     figure 3",
"    </a>",
"    ). Regardless of the approach, complete (R0) resection, a 4 cm (distal) gastric margin, a 5 cm esophageal margin, and resection of at least 15 nodes in basins appropriate for the primary tumor location is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The extent of the esophageal resection that can be achieved transabdominally (transhiatal esophagectomy) is limited, and therefore this approach is not accepted for tumors that involve the distal esophagus due to difficulties in achieving an adequate negative proximal margin.",
"   </p>",
"   <p>",
"    The contemporary operative approach for EGJ cancer is based upon findings from two surgical phase III trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], which randomly assigned patients to the operative procedure on the basis of the Siewert classification of EGJ adenocarcinoma (",
"    <a class=\"graphic graphic_figure graphicRef64783 \" href=\"mobipreview.htm?32/24/33159\">",
"     figure 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III Dutch trial randomly assigned 220 patients with Siewert type I or II EGJ adenocarcinoma to transhiatal esophagectomy (TH) versus extended thoracic resection (transthoracic esophagectomy with an extended en-bloc lymphadenectomy via the right thoracic approach, RTA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/68,82\">",
"       68,82",
"      </a>",
"      ]. In-hospital mortality did not differ between the groups but pulmonary complications and postoperative chylous leakage were significantly more frequent after RTA; in addition, intensive care unit (ICU) and total hospital stays were also longer in this group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Five-year overall survival rates were similar (36 versus 34 percent for RTA and TH, respectively), but there was a trend toward better survival with extended thoracic resection in the patients with a type I tumor (five-year survival 51 versus 37 percent, p = 0.33). The authors concluded that given the greater hazards associated with extended transthoracic resection, it could only be recommended for patients with type I and not type II tumors.",
"     </li>",
"     <li>",
"      A Japanese trial (JCOG 9502) compared transhiatal esophagectomy versus extended esophagectomy using a left thoracoabdominal approach (LTA) for patients with type II or III adenocarcinoma of the EGJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/83\">",
"       83",
"      </a>",
"      ]. Patients in the TH group received a total gastrectomy plus a D2 lymphadenectomy (including splenectomy) and para-aortic lymph node dissection. This approach involved a laparotomy only, and therefore only resection of the lower esophagus. Thoracotomy was utilized only if there was a positive proximal margin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"       \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The patients in the LTA group underwent thorough mediastinal nodal dissection below the left inferior pulmonary vein as well as the same lymphadenectomy procedure in the abdominal cavity as the TH group.",
"      <br/>",
"      <br/>",
"      The trial closed prematurely when a planned interim analysis concluded that it was unlikely that LTA would be significantly better than TH. Five-year survival rate was lower in the LTA group (38 versus 52 percent), although the difference was not statistically significant. In addition, complications were observed more frequently after LTA, and in-hospital mortality was higher (4 versus 0 percent). The authors concluded that LTA could not be recommended for type II or III tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the results of these, the surgical approach for resection is summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Siewert type I tumors should undergo a transthoracic en bloc esophagectomy and partial gastrectomy with two-field lymphadenectomy.",
"     </li>",
"     <li>",
"      Patients with Siewert type II and III tumors should undergo a total gastrectomy with a transhiatal resection of the distal esophagus with lymphadenectomy of the lower mediastinum and an extended lymph node dissection including nodes along the hepatic, left gastric, celiac, and splenic arteries as well as those in the splenic hilum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"       \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The operation should be extended into a transhiatal or transthoracic esophagectomy in the setting of a positive proximal resection margin at frozen section examination. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89045791\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF SURGICAL RESECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191450580\">",
"    <span class=\"h2\">",
"     Operative approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191461974\">",
"    <span class=\"h3\">",
"     Open versus minimally invasive",
"    </span>",
"    &nbsp;&mdash;&nbsp;An esophagectomy can be performed as an open or laparoscopic approach. In addition, a minimally invasive esophagectomy (MIE) can be performed by thoracoscopically resecting the thoracic esophagus and mediastinal nodes, in conjunction with a laparoscopic or laparotomy approach to resecting the intra-abdominal esophagus, stomach, and lymph nodes.",
"   </p>",
"   <p>",
"    The advantages of minimally invasive surgical procedures relative to an open procedure include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smaller incisions",
"     </li>",
"     <li>",
"      Less intraoperative blood loss",
"     </li>",
"     <li>",
"      Fewer postoperative complications",
"     </li>",
"     <li>",
"      Shorter admission to the intensive care unit and overall hospital stay",
"     </li>",
"     <li>",
"      Better preservation of postoperative pulmonary function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Areas of uncertainty include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimal minimally invasive procedure &nbsp;",
"     </li>",
"     <li>",
"      Adequacy of the esophageal and gastric surgical margins",
"     </li>",
"     <li>",
"      Extent of lymph node dissection",
"     </li>",
"     <li>",
"      Safety of minimally invasive esophagectomy in patients who have undergone preoperative radiation therapy",
"     </li>",
"     <li>",
"      Long-term oncologic outcomes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of minimally invasive esophagectomy (MIE) was confirmed by several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/85-95\">",
"     85-95",
"    </a>",
"    ]. However, there is no consensus that MIE is associated with a decrease in 30-day mortality and overall morbidity, as found in the following retrospective and prospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 75,502 esophagectomy procedures (n = 1155 minimally invasive approach) from a population based national data bank found no significant benefits as defined by a decrease in 30-day mortality and overall morbidity (4.3 versus 4.0 percent and 38.0 versus 39.2 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/96\">",
"       96",
"      </a>",
"      ]. The reintervention rate was significantly higher for patients undergoing a minimally invasive esophagectomy (MIE) compared with an open esophagectomy (21.0 versus 17.6 percent).",
"     </li>",
"     <li>",
"      A prospective trial found that patients undergoing a MIE have a better perioperative hospital course. In a randomized trial of 56 patients with esophageal cancer, patients undergoing a MIE had a lower rate of pulmonary infections in-hospital compared with patients undergoing an open esophagectomy (12 versus 34 percent, relative risk [RR] 0.35, 95% CI 0.16-0.78) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/85\">",
"       85",
"      </a>",
"      ]. Patients undergoing a MIE also had a lower perioperative (first two weeks after surgery) rate of pulmonary infections compared with patients undergoing an open esophagectomy (9 versus 29 percent, RR 0.30, 0.12-0.76).",
"     </li>",
"     <li>",
"      A systematic review and meta-analysis of 12 studies of patients undergoing minimally invasive esophagectomy (MIE) or hybrid minimally invasive esophagectomy (HMIE) (n = 672) found no significant difference in 30-day mortality compared with open esophagectomy (n = 612) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/94\">",
"       94",
"      </a>",
"      ]. While there was no significant difference in frequency of anastomotic leak between the MIE and open esophagectomy, patients undergoing a HMIE had significantly fewer leaks compared with the open procedure (OR 0.51 95% CI 0.28-0.91). The minimally invasive procedures were associated with significantly lower blood loss, shorter intensive care unit and hospital stay, and fewer respiratory complications than the open procedure. Patients undergoing a MIE had a 50 percent reduction in total morbidity compared with open surgery, while total morbidity was similar for HMIE procedure and open esophagectomy. The differences between MIE and HMIE may be attributed to the thoracotomy or laparotomy portion of the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consistent difference in outcomes for patients with cancer at the esophagogastric junction (EGJ) or intra-abdominal esophagus managed with either an esophagectomy with partial gastrectomy or an extended gastrectomy, with or without thoracotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/10,80-82,97\">",
"     10,80-82,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7387944\">",
"    <span class=\"h4\">",
"     Total MIE approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total minimally invasive esophagectomy (MIE) is technically feasible, but data for oncologic outcomes are limited due to short follow-up and small number of patients evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/92,93,98-103\">",
"     92,93,98-103",
"    </a>",
"    ]. In the largest series with oncologic outcomes, 70 of 77 attempts to perform a total MIE were successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/92\">",
"     92",
"    </a>",
"    ]. The procedure was abandoned in six patients because of the identification of unsuspected metastatic disease and in one patient with previous extensive upper abdominal surgery that precluded sufficient mobilization of the conduit for a cervical anastomosis. At a median follow-up of 21 months, of the 65 patients who successfully underwent MIE for an invasive esophageal cancer, the two-year overall and disease-free survival rates were 81 and 74 percent, respectively. Recurrence was documented in 14 patients, 11 of which were distant recurrences.",
"   </p>",
"   <p>",
"    Whether these results are at least as good as those achievable following an open esophagectomy is unclear. There are no randomized trials comparing any form of minimally invasive esophagectomy to an open procedure. However, a retrospective Australian series compared outcomes among 114 patients who had open esophagectomy, 309 patients who had thoracoscopic-assisted surgery (TAS), and 23 who had a total MIE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/104\">",
"     104",
"    </a>",
"    ]. There were no differences in the rate of margin positivity or the number of lymph nodes retrieved in any of the groups, and no difference in the time to recurrence or median or three-year overall survival when patients were compared stage for stage.",
"   </p>",
"   <p>",
"    While the data suggest potential for a total MIE approach, this cannot be considered a standard approach. Additional data, particularly regarding long-term complications and oncologic outcomes, are needed before it can be concluded that results are comparable to those seen with open surgical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191460223\">",
"    <span class=\"h4\">",
"     Combined approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thoracoscopic approach to mobilization of the intrathoracic portion of the esophagus and node dissection is an accepted alternative to open thoracotomy in centers with surgeon expertise in these techniques, and when performed in conjunction with open laparotomy for completion of the mobilization and upper abdominal node dissection. This represents the most popular MIE technique with the most extensive published experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/87-91\">",
"     87-91",
"    </a>",
"    ]. Relative contraindications to thoracoscopic surgery include inadequate pulmonary function, extensive pleural adhesions, prior pneumonectomy, bulky tumors, and locally infiltrative tumors, particularly those with airway involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29382338\">",
"    <span class=\"h2\">",
"     Circumferential resection margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic role of a positive circumferential resection margin (CRM) for patients with esophageal cancer was unclear, in part due to a lack of clear definition of a positive margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/105\">",
"     105",
"    </a>",
"    ]. The College of American Pathologists (CAP) defines a positive CRM as the presence of esophageal cancer at the resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/106\">",
"     106",
"    </a>",
"    ]. However, the United Kingdom Royal College of Pathologists (RCP) defines a positive CRM as the presence of esophageal cancer within 1 mm of the resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CAP criteria differentiate a higher-risk group of patients with resectable esophageal cancer than the RCP criteria. A meta-analysis of 14 cohort studies including 3566 patients with resectable esophageal cancer found the overall",
"    <strong>",
"     five-year mortality rates",
"    </strong>",
"    were higher for patients with a positive CRM compared with a negative CRM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/105\">",
"     105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CAP criteria &ndash; 15.3 percent positive margins",
"      <span class=\"nowrap\">",
"       (173/1133),",
"      </span>",
"      OR 4.02, 2.25-7.20, p&lt;0.001",
"     </li>",
"     <li>",
"      RCP criteria &ndash; 36.5 percent positive margins",
"      <span class=\"nowrap\">",
"       (889/2433),",
"      </span>",
"      OR 2.52, 1.96-3.25, p&lt;0.001",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with CRM involvement between 0.1 and 1 mm of the resection margin had a significantly higher five-year mortality rate compared with patients with tumor more than 1 mm of the resection margin (OR 2.05, 1.41-2.99, p&lt;0.001).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7383196\">",
"    <span class=\"h2\">",
"     Extent of lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate extent of lymphadenectomy during esophageal cancer surgery is debated. The minimum number of lymph nodes that should be removed during potentially curative esophagectomy has not been established. However, as many lymph nodes should be removed as is feasible, since more extensive lymphadenectomy has been associated with better survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/40,109-112\">",
"     40,109-112",
"    </a>",
"    ]. For example, in a retrospective review of 972 patients with node negative esophageal cancer, the five-year disease-specific survival was 55 percent when less than 11 nodes were resected, 66 percent for 11 to 17 nodes resected, and 75 percent for 18 or more nodes resected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/109\">",
"     109",
"    </a>",
"    ]. The data suggest that the higher number of nodes retrieved correspond to a more extensive resection.",
"   </p>",
"   <p>",
"    Many high-volume surgical centers routinely perform en-bloc esophagectomy with a two-field (mediastinal, upper abdomen) lymph node dissection in the belief that this contributes to better locoregional control because of removal of metastatic lymph nodes. An even more extensive lymphadenectomy, three-field lymphadenectomy of the mediastinal, abdominal and cervical nodes, is commonly practiced in Asian countries for upper thoracic esophageal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/34-40,113\">",
"     34-40,113",
"    </a>",
"    ]. In a retrospective review of 1361 patients with squamous cell carcinoma of the thoracic esophagus, the frequency of nodal metastasis was neck (9.8 percent), upper mediastinum (18.0 percent), middle mediastinum (18.9 percent), lower mediastinum (11.8 percent), and upper abdomen (28.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/113\">",
"     113",
"    </a>",
"    ]. However, while this approach increases the accuracy of staging, whether local control or survival is improved compared with two-field lymphadenectomy is uncertain.",
"   </p>",
"   <p>",
"    Proponents of extended lymphadenectomy emphasize the relationship between total lymph node count and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/40,110-112\">",
"     40,110-112",
"    </a>",
"    ] and quote long-term survival rates as evidence of its therapeutic benefit. As an example, in one American series of 80 patients undergoing this technique in conjunction with en bloc esophagectomy, the overall five-year survival rate was 51 percent (88 percent for node-negative and 33 percent for node-positive patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/114\">",
"     114",
"    </a>",
"    ]. However, since the extent of lymph node dissection can affect the assignment of the final stage of disease, this resulting stage migration phenomenon hampers a stage-by-stage comparison between different forms of surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/115\">",
"     115",
"    </a>",
"    ]. Furthermore, although unsuspected metastases in the recurrent laryngeal or cervical nodes were detected in 36 percent of patients in the above noted series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/114\">",
"     114",
"    </a>",
"    ], others report a low incidence of cervical nodal recurrence following a two-field lymphadenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/116\">",
"     116",
"    </a>",
"    ]. The location of the tumor (upper versus middle to lower-third) may have an influence on the frequency of finding cervical nodal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two randomized trials have compared different extents of lymphadenectomy during esophageal cancer surgery, although neither provides a conclusive result as to the benefit of extended lymphadenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/82,118\">",
"     82,118",
"    </a>",
"    ]. In the US, en-bloc resection of the mediastinal and upper abdominal lymph nodes is considered a standard component of transthoracic esophagectomy, and a three-field lymphadenectomy is not considered a standard treatment for patients with esophageal cancer. However, if a lymph node dissection is not done, then lymph node sampling should be carried out to accurately stage the patient and to gauge the response to induction treatment in patients enrolled in trials using neoadjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1813059\">",
"    <span class=\"h2\">",
"     Hand-sewn versus stapled anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anastomotic closure techniques include hand-sewn (single versus double layer), stapled (circular versus side-to-side linear), and hybrid linear stapled technique, with surgeon experience likely being the most important determinant at present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/119-128\">",
"     119-128",
"    </a>",
"    ]. For example, in a meta-analysis of 12 randomized controlled trials that included 1407 patients, the rate of anastomotic leak was similar for a circular stapled anastomosis compared with a hand-sewn anastomosis (odds ratio [OR] 1.02, 95% CI 0.66-1.59) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/128\">",
"     128",
"    </a>",
"    ]. However, a stapled anastomosis was associated with a significantly higher rate of anastomotic stricture (OR 1.67, 1.16-2.42).",
"   </p>",
"   <p>",
"    A hybrid linear stapled technique was developed in the 1990&rsquo;s which demonstrated a 65 percent increase in the anastomotic cross-sectional area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/125\">",
"     125",
"    </a>",
"    ], and reduced morbidity for patients undergoing a cervical esophagogastric anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/127\">",
"     127",
"    </a>",
"    ]. In a review of 274 patients, those undergoing a hybrid anastomosis (modified Collard technique, n = 86 patients) had fewer cervical wound infections compared with patients undergoing a hand-sewn anastomosis (8 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/127\">",
"     127",
"    </a>",
"    ]. Patients undergoing a hybrid anastomosis had a statistically similar leak rate, but required fewer anastomotic dilatations (4 versus 11 percent, mean 2.4 versus 4.1 per patient, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1813131\">",
"    <span class=\"h2\">",
"     Cervical versus thoracic anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed using a standardized technique, cervical and thoracic esophagogastric anastomoses are equally safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/121,129\">",
"     121,129",
"    </a>",
"    ]. In a randomized trial of 83 patients undergoing an esophagogastric anastomosis, the additional 5 cm esophageal resection to permit a cervical esophagogastric anastomosis did not increase tumor removal and survival or adversely influence morbidity, anastomotic diameter, or body weight development compared with a thoracic esophagogastric anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the choice of anastomotic location remains clinician dependent. A cervical anastomosis has a higher leak rate and risk of injury to the recurrent laryngeal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/71,121\">",
"     71,121",
"    </a>",
"    ]. However, the anatomic confines of the neck and thoracic inlet limit surrounding tissue contamination and, thus, limit morbidity. A systematic review of four clinical trials that included 267 patients found that patients undergoing a cervical esophagogastric anastomosis (n = 132) had a higher rate of anastomotic leak compared with those undergoing a thoracic esophagogastric anastomosis (18 versus 4 percent, odds ratio [OR] 3.43, 95% CI 1.09-10.78) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/121\">",
"     121",
"    </a>",
"    ]. A cervical esophagogastric anastomosis has a significantly higher rate of recurrent laryngeal nerve injury (OR 7.14, 1.75-29.14), but there was no difference in rate of pulmonary complications, perioperative mortality, benign stricture formation, or tumor recurrence at the anastomotic site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141770#H92141770\">",
"     \"Esophagectomy: Complications and management\", section on 'Anastomotic leak'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, utilizing the SEER database, a retrospective cohort review was performed comparing 225 transhiatal resections to 643 transthoracic resections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/71\">",
"     71",
"    </a>",
"    ]. The unadjusted anastomotic complication rate, identified by need for postoperative endoscopic dilation, was higher (43.1 versus 34.5 percent; P = 0.02) in the transhiatal group; however, there was no significant difference in risk-adjusted five-year survival between groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191451188\">",
"    <span class=\"h2\">",
"     Orthotopic placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic placement of the neoesophagus in the posterior mediastinum is generally preferred by most thoracic surgeons. A meta-analysis of trials comparing the posterior mediastinal route and the retrosternal route was performed, and was unable to demonstrate any difference in postoperative morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/130\">",
"     130",
"    </a>",
"    ]. Other series, however, have revealed a higher anastomotic leak rate in the retrosternal route, likely due to increased length requirements for the conduit as well as compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. Conduit choice may also affect anastomotic integrity, although the majority of surgeons presently prefer the stomach due to its ease of preparation, robust blood supply, and sufficient length, with alternative conduits including colon and jejunum only being chosen out of necessity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191454073\">",
"    <span class=\"h2\">",
"     Role of pyloroplasty or pyloromyotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of a pyloroplasty or pyloromyotomy to reduce the risk of gastric outlet obstruction following a gastric pull-up procedure has been challenged by prospective studies and randomized trials, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 242 patients undergoing an esophagectomy with gastric conduit found that patients with a pyloromyotomy (n = 159) did not have significantly lower rates of gastric outlet obstruction compared with those without a pyloromyotomy (9.6 versus 18.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/134\">",
"       134",
"      </a>",
"      ]. In addition, there was no significant difference for rates of pneumonia or mortality (27.7 versus 19.5 percent, and 2.4 versus 2.5 percent, respectively). Management with pyloric dilation was effective in relieving symptoms in approximately 97 percent of symptomatic patients.",
"     </li>",
"     <li>",
"      A meta-analysis of nine trials and 553 esophagectomy patients randomized to pyloromyotomy versus none found a lower risk of gastric outlet obstruction for patients treated with a pyloromyotomy (OR 0.18, 0.03-0.97, p&lt;0.046) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/135\">",
"       135",
"      </a>",
"      ]. There was no difference for operative mortality, esophagogastric anastomotic leaks, pulmonary morbidity, or fatal pulmonary aspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Functional conduit disorders and their management are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141810#H92141810\">",
"     \"Esophagectomy: Complications and management\", section on 'Functional conduit disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191450878\">",
"    <span class=\"h2\">",
"     Recurrent laryngeal nerve identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent laryngeal nerve (RLN) injury can occur during dissection of the cervical and thoracic esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/48,59,60,79\">",
"     48,59,60,79",
"    </a>",
"    ]. Rates of injury range from 2 to 17 percent, and occur more commonly when a cervical approach is utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/74,131,136,137\">",
"     74,131,136,137",
"    </a>",
"    ]. Principles for the avoidance of RLN injury include precise knowledge of cervical esophageal anatomy (",
"    <a class=\"graphic graphic_figure graphicRef74541 \" href=\"mobipreview.htm?23/37/24146\">",
"     figure 16",
"    </a>",
"    ), maintaining the plane of dissection as close as possible to the esophagus, and avoidance of metal or rigid retractors along the tracheoesophageal groove.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191465190\">",
"    <span class=\"h2\">",
"     Jejunal feeding tube placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A feeding jejunostomy tube is inserted at the time of the surgical resection for all patients undergoing an esophagectomy and for select patients who require nutritional support during induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. The jejunostomy tube is inserted 40 cm distal to the ligament of Treitz, using either a laparoscopic approach if technically feasible or through a small laparotomy incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7393650\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral feedings are started on postoperative day two and slowly advanced until feeding goals are attained at approximately postoperative day five. A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow is performed on postoperative day seven to evaluate for leak and emptying of the conduit. The nasogastric tube generally remains in place until the barium swallow is performed and demonstrates no anastomotic leak. Patients are maintained on a minimal liquid diet for approximately two weeks to allow the conduit to remain decompressed and straight in the mediastinum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141763#H92141763\">",
"     \"Esophagectomy: Complications and management\", section on 'Conduit-related disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures to reduce the risk of postoperative cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac arrest have included perioperative beta blockade, although the results of the Perioperative Ischemic Evaluation (POISE) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/138\">",
"     138",
"    </a>",
"    ] have generated some measure of caution for this practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/139\">",
"     139",
"    </a>",
"    ]. In a randomized trial that included 8351 patients with, or at high risk of, atherosclerotic disease and scheduled for a noncardiac operation, patients receiving extended-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate had a higher mortality rate compared with patients receiving a placebo (3.1 versus 2.3 percent, hazards ratio [HR] 1.33, 95% CI 1.03-1.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/138\">",
"     138",
"    </a>",
"    ]. In addition, the risk of a cardiovascular accident (stroke) was also higher for the patients receiving metoprolol (1.0 versus 0.5 percent, HR 2.17, 1.26-3.74). We prefer not to routinely use beta-blockers for patients who have a minimally invasive esophagectomy since their risk of atrial fibrillation is low.",
"   </p>",
"   <p>",
"    The guidelines for the perioperative management of patients with cardiac disease, including the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Chest Physicians Guidelines on the Prevention of Venous Thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/140\">",
"     140",
"    </a>",
"    ] classified esophagectomy as a high-risk procedure, and thus recommends postoperative thromboprophylaxis with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , unfractionated subcutaneous heparin three times daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    . Conversely, some would classify esophagectomy as high-risk for bleeding, especially in the setting of blunt mediastinal dissection, and thus argue for less aggressive prophylaxis. Further complicating the matter is the frequent use of neuraxial anesthesia, which further limits the use of perioperative anticoagulants for thromboprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/141\">",
"     141",
"    </a>",
"    ]. Unfortunately, a paucity of data exist to help clarify these issues and, therefore, clinical practice varies. We use subcutaneous heparin and pneumatic boots beginning in the operating room and continuing until postoperative day seven or until they are ambulatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7389764\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An esophagectomy can exert temporary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/142-149\">",
"     142-149",
"    </a>",
"    ] and long-term detrimental impacts on health-related quality-of-life (HR-QOL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/146,148,150-152\">",
"     146,148,150-152",
"    </a>",
"    ]. In most patients, recovery seems to occur within 12 to 24 months, but even after three or more years, a substantial number of long-term survivors still report residual problems with eating, breathlessness, diarrhea, reflux, fatigue, and odynophagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/146,148,150,151\">",
"     146,148,150,151",
"    </a>",
"    ]. In a self-reported quality-of-life study among 117 long-term-year survivors of esophageal cancer surgery, physical function was stable or improved at five years in 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of HR-QOL may be related, at least in part, to the occurrence of postoperative complications. A prospective study that included 141 five-year survivors following an esophagectomy for cancer found that patients who sustained a major postoperative complication (eg, pneumonia, anastomotic leak) (n = 46) had clinically and statistically significant more dyspnea compared with patients who did not have a major complication (mean score difference 15, 95% CI 6-23) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/30/34282/abstract/152\">",
"     152",
"    </a>",
"    ]. Patients with major postoperative complications also had significantly more fatigue and eating restrictions (mean score difference 13, 5-20, and mean score difference 10, 2-17, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32960317\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical spectrum of esophageal cancer has changed over the last few decades, with an increase in incidence of adenocarcinoma in the distal esophagus and a decrease in squamous cell carcinoma. However, patients with squamous cell carcinoma and adenocarcinoma are managed similarly from an operative point of view. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection criteria for eligibility for a surgical resection include localized T1 to T3 lesions and select T4 lesions that involve the pericardium, pleura, or diaphragm. (See",
"      <a class=\"local\" href=\"#H7395532\">",
"       'Criteria for resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because most patients with a cervical esophageal cancer present with advanced disease, a surgical resection usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus. If there is sufficient margin on the upper esophageal sphincter, we perform a tri-incisional esophagectomy with a hand-sewn anastomosis to preserve esophageal length. (See",
"      <a class=\"local\" href=\"#H7377428\">",
"       'Cervical esophageal cancer resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a thoracic esophageal cancer, we perform a total thoracic esophagectomy with cervical esophagogastrostomy, radical two-field lymph node dissection, and jejunostomy feeding tube placement. (See",
"      <a class=\"local\" href=\"#H7377436\">",
"       'Thoracic cancer resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally prefer a tri-incisional approach that consists of initial right posterolateral thoracotomy or thoracoscopic approach, followed by a laparotomy to obtain complete esophageal dissection and mobilization of the gastric conduit, en bloc resection of both mediastinal and upper abdominal lymph nodes, and a left neck incision and cervical anastomosis. (See",
"      <a class=\"local\" href=\"#H7378101\">",
"       'Tri-incisional esophagectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an esophageal gastric junction cancer, we generally perform a total esophagectomy with cervical esophagogastrostomy with a partial gastrectomy or an extended gastrectomy, depending upon the extensiveness of the gastric involvement. An alternative to the total esophagectomy is the minimally invasive Ivor-Lewis procedure, with a thoracic esophagogastrostomy. However, there are insufficient data from randomized trials to determine the superiority of one approach over the other.(See",
"      <a class=\"local\" href=\"#H7377444\">",
"       'Esophagogastric junction cancer resection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=see_link&amp;anchor=H92141763#H92141763\">",
"       \"Esophagectomy: Complications and management\", section on 'Conduit-related disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The integration of surgery into multimodality treatment of localized cancer of the esophagus is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Stat Fact Sheets: Esophagus; Survival and Stage. seer.cancer.gov/statfacts/html/esoph.html#survival (Accessed on May 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/2\">",
"      D'Amico TA. Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007; 1:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/3\">",
"      Hirst J, Smithers BM, Gotley DC, et al. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 2011; 18:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/4\">",
"      Miyata H, Yamasaki M, Kurokawa Y, et al. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg 2011; 59:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/5\">",
"      Ajani J, D'Amico TA, Hayman JA, et al. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2003; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/6\">",
"      Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/7\">",
"      Roth JA. Treatment of esophageal cancer: does surgery make the cut? Gastrointest Cancer Res 2007; 1:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/8\">",
"      Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 2012; 16:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/9\">",
"      McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep 2012; 14:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/10\">",
"      Narsule CK, Montgomery MM, Fernando HC. Evidence-based review of the management of cancers of the gastroesophageal junction. Thorac Surg Clin 2012; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/11\">",
"      Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/12\">",
"      Cooke DT, Lau CL. Primary repair of esophageal perforation. Operative Techniques in Thoracic and Cardiovascular Surgery 2008; 13:126.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge S, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/14\">",
"      O'Reilly S, Forastiere AA. Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol 1995; 6:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/15\">",
"      Coia LR. Esophageal cancer: is esophagectomy necessary? Oncology (Williston Park) 1989; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/16\">",
"      Inoue J, Ono R, Makiura D, et al. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer. Dis Esophagus 2013; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/17\">",
"      Affleck DG, Karwande SV, Bull DA, et al. Functional outcome and survival after pharyngolaryngoesophagectomy for cancer. Am J Surg 2000; 180:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/18\">",
"      Mansour KA, Picone AL, Coleman JJ 3rd. Surgery for high cervical esophageal carcinoma: experience with 11 patients. Ann Thorac Surg 1990; 49:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/19\">",
"      Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 2001; 136:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/20\">",
"      Wei WI, Lam LK, Yuen PW, Wong J. Current status of pharyngolaryngo-esophagectomy and pharyngogastric anastomosis. Head Neck 1998; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/21\">",
"      Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol 2006; 93:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/22\">",
"      Peracchia A, Bonavina L, Botturi M, et al. Current status of surgery for carcinoma of the hypopharynx and cervical esophagus. Dis Esophagus 2001; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/23\">",
"      Saito R, Suzuki H, Motoyama S, et al. A clinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus. Jpn J Thorac Cardiovasc Surg 2000; 48:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/24\">",
"      Amatsu M, Mohri M, Kinishi M. Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus. Laryngoscope 2001; 111:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/25\">",
"      Kelley DJ, Wolf R, Shaha AR, et al. Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus. Am J Surg 1995; 170:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/26\">",
"      Daiko H, Hayashi R, Saikawa M, et al. Surgical management of carcinoma of the cervical esophagus. J Surg Oncol 2007; 96:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/27\">",
"      Ott K, Lordick F, Molls M, et al. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 2009; 96:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/28\">",
"      Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/29\">",
"      Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg 1999; 117:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/30\">",
"      Kato H, Tachimori Y, Watanabe H, et al. Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer 1992; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/31\">",
"      Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg 2007; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/32\">",
"      Korst RJ, Altorki NK. Extent of resection and lymphadenectomy in early Barrett's cancer. Dis Esophagus 1997; 10:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/33\">",
"      Collard JM, Romagnoli R, Hermans BP, Malaise J. Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus. Am J Surg 1997; 174:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/34\">",
"      Igaki H, Kato H, Tachimori Y, et al. Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 2001; 19:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/35\">",
"      Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995; 222:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/36\">",
"      Osugi H, Takemura M, Takada N, et al. Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer. Br J Surg 2002; 89:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/37\">",
"      Watanabe H, Kato H, Tachimori Y. Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res 2000; 155:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/38\">",
"      Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005; 189:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/39\">",
"      Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol 2010; 5:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/40\">",
"      Hsu PK, Wang BY, Chou TY, et al. The total number of resected lymph node is not a prognostic factor for recurrence in esophageal squamous cell carcinoma patients undergone transthoracic esophagectomy. J Surg Oncol 2011; 103:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/41\">",
"      Cense HA, Visser MR, van Sandick JW, et al. Quality of life after colon interposition by necessity for esophageal cancer replacement. J Surg Oncol 2004; 88:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/42\">",
"      Mansour KA, Bryan FC, Carlson GW. Bowel interposition for esophageal replacement: twenty-five-year experience. Ann Thorac Surg 1997; 64:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/43\">",
"      Davis PA, Law S, Wong J. Colonic interposition after esophagectomy for cancer. Arch Surg 2003; 138:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/44\">",
"      DeMeester SR. Colon interposition following esophagectomy. Dis Esophagus 2001; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/45\">",
"      Rao YG, Pal S, Pande GK, et al. Transhiatal esophagectomy for benign and malignant conditions. Am J Surg 2002; 184:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/46\">",
"      Swisher SG, Hofstetter WL, Miller MJ. The supercharged microvascular jejunal interposition. Semin Thorac Cardiovasc Surg 2007; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/47\">",
"      Ellis FH Jr, Gibb SP, Watkins E Jr. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia. Ann Surg 1983; 198:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/48\">",
"      Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/49\">",
"      Macha M, Whyte RI. The current role of transhiatal esophagectomy. Chest Surg Clin N Am 2000; 10:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/50\">",
"      van Sandick JW, van Lanschot JJ, ten Kate FJ, et al. Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg 2002; 194:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/51\">",
"      Pa&ccedil; M, Ba��oglu A, Ko&ccedil;ak H, et al. Transhiatal versus transthoracic esophagectomy for esophageal cancer. J Thorac Cardiovasc Surg 1993; 106:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/52\">",
"      Baba M, Aikou T, Natsugoe S, et al. Appraisal of ten-year survival following esophagectomy for carcinoma of the esophagus with emphasis on quality of life. World J Surg 1997; 21:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/53\">",
"      Urschel JD. Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg 1995; 169:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/54\">",
"      M&uuml;ller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/55\">",
"      Patil PK, Patel SG, Mistry RC, et al. Cancer of the esophagus: esophagogastric anastomotic leak--a retrospective study of predisposing factors. J Surg Oncol 1992; 49:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/56\">",
"      Agrawal S, Deshmukh SP, Patil PK, et al. Intrathoracic anastomosis after oesophageal resection for cancer. J Surg Oncol 1996; 63:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/57\">",
"      Whooley BP, Law S, Alexandrou A, et al. Critical appraisal of the significance of intrathoracic anastomotic leakage after esophagectomy for cancer. Am J Surg 2001; 181:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/58\">",
"      Griffin SM, Lamb PJ, Dresner SM, et al. Diagnosis and management of a mediastinal leak following radical oesophagectomy. Br J Surg 2001; 88:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/59\">",
"      Mathisen DJ, Grillo HC, Wilkins EW Jr, et al. Transthoracic esophagectomy: a safe approach to carcinoma of the esophagus. Ann Thorac Surg 1988; 45:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/60\">",
"      Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997; 113:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/61\">",
"      Akiyama H, Tsurumaru M, Watanabe G, et al. Development of surgery for carcinoma of the esophagus. Am J Surg 1984; 147:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/62\">",
"      Turnbull AD, Ginsberg RJ. Options in the surgical treatment of esophageal carcinoma. Chest Surg Clin N Am 1994; 4:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/63\">",
"      Visbal AL, Allen MS, Miller DL, et al. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/64\">",
"      Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management. J Am Coll Surg 2002; 194:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/65\">",
"      Boyle MJ, Franceschi D, Livingstone AS. Transhiatal versus transthoracic esophagectomy: complication and survival rates. Am Surg 1999; 65:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/66\">",
"      Stark SP, Romberg MS, Pierce GE, et al. Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Am J Surg 1996; 172:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/67\">",
"      Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997; 174:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/68\">",
"      Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/69\">",
"      Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993; 80:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/70\">",
"      Rentz J, Bull D, Harpole D, et al. Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. J Thorac Cardiovasc Surg 2003; 125:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/71\">",
"      Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/72\">",
"      Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/73\">",
"      Krasna MJ. Left transthoracic esophagectomy. Chest Surg Clin N Am 1995; 5:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/74\">",
"      Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001; 72:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/75\">",
"      Swanson SJ, Sugarbaker DJ. The three-hole esophagectomy. The Brigham and Women's Hospital approach (modified McKeown technique). Chest Surg Clin N Am 2000; 10:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/76\">",
"      McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus. Br J Surg 1976; 63:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/77\">",
"      McKeown KC. The surgical treatment of carcinoma of the oesophagus. A review of the results in 478 cases. J R Coll Surg Edinb 1985; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/78\">",
"      Finley FJ, Lamy A, Clifton J, et al. Gastrointestinal function following esophagectomy for malignancy. Am J Surg 1995; 169:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/79\">",
"      Vigneswaran WT, Trastek VF, Pairolero PC, et al. Transhiatal esophagectomy for carcinoma of the esophagus. Ann Thorac Surg 1993; 56:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/80\">",
"      Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg 2004; 199:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/81\">",
"      Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007; 246:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/82\">",
"      Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/83\">",
"      Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/84\">",
"      Schiesser M, Schneider PM. Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010; 182:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/85\">",
"      Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/86\">",
"      Santillan AA, Farma JM, Meredith KL, et al. Minimally invasive surgery for esophageal cancer. J Natl Compr Canc Netw 2008; 6:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/87\">",
"      Law S, Fok M, Chu KM, Wong J. Thoracoscopic esophagectomy for esophageal cancer. Surgery 1997; 122:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/88\">",
"      Yamamoto S, Kawahara K, Maekawa T, et al. Minimally invasive esophagectomy for stage I and II esophageal cancer. Ann Thorac Surg 2005; 80:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/89\">",
"      Akaishi T, Kaneda I, Higuchi N, et al. Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy. J Thorac Cardiovasc Surg 1996; 112:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/90\">",
"      Osugi H, Takemura M, Higashino M, et al. A comparison of video-assisted thoracoscopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation. Br J Surg 2003; 90:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/91\">",
"      Smithers BM, Gotley DC, McEwan D, et al. Thoracoscopic mobilization of the esophagus. A 6 year experience. Surg Endosc 2001; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/92\">",
"      Berrisford RG, Wajed SA, Sanders D, Rucklidge MW. Short-term outcomes following total minimally invasive oesophagectomy. Br J Surg 2008; 95:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/93\">",
"      Roig-Garc&iacute;a J, Giron&eacute;s-Vil&agrave; J, Garsot-Savall E, et al. [Transthoracic and transhiatal esophagectomy using minimally invasive techniques. Experience in 50 patients]. Cir Esp 2008; 83:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/94\">",
"      Nagpal K, Ahmed K, Vats A, et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc 2010; 24:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/95\">",
"      Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg 2012; 147:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/96\">",
"      Mamidanna R, Bottle A, Aylin P, et al. Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg 2012; 255:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/97\">",
"      Johansson J, Djerf P, Oberg S, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg 2008; 32:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/98\">",
"      Dapri G, Himpens J, Cadi&egrave;re GB. Minimally invasive esophagectomy for cancer: laparoscopic transhiatal procedure or thoracoscopy in prone position followed by laparoscopy? Surg Endosc 2008; 22:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/99\">",
"      Galvani CA, Gorodner MV, Moser F, et al. Robotically assisted laparoscopic transhiatal esophagectomy. Surg Endosc 2008; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/100\">",
"      Braghetto I, Csendes A, Cardemil G, et al. Open transthoracic or transhiatal esophagectomy versus minimally invasive esophagectomy in terms of morbidity, mortality and survival. Surg Endosc 2006; 20:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/101\">",
"      Avital S, Zundel N, Szomstein S, Rosenthal R. Laparoscopic transhiatal esophagectomy for esophageal cancer. Am J Surg 2005; 190:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/102\">",
"      Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003; 238:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/103\">",
"      Singh RK, Pham TH, Diggs BS, et al. Minimally invasive esophagectomy provides equivalent oncologic outcomes to open esophagectomy for locally advanced (stage II or III) esophageal carcinoma. Arch Surg 2011; 146:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/104\">",
"      Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007; 245:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/105\">",
"      Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg 2013; 100:456.",
"     </a>",
"    </li>",
"    <li>",
"     College of American Pathologists. Surgical Pathology Cancer Case Summary (Checklist): Esophagus. College of American Pathologists: Northfield, 2005.",
"    </li>",
"    <li>",
"     Mapstone N. Minimum Dataset for Oeophageal Carcinoma Histopathology Reports (1st edn). Royal College of Pathologists: London, 1998.",
"    </li>",
"    <li>",
"     Mapstone N. Dataset for the Histopathological Reporting of Oesophageal Carcinoma (2nd edn). Royal College of Pathologists: London, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/109\">",
"      Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008; 112:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/110\">",
"      Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 2007; 11:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/111\">",
"      Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/112\">",
"      Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010; 251:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/113\">",
"      Li B, Chen H, Xiang J, et al. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. J Thorac Cardiovasc Surg 2012; 144:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/114\">",
"      Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/115\">",
"      Hulscher JB, Van Sandick JW, Offerhaus GJ, et al. Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the oesophagus or gastric cardia. Br J Surg 2001; 88:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/116\">",
"      Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/117\">",
"      Fujita H, Sueyoshi S, Tanaka T, et al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003; 27:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/118\">",
"      Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998; 175:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/119\">",
"      Saluja SS, Ray S, Pal S, et al. Randomized trial comparing side-to-side stapled and hand-sewn esophagogastric anastomosis in neck. J Gastrointest Surg 2012; 16:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/120\">",
"      Kim RH, Takabe K. Methods of esophagogastric anastomoses following esophagectomy for cancer: A systematic review. J Surg Oncol 2010; 101:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/121\">",
"      Biere SS, Maas KW, Cuesta MA, van der Peet DL. Cervical or thoracic anastomosis after esophagectomy for cancer: a systematic review and meta-analysis. Dig Surg 2011; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/122\">",
"      Law S, Fok M, Chu KM, Wong J. Comparison of hand-sewn and stapled esophagogastric anastomosis after esophageal resection for cancer: a prospective randomized controlled trial. Ann Surg 1997; 226:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/123\">",
"      Hsu HH, Chen JS, Huang PM, et al. Comparison of manual and mechanical cervical esophagogastric anastomosis after esophageal resection for squamous cell carcinoma: a prospective randomized controlled trial. Eur J Cardiothorac Surg 2004; 25:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/124\">",
"      Beitler AL, Urschel JD. Comparison of stapled and hand-sewn esophagogastric anastomoses. Am J Surg 1998; 175:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/125\">",
"      Collard JM, Romagnoli R, Goncette L, et al. Terminalized semimechanical side-to-side suture technique for cervical esophagogastrostomy. Ann Thorac Surg 1998; 65:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/126\">",
"      Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg 2000; 119:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/127\">",
"      Ercan S, Rice TW, Murthy SC, et al. Does esophagogastric anastomotic technique influence the outcome of patients with esophageal cancer? J Thorac Cardiovasc Surg 2005; 129:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/128\">",
"      Honda M, Kuriyama A, Noma H, et al. Hand-sewn versus mechanical esophagogastric anastomosis after esophagectomy: a systematic review and meta-analysis. Ann Surg 2013; 257:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/129\">",
"      Walther B, Johansson J, Johnsson F, et al. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg 2003; 238:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/130\">",
"      Urschel JD, Urschel DM, Miller JD, et al. A meta-analysis of randomized controlled trials of route of reconstruction after esophagectomy for cancer. Am J Surg 2001; 182:470.",
"     </a>",
"    </li>",
"    <li>",
"     Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. Sep 2007; 246:363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/132\">",
"      Collard JM, Tinton N, Malaise J, et al. Esophageal replacement: gastric tube or whole stomach? Ann Thorac Surg 1995; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/133\">",
"      Ngan SY, Wong J. Lengths of different routes for esophageal replacement. J Thorac Cardiovasc Surg 1986; 91:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/134\">",
"      Lanuti M, de Delva PE, Wright CD, et al. Post-esophagectomy gastric outlet obstruction: role of pyloromyotomy and management with endoscopic pyloric dilatation. Eur J Cardiothorac Surg 2007; 31:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/135\">",
"      Urschel JD, Blewett CJ, Young JE, et al. Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. Dig Surg 2002; 19:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/136\">",
"      Atkins BZ, Shah AS, Hutcheson KA, et al. Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg 2004; 78:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/137\">",
"      Gockel I, Kneist W, Keilmann A, Junginger T. Recurrent laryngeal nerve paralysis (RLNP) following esophagectomy for carcinoma. Eur J Surg Oncol 2005; 31:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/138\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/139\">",
"      Devereaux PJ, Guyatt G, Yang H, et al. Essay for the CIHR/CMAJ award: impact of the Perioperative Ischemic Evaluation (POISE) trial. CMAJ 2011; 183:E351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/140\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/141\">",
"      Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/142\">",
"      Blazeby JM, Sanford E, Falk SJ, et al. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2005; 103:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/143\">",
"      Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000; 88:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/144\">",
"      de Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004; 22:4202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/145\">",
"      Reynolds JV, McLaughlin R, Moore J, et al. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 2006; 93:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/146\">",
"      Viklund P, Wengstr&ouml;m Y, Rouvelas I, et al. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006; 42:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/147\">",
"      Parameswaran R, McNair A, Avery KN, et al. The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review. Ann Surg Oncol 2008; 15:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/148\">",
"      Dj&auml;rv T, Lagergren J, Blazeby JM, Lagergren P. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008; 95:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/149\">",
"      Dj&auml;rv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life after esophagectomy for cancer. J Clin Oncol 2009; 27:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/150\">",
"      Gockel I, G&ouml;nner U, Domeyer M, et al. Long-term survivors of esophageal cancer: disease-specific quality of life, general health and complications. J Surg Oncol 2010; 102:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/151\">",
"      Hurmuzlu M, Aarstad HJ, Aarstad AK, et al. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. Dis Esophagus 2011; 24:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/152\">",
"      Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol 2012; 30:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/30/34282/abstract/153\">",
"      Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 2012; 30:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2530 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-7BCA055868-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34282=[""].join("\n");
var outline_f33_30_34282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32960317\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32960253\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7375097\">",
"      HISTOLOGY OF ESOPHAGEAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32960261\">",
"      TNM STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32960269\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7376975\">",
"      SELECTION OF OPERATIVE CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7395532\">",
"      Criteria for resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8510484\">",
"      - Esophagectomy as first line of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8510491\">",
"      - Esophagectomy post-adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8510535\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7383708\">",
"      Indicators of unresectability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1459411\">",
"      PREOPERATIVE RESPIRATORY REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32960293\">",
"      OPERATIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7377428\">",
"      Cervical esophageal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7377436\">",
"      Thoracic cancer resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7378087\">",
"      - Transhiatal esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7378094\">",
"      - Ivor-Lewis transthoracic esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89042319\">",
"      - Modified Ivor-Lewis transthoracic esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7378101\">",
"      - Tri-incisional esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7377444\">",
"      Esophagogastric junction cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89045791\">",
"      PRINCIPLES OF SURGICAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191450580\">",
"      Operative approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H191461974\">",
"      - Open versus minimally invasive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7387944\">",
"      Total MIE approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H191460223\">",
"      Combined approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29382338\">",
"      Circumferential resection margin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7383196\">",
"      Extent of lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1813059\">",
"      Hand-sewn versus stapled anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1813131\">",
"      Cervical versus thoracic anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191451188\">",
"      Orthotopic placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191454073\">",
"      Role of pyloroplasty or pyloromyotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191450878\">",
"      Recurrent laryngeal nerve identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191465190\">",
"      Jejunal feeding tube placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7393650\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7389764\">",
"      QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32960317\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2530|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/9/38035\" title=\"diagnostic image 1\">",
"      EUS five layer pattern",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2530|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/60/31684\" title=\"figure 1\">",
"      Anatomy of the thoracic esophagus anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/21/2390\" title=\"figure 2\">",
"      Anatomy of the thoracic esophagus posterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/63/26610\" title=\"figure 3\">",
"      Anatomy of the intra-abdominal esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/36/4678\" title=\"figure 4\">",
"      AJCC diagram of the esophageal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/2/9253\" title=\"figure 5\">",
"      Anatomy of the cervical esophagus - longitudinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/16/24838\" title=\"figure 6\">",
"      Anatomy of the cervical esophagus - cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/16/15620\" title=\"figure 7\">",
"      Anatomy of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/53/36689\" title=\"figure 8\">",
"      Perforation of the cervical esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/13/39124\" title=\"figure 9\">",
"      Blood supply of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/17/16661\" title=\"figure 10\">",
"      Venous drainage of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/35/9780\" title=\"figure 11\">",
"      Lymphatic drainage of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/38/14948\" title=\"figure 12\">",
"      Thoracic lymph nodes - Posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/47/4853\" title=\"figure 13\">",
"      Lymphatic drainage of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/18/28975\" title=\"figure 14\">",
"      Mobilization of the cervical esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/24/33159\" title=\"figure 15\">",
"      Definition and extent of resection for adenocarcinoma of the EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/37/24146\" title=\"figure 16\">",
"      Dissection of recurrent laryngeal nerve lateral view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/38/13934\" title=\"table 1\">",
"      TNM staging esoph SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/35/4668\" title=\"table 2\">",
"      T stage esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/24/4494\" title=\"table 3\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/29/43481?source=related_link\">",
"      Esophagectomy: Complications and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_30_34283="NCI CTCAE v40 grading for thromboembolism";
var content_f33_30_34283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cancer Institute Common Terminology Criteria for a thromboembolic event* (CTCAE v 4.0)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td>",
"        Venous thrombosis (eg, superficial thrombosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td>",
"        Venous thrombosis (eg, uncomplicated deep vein thrombosis), medical intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td>",
"        Thrombosis (eg, uncomplicated pulmonary embolism [venous], nonembolic cardiac mural [arterial] thrombus), medical intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td>",
"        Life-threatening (eg, pulmonary embolism, cerebrovascular event, arterial insufficiency); hemodynamic or neurologic instability; urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute. Available at:",
"     <a href=\"file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\">",
"      file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf",
"     </a>",
"     (Accessed December 17, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34283=[""].join("\n");
var outline_f33_30_34283=null;
var title_f33_30_34284="Nonresectoscopic ablation";
var content_f33_30_34284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonresectosopic endometrial ablation methods (available in the United States)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Ablation method (device names)",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Endometrial preparation",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Device diameter (mm)",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Treatment time (min)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Sounded uterine length (cm)*",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Treatment in women with submucosal leiomyomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Minimum",
"      </td>",
"      <td class=\"subtitle2\">",
"       Maximum",
"      </td>",
"      <td class=\"subtitle2\">",
"       Diameter (cm)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Published evidence",
"      </td>",
"      <td class=\"subtitle2\">",
"       Women with leiomyomas included in trials for US FDA approval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bipolar radiofrequency (Novasure&reg;)",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       7.5",
"      </td>",
"      <td>",
"       1 to 2",
"      </td>",
"      <td>",
"       6&bull;",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       &lt;3",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Microwave (Microwave Endometrial Ablation)",
"      </td>",
"      <td>",
"       Hormonal suppression",
"      </td>",
"      <td>",
"       8.5",
"      </td>",
"      <td>",
"       3 to 5",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       &le;3",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hot liquid filled balloon (ThermaChoice&reg;)",
"      </td>",
"      <td>",
"       Hormonal suppression or uterine curettage",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       &le;3",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryoablation (Her Option&reg;)",
"      </td>",
"      <td>",
"       Hormonal suppression",
"      </td>",
"      <td>",
"       5.5",
"      </td>",
"      <td>",
"       6 to 18",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       Not applicable",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Circulating hot water (Hydro ThermAblator&reg;)",
"      </td>",
"      <td>",
"       Hormonal suppression",
"      </td>",
"      <td>",
"       7.8",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       10.5",
"      </td>",
"      <td>",
"       &le;4",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FDA: Food and Drug Administration.",
"     <br>",
"      * Sounded uterine length is from the external cervical os to the uterine fundus.",
"      <br>",
"       &bull; For bipolar radiofrequency ablation, the minimim cornu to cornu distance is 2.5 cm.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: ACOG Practice Bulletin No. 81: Endometrial Ablation. Obstet Gynecol 2007; 109:1233. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34284=[""].join("\n");
var outline_f33_30_34284=null;
var title_f33_30_34285="Medical history in pregnancy";
var content_f33_30_34285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Basic medical history for the pregnant woman and her family",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Endocrine disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Thyroid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Adrenal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diabetes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Cardiovascular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypertension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Arrhythmia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Atherosclerotic disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Congenital anomalies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Rheumatic fever",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Thromboembolic disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Kidney disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Urinary tract infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Anomalies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Neurologic or muscular disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Seizure disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Myotonia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Aneurysm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Arteriovenous malformation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Headaches",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Gastrointestinal disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Gall bladder disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Inflammatory bowel disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Psychiatric problems",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Eating disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Depression",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Psychosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Domestic violence/sexual abuse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cancer",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Autoimmune disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Systemic lupus erythematosus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Rheumatoid arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          History of blood transfusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          History of trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Pulmonary disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Asthma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Tuberculosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Hematologic problems",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Bleeding diathesis or thrombophilia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Breast disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Infectious diseases",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Herpes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Gonorrhea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Chlamydia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Syphilis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          HIV",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Human papillomavirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Gynecologic history",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diethylstilbestrol exposure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Abnormal PAP smear",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Genital tract disease or procedures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Surgical procedures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Problems with anesthesia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hospitalizations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Allergies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Medications",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Substance use",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Alcohol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cigarettes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Recreational drug use",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34285=[""].join("\n");
var outline_f33_30_34285=null;
var title_f33_30_34286="Beta hCG following evacuation";
var content_f33_30_34286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serum beta-human chorionic gonadotropin following uterine evacuation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The time course of serum beta-hCG concentration serially measured following termination of normal and molar pregnancies. The time course of hydatidiform mole is indicative of complete regression, while in persistent trophoblastic disease, a plateau in the decline of serum beta-hCG followed by rising levels indicates the need for chemotherapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pastorfide GB, et al. Am J Obstet Gynecol 1974; 118:293, and Pastorfide GB, et al. Am J Obstet Gynecol 1974; 120:1025.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34286=[""].join("\n");
var outline_f33_30_34286=null;
var title_f33_30_34287="Erythema ab igne";
var content_f33_30_34287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema ab igne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 338px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFSAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDoR1FTI2OvTt7VAhG3mpEbtXxzPo0Wo2A/xqQPjGKqhwOlPVskDpWbGXkbJw2MUeYB2qFXx6U9WBx2qWNEu4kdvwpBnB7e1NGBjuKV3AH1pFXFzx1wR1qORsfj3pCx7ZP9aikYZNSIZKxzlcn8agQ46nBNSH25+pqMZVhnn2FBSJRxknOBxSO+9RwcdacpXHJwPzojwGweAe2aQ0RovGSeBT5UVeSRkc058fRR2JqMru+Zh7YpD6kEhBU460sStnGBuxSyY6c/WnqhA75BzxTKCYOEBUAk8YzTo+Yyc4PfjpT1Py/N2pjyosgAPBHQUgA5CkdTjr0qItlWAXkVMM7sEjae9JINoOSBzxSGV1UliGHQdqFjHXnH9Kk5XJGN1NT7+PxpjHIMdRx6Cp0KAAMKqs583aM8VOhX5eR+NAmOcc5Q5A46VC3XJOO2MVO5wAvGe+O9NI3cHPHQ0CINhJAUge/fFMBZMjcM5qdA20DgVEyEnBAyO9Aw3Kq/Llj6d6cy8YbqeeDUYUJ/U45xS7wxyuADxikNksR2tz0/UVLtB5456mq0RDkso4HWp45Qx6429jSJYrDOAvOOPpVdgC3J+UGrUgx8wPPfNQSHBxx700A3nb0x396YevIyP51YjwyEDr3xTWQA85zjoKAuVZPvA88elNBJP61ZKkE479M1Ay8llyMce1UFySIjGWNWYmDHrknt61TUADFP6LwfbimSy9uwMMevaopehGMe9QrIduMjIpDLk8UAiOT5Bx0P6VRLZkz3q5I4wc4qhJw+QBTQyXzCpGOBUhkxyPrVfO5e+ahmk2cA81aQmTzsHPuKgLE+tQiRix5605gc8GtoozehsoRT9wAHYmooxzj1p5HIA/WkyEPDEtShueDQqkCnEACoZSFVyRgE5qwknFQDA5GaVehJB9KhlFqOQ7eaZIecnpUSsQ2M/nR94EEc1LAeCcimOCSeT+NKBg8dc4oYk56/WkIbjaccc84xSgE44yfWgcN6UNyMDI+lMYmSgJbnPUCpMbQTgfWmINp+br9aUcdScHoAKkpCFh5eOhJ70hIXjJxjvQ4HTGO/FRggt0/OhIY6MEkHHX8atZBGPT3xUMYBB5wOntmnAFGxgkCkx7iSAclT17EUixhcc9+4qaKLcQMj1qQxhSwPXOaQXKzrgYGaUAFcd/U81KwJJx0FI6d1HIGPpQMgOSSCv/1qhYkuVbgZxxVnyiMdfUZNQ3AYAsoyemKYyJ8gjH51JyF5wT2pkfzIGbIOOn+FSZyoyOfSgZJGS3XBB6VJgEHA/pUAl56Z/Sntkjax/CkIbnbIB0HWg5duhOOlRybucAHv700OdvIP4ikAkxAJwSaaWLMN1Obv6+tAU7c4J78GgYnmep+lOBI/PPNM2hj6ds09VLYwee1MGPklLgENgg9DTQ+5iT09TTAuGzkkU8RFjxkdhQIVDjrk/hUxGRuJ/DrTFiOMkkD0py9gwH5UCI5COnAFVHk+YgA/nVi5TLYyBmqTj5j69M1QWJGbng8igyHsetRH7mSCMVCW4Oeg4p2FYsrJ+f8AOjJPQ/UVWVhxjtTxISDTsA2ZyMjJqqzkoAamf525qtICO/eqiMsRuNvvVS4JJ46U6J8ZyMU4YZiD1rSKsQyONdpz2q1t9qY0Y2inbvetEZPU1uo460Z5A9qEJLZGOaUqQTUsiI8ZFPYksAaYeME/SkBywzxUMtE5YYpI2GDgmoyQ1CnaDipaLRKCBn1pVPU9/Wot4JJ46c0pfjpU2GKW3YOTUiOCx6g1WGT09e9Sphl47UrA7EzYKnoD/OmRjruPFMUHJ5P0qQfKOcAGkA7pxj6e9Kg3Hnt0HamKx5NPchsEcD3PFA9hHXgqM88VFHHtJJ49qmkHGTjGOppoQMM9gKRSYqqAMhf/AK9Rs5HJHNSDaq4JGetRuMjgD6YoGhVdmxgYGOtWkHvkjjmqsf5DNSxs3c5pA0Sjnk1G7lScg5B7UjZB6nb1pxbceDz70gBHJ6N0FVpWLHgfL1A9aJGHUevUd6Vfm5J4AzT2BDQuRjG7H6UkikDABweB7e9SlwnBxk8D6VAJOcKPzpFAv3sn9KdHKH3Bd3HBzUDMzAgEAj8KQMcbsdu3ShhYnU4B6k1KQpUD8gKqxyZbLjpzVtXDgKozjoDRYQ2WIFVOMAc+lIQACOPXr1qZ+c47dBUW3jDZB6Y7fhUgR9Qe34U4nanAx9KQrjHPFNY7l+bpmqAVP3gAbOfWnNnOVxn3pBgD0+nWhSSfmHTmkBKN2QCBgnOOlIRhmIGFPepMgjpke/FDDHT0p2EVZgOucfQVWlTkHceatTjHOM+9VCSTtAIHbNNAhApIIyDVdkzxzmrSqcA5OKQx5JOBVJgU9nljp+NOUcdOtTSLnsMUwZxkjOKoQ1UABPX2qCdeec5NWz69OKruu5wOcU0IqSqccCmxZEgPerrx5zVQkCQdRzWsXoQWGyq896hk5bip3IZAM81EFNXEhmyig9TjmlYc98U1T8o9c05zxUSIiGCx9qmHLADpTFBwAKlTC9TUs0RFIh/hIVs9TRyTjH1qQ/MeKAyh8ZG70qLlIbtA+nenbgTiiTjkdaYCFB6ZpAIR1AP401SynnI+tLyT6+gpARv65oAV2c4UfpSxArwc/wCNKuM1IMLzSbKQqqdwI+6PWnhucMPyoRgRz1NKc9QfrUgMkK+w+tOiPOF6d+aYwznvRnaQMdvyplEzhcYDH0wO9VQGAC5Jz36YFTbiMnnnrQAMgMwz61I1oPG0IBkmmjBY9c+uKXco4xmkZhjJBzmgGSAAx8kZNQSOFXan6012wck4z0pr5Kgg4zxQCQ0kZ+anRyKHwwGKruGLDA4HU+tADFsA5NNlWRLK25iOcDnjvTo1PXH4U2BTu5J9KsJjIV+e4pAVmCk5AHuKaUGAQPzq3MisM4wR1qNhhRjn39aBXKwUAndjIqa3OWDDr3ycUwIFc7sE560q4B2+vpQxlwPhs5Gcd6ZJKA2P5VG8gO0Drj8KSVe4xUiGySLkhcZ7jNNMgwOef6VByGYsNoFORic/pgUxtEiSAkjkD6VKuN+D/Oq/LOvOMdKcScjBGAfSmJl0EgnAJGMZpjy4IBzt7VE0uFyMenJqNp8HBHWkTZivLlyvGeoxULgBw36+tDtn3PtUbsDz+FVuOxOjjBx+NJuweTj61VDYJNIZQV9TRYLEk2W6Hio+n1pm8sRnIFGfm4q0A45I7UqjnPrTd2DyCR04qU8LxQSyKZivzAZqlguSW61Pcy4Q81WRyDjFaxJZLjaoxShhjkUrH5aFAI61pFGbNFW5A7VM56c5FQd6lj5Hcj3pSRESZc5HvTs5JAGKavzdDwKVeOnWs2aoXcC22lCLklRzTEGGPqe9SngDHT3qWMjlY46c1WJZiPSppeBxTd30pIdxG3FQP60A46DBprSHPHH1oZhjnrQwJUJNS8EYHWqqBgRinlmznIFSxk65z1H4U4sWBCd6hXPHGKd8w6AE96RRKoCnIPPenggg5zUMbYHI6npTnJBGCOfSgTJfmxlRkH1NQnO8gnj1pY3AjPfHeo2kB+XoPUmpsNEoYA4JyfQdqVmJ49BmquSrk5GKeJCwI6n3oKHSDcNu7mmnhcE9OKjIZW6nFMYktjJH1phYkyAhIPPtSovOeMYqsTvPtT1bbxkDn/IosOxcTAU4Az6ZqYcjIAC1XhwCc9KkZ8jC9AfzoEPmJ5wPlFQSSMVBHb8qWV9q/wBTVPzg0hX8OtFhpXJyeSQQ2P0qtPhTlTyT2qSVsL8pwRVZ2LNyMChIaQ8TsB82TmpFlDKAfSoWQlBgjPpTVJycj8KLBYnTJyDj86VwR82cfjUaMRj5efrTsnr68UrCJFK9846ZFOAHX174pqDrz8pH5U1n2k8/TNFhD5CvAz096YecYwajwd3Bx64qSMAMSMfSiw9gIBPPFRyKewyanfaSOmTTGA2nGKaJZVJzgHvTljB7CnOmDyc0iEbjnOaoBxUbcAVD5YUkjrVrIx3qAjnjvRcCVVyO34UjKQOOtOjK7RmmzFt67QNp6mmhWM66zvwKNny7j1qa6Aye/YUnBiArZMlkTHKHPWokkwvWiQ4JGc0gXA61stDGTNyRdkhUjoadGQMgjNavi6wFhrDqg/dSAOv48H9RWUvByRxRVjaTRjSlzRTJjnaMD607oBnik3d6HYHjGa52dCAH5utPc/KMdPeoSSp69aZIWK0mVa46Rs4AqEsDntihWI69akSPd1HBo2KtYhVgc5zThgcnHWpDEUfjNDg59QOtSwQisM+1O3A+/wBaTG4f54p2zOMH5u1INh4O7n9aViB279qYqkDLH6U1yRnnn+dADvMGcHrS+ZkYPHtVYg4zj65oXJOegH60rF2JvNIODn0zTXAyTnOO1LnIphGTyCKVgQ5DznqKkLgA4A9uKYpCgHOBmmu+T7elAx+8nkjjFQM4LE4zSSPkDBI4zUBkwOKaQx5byxtUf40A7RnkioZHydyEYp5TIz/WnYC5DLubAyB0NTLIBwoOaooWQgDrSbmLA7sLSsO1yeWcFcYO7tmqqjDk9+9SsOGJ5HpRGUCtxu9qEO9iSEbj85GKJFAGOKiJOARxjnjtUyvu5PHrkUrWJECcccgdTSqFxyPlFSSr8nyHPpUe75PnAJ9jSHcQICewFIMIcYJBqQkE5BPPb0pjBscYyaBDDMA5QcEdz6U3HU+/Sjy+pJ69OOlDusfr/jTAcCOnenpkZqOP5juyPUipsqVI6mkJsYfr04qJmKuDmpHBUZ/SoGGec8GmA5pCTgEAURqTz3FQt16flVm2AHPPSnYBNxyAR+lSoNxxjpSsFB9/SozINw2n8qAHuPmAApJOQeOlKXULyRVcyAgjNNEkcmGfnHrUIbnjOCaGbaxOM06MBuRWqREiuV/eAn6U9uDg06UBWFGC3OK6YK5zzZ6l8QrTzNOgulX5on2N9G/+vXB4DIAT3r1fXLf7bpV3b4yXjOPqOR/KvJvT1rbFQ96/c5MNLSxMx9ec08AAZ5pmR1P3cU9TwBgVwPQ70wCk9BSSdMcfWpf4cdKhPAwRyagtMjUjPPT6VYjYbQcc+lR7BjOBSA7R7UPUp6j3OR83SoHOWB6Y96kPI5FQ4bf7fSkkCHBy3FSjHsBUA+UgdvWnhgR60Mdh+0EgA5FSYB6dB2pqAkK39aa3ysTxjvUiI5FAHp/OmJwRnv2qWVgQMcfhUPTjBoLRKTwexFV5JsE4YD1pmSD1yDVdt7O/mYKegFOw0i2Hz1I+tPIJ4zVMMFAwMD9KlibJFFh2HSYUZJyP5VWkAJ46danuOhxz7VCSC447UwFyAvy4ye9SghlwOvrVZzuBHANPjbaig9fQUNCLLcD146UyQ7hyRjvTS4A+YgZ7UwkEde9Kw0KZeqg8+ppkLN5pDE07AyCelMRSHB7etMdy2jZIJXA9KezY6du9AGVxjg0jqMH09BUCF8wtnDd6CDwc/SmpF6ZxigAgEYpATjBORxjiiQqxAxUStg9etMOeeeKLAPcAjAzmoJVxwf07U4tkcZJqJZN2R0weppiJRyRjpU2AMEnP0qsvJIzz1p3mEDkDI5oGPkYs3AwfemgjcSR16UgJY5FPZcL0yaBEb498CiHJ5XOBVd2bf1GKnifaoI61QFkgFf1zVObJfI7dKeJsZGajcg9+aEhIkRi4PUVEQVYjH41NGB0FO2ZOaaBsozAk4p0LER89alnU5GAfrUDH5OeDmto6mUmJI2G3V3/hfwtY3OhWl1fvKJrhTJhTgBckD+VcBJGZCsaclyFH1PAr2u4iWzWC1CDEEKRjB6YGK9rLKEal3NHi5jXlT5VF7mi5VRucgKK8n1aEW+pXKD7okO36ZyK9PkjMz/vDhR2rhfHNsItX3qMLJGp/EcGscTG8Ey8O7Tt3MFW3Eg9KfkKBUO3GTzTlbK49K8uSPSiyUuQucZyaXGcE9aaOcEnFOZgABxWbRpcbLkLntUG7A56npUxO5SKiK4PPSkUmPGSBQ6lRkcigPjimmUEEfrQMZuUkA1Iu0qcH86h4Lcc8VIoC4PrSZRIWI70yWTv1NJIN3fiouSMfoO9KwaCLKSCVOTUW4luc8/pTghBwc5z+VEhO4DgHsKqw7i9QR0+lQMOQRkZqwgwSDio5VyMg8ikCYHlR3puMAN0pEbC4P50pcEYpjuIX4JP5VWkLH2p8rYUnOD6VXLgkcHBqkhjkHXp/hT4+ueSelQK3zZTJHp3q5gKpIoYDSSRyOPXvREmCAuCPWmCTLbSME1Kv3yegosBMybR1600ZYYOTQZBwOo6ZNOVsjOfzqRXJFOB940rEkDnA9qYMbcMMU/IIBbJxUMLksZABGSfrTOmetRhzy3akaTIJ6Y70WAczcHA6U0sMbsflQzZXIwTTBn+Hg0WBDnYgep9qFUHrxn1FCpzkZz2qQYIBx9KAuO2DGR2qGVOBjNWP+WfzHk9Kil6f1pAQISrAg1ZDgpkgVQmYhgc4p6SZQ96q1waElbk4FNibKkd6jdiSSKdEvGaoZIo6nHP8qY7bTyM1Lnau7H1qpMd7cA+9CRJLDKd+CQB2q15pBHoaowpkc9asxKTk474qmlcUhZHLKc1DNxF09qtAADntVS4BKg1rT3MmzV8H2xvfFWk2+MqJhI30X5v6V6jqr7r+U89a4b4TW/m+I5rg/wDLC3bH1YgV28/7y4lb/aNfS5fHloX7s+ax8ubEcvZI1SuBk1yPjyEtDazEdCU/rXXPJge9ch4zuQ6xxN3PH1rgqLmgzrg+WaOOHvSZC0j8N+opQNy5xXkyPVixRIQeRTsjk9qifleDQo+Xk59qzZqkKxwAelK0gYGms/r29ahBDcj8qRViQNnpz+NMY49Md6BGEzg9aiZfmzmgaJYmxk5zU2cnrVUnjqD7ChpMD/JNLluMtjGSM0xnC9MVXFwewzTN5MnP3fWlYCdjkkmmMSDkgZp7MOo/DNRnDHC9aAQ0uwAwR+VIxZhxnBqSPgEHNDDDkDOPSgdyuAd3Q59KQNtJyefSpypBPf8AGq87BWOfrwKaQ0yvOAQeT9KhzxkAnFPlfLdOP51IqgjbjFaLQd7ECPsfI6mpDOxGCaSVQnAxio1TvjinoMsQ7pAM8Y71MylTkDNRRSAE4A4oeYYb1qXuIjkkKSDcOO/erSSALnv61REu760GYhuD+lDVwZp+Zx89MacbRyeKpG5wvNM3Et9489qnlCxdM5zwTS+dwBmq6HpzxSOeQc4A7CkBeBxtPSnhzu4AxVeMk7asx5zyuTUMTJkwSOCDT5FAzzjFG0FAcChgdnakIiDFQMfMtQynk4qRD2pGBORjJpjuVJFJ/rTRwMcCpmQjrx7VW4L7e46VQ07jiCCOKTPl9jT2PyjvVOdzvGPwppXDctu525A/CoGYEHA61EXLjJpBnrVqI7EqXGzjFSx3IGe3FQIoZvepfJBwQOTTsjNj2uCwG3GOlJO4WHGKXytueOlVZ3JUitaauzGZ6b8IYdthqlzxyUjH4Ak/zrqLZN6MxGSWNY3w2jFv4KlkIwZZnJ98ACug05P9FXjqa+twkP3MEfJYmd69R+Y6Qgjj868n+ImqNF4k023TO0zAk9sdP616nenZEdgDN7GuL1zw1/bmmm7UYuYX8yM/Q9K8dP3Gep9pHPSj94aajYH0qS4B8w4GOcn2qtuKnmvJkj1Yj2cHFM3he/4VGznd35/Sg84rNo2RIVLfhRGpHAFOJ2qTTUZQMnk1BVxWB24HX61AxKqR39KkkmAPTFRSMWOTiiw0yGUnPsKijYljk/WpJskHHSq5UopNUiidjnHNKkigY/lVdGG/I4qQYA+vakBKZOeOnrUkT46dapBvmPY1IHKkAd6Vh2L6nnjrQo5znPpVaORivPU/rUyOMcYGO9JoLCSDgnP5VRkbcDxx+tWpZfnwMYIqu+AeD+HrTQFRFw3Xj3NWlZQu7jJ4qB/lJJ5Hah8ggg5U9K0tcGPlI3YxTG5GAcChvlG4k89zVbzWJ2jnnrTirhcngxyR1qPeDuHf3p0BPPtSOhGSevuKb3GhIoyWyAQKmMYDjBw31zTLc/MAcmp2QFtx6+lS9wInTeNvAP8AOoh8jc84qyTnPHQdqqTS4OBSSuNMsRtkdMY5xUmCw46GqCTBgAMjmrkcnBpSi0JlhJPmVTjirqybW4XJascOBIT75q3FKTtI4HrUuIjTjYjO4YqOV8Lx0qMTgpkn8KZK4wQSMEd6ixIiy/Mc5HpTll55IJFZkjsDgH6c01ZG7mr5CjQkl3PgGq0jFCTioY3ZtzHqKZK/XnFUo6giQ3GB2zUZcsxOKrBtzZxVpYiEJJGPUVbioj2HRAEinv8AIMdaZGyp1oZw+SOam2pLCNmz7VeSQFR0rNU5PNWQNqA02hMneQAHnI6YqhCA8wB6ZqVlJ7nBNJGmxsitoKyMJHsfhv8AceArID+IM35sa2rHItUrDtj5XhXSojx+5XI+vP8AWteJyIkGR0r7TDwskuyR8XXlduXdsj/sULE3lzPuI7mpNIR7e0S3miKlT19aii12OQKzgRIe7HFFz4l0qIYluos/71fKqa7n0HK27nn2vxCDU72JeAsrYFY0mSvv2ra128g1HU57q1cNE56j1Awaxpe571xy3O6l8KI8ZINBbB+XOOlNVt3Xj2pdwJGelQ0boGfnBOaVHJqCZtjEk8jtTo3BHTmlbQroEwJIpuSvJ596eWO7kUxzleOPWlYYmSQc1EFJBBPNODBc8/jVaWbbkdBQkxoYxKOQMGpQcgAfiaqq7O+atxLjGM/WqaLJFXK5zz2quXZXIJ781OSQpCGo2j5BxyOc1KGmPeQDGDijzOOSBxTdpJHU0yUD2NFh3FLkP160FwBn/IqtIxzyTUQYnntVKIE7vufrkDrU2QIwvbr0qh5mG7fWh52zwcVXKItTsAPm6DoKbDGh5BzVOSVnI+bJq1aZK8/gabVkS2WQpRM8Yz3pC4BJzStnbtzxUTJ3BP4ioKQ5RxnOKU5EeecCot+3AH404zqeG60WYNld5ixPJAHTHFMaUkfMetDnLnaPpilI3LnAyKtBcEVQBjrmrBJVQd2aqh9uOBTmkJDYyStJoExzt8wx/OphMR7VWiXdyy9f0p7LsJz+FDSGyyZyVAyBQ1wSmO1U/MAJwKcrF8gnApcpJMvzHrj2qR1AUnrTYNuammKhMCpYFZpNowODVcuS2OxqSUA9/wAaZDGSf881orJAnYmhTLdOnrV5hiIDHFQR4HX5frTjKD8uTmoerJbK8xOdvFRqSy8HGKmCbjuOajk+UnpVoOYQPtbHerSyfIMnpVSPHoKfKyqKdrsTZbRtxz2oVgZAOueKgilBXjOKdbH/AEgk9BWkFYwmdtL4gd4bWJGIWFQpH0FaS+KAFA3CuIjOSaUtz0rvhi6sNUzx5YenLdGbPPc3QAuLiVgOgzxTEtUzk5J9zUijipUFeconotpGlpmFs2jUY2tnH1p0zYHWotPOGdc9RmnykEEYomtSoO6KskoDY5pCxZaSZBgN1pgapaRuhZW4BPNOjkOMjoKhkI+tRh9q8UrFIttKKhlmG3qKhkkBXB4/Gq+d0mM8UKA0TyT4Xj86qmZmz71MUJyOOahMZTPFNJFoVJOduOlW45gB71TUqOOrVYhGew5qWh3RZjky2TyafKxYcACoGADAgnPTipFBINQ0guM3HdildAWBP44oMZU5yKl44GcmgdyCWPcOMD61SmUocKcA1oSybBwOe5qi8m5j25qojuQKjE5I/E0xuWAI+appXwpxx2qKI9WPOBWqJbFACrnuKmiuQuc9uKpyykng570RIHbnp1p8t1qI0FcSPkngVOcsNo5J4yKr28eHHp6VZY+WN2TmsnYpjHgAHSqjIeewqW5ucHrjNUnnO7GeKqMXYV2SAhRzzSMd74BAFV97bicHFSRKWOVJz9arlADuzgdqeXOAM8inKhOexqMcYz2oWpVy5Ay7ATRLIj52kk+lMQqFzUMoycr+VQlqJijg88VNkgZFVSS2B/kVKoZV4qmgZMH2c9KY87Mev41UeRt5BIoQ4zmmoEkyuS3JqUS4XgjiqTMOSppI25yeBVcgzQDswOcD2pDJhx2qDzsDAFMVmPep5CGXZZ8Ac/WqUsrFiM478UkkoHHJqIsD9auMO4iws56U18seWNQRfnTurdeKpRs9BSZo27gJtH41PaOBOWb7o5NZ8BJOFP1qzd/udOl5wXwtOKszCpszVN3B1BAU003Frn/WVy24kck8Uxi+eG4+teiq0+qX3I8p0ovq/vOoqRMVEKlQ15qR2Nk0LiOVW9DzU1xw1Uie2eat7vMt1cdRwfrRNaXLpPoRk5XBqtNwPSp8bl61DMCUNYnSimZCeD+FOXp61HJGVwRyO9IrbTzVWVtC/QZOW7dBSRMO3WpZhlSemaqRjLZyRQthl5HBGCcGiQZFRpxjnPpUjDI64qGtR3KbA76mWQqAAKGCgEE8DnNRiVXTfGwZCcA1Vmx3JjPk9qmilYkY6CqhXcARxmpI5PLOD3qWii08hRd2eP5UnnKFz3pruHQhsYNVWxyBnFSojRK0xkJqqVKvk9M1NEASRTpI92Aoqk7DKsm4r04qs0hxgdDVu54AB/SqjKSwx0NaxENRdxrRgjQdOv6VS+bOzb171LG5DAA/WiWpJrRqNo9R6U2dl2nJ5+tVPtIHyE4qKSbt1A4rLk1Hcin/AHjFR2qSODcgwOaBED1IFTRllXg5I7VbelkFyu8YQdMGn2YAkzxj1pZmLjnrVWJvLkxyRQldDNF9u+qtyAnzZ69KYZFZwVJq0FjKnNT8IyqrfNtz2qxgMnH61C8YDdPxpVZdwyccU3qIaAVY+lSl2UFcg1FM+OnJ+tQs5JzVJXE2EmN3PWm4LdKQ5Yg05W7VYhrrjNIvJ5pWDZ579zTlUkc9M07iAZLjmnE44PFJ90U2QZ6GjcBspyoxRErBaYqnq2c1PuA6elV0shMAQOD1p0ak5IqIEluelWgQEwOtJ6EsdaqVfmsjx1rLabHZQQqGeTc7Z9BwP61uQA7x69BXnXjWdtQ16YxfNHCPKXHt1P55rqwlPnqXfQ4cXPljoCeKpufMhBHsan/4SfIz5H61zBgkB5Q/lVhYyFGVr1HSh2PL55I9uFSr0qFDnmpC2K8FHo3EdqztI1RTrEtm5ASYfJ/vDt+NS6lP5Nq7e1ee6leSwTxTwttlR96n0Irro0faRsZSqcjuerPw270pkmHGSOKgsb6LUdOhuoeElUMV/unuPzzUqkYx2rzpRto+h6MXfVDHUBfUVnyqWORx61oM6hsdjVST/WY6e9SjRFUbiQCxqRFIyMVL5WGBHNSOoxuB/CqbKuVyrKM9TjmoC8mcZ6cVoKpKZznNV5VCngc0kwIo8OpDYI6EYp5RVQIigAdAKhY/NheoqQM5HOKqwxUYhgp/WnuuVzTFbqWGOe9P+0DBWpaH6EQdt2GqZQSTggmopPmwQKWNm4x60rF3LcUQDZIx9KaSFbg8U2SX5COAR6VAXZwMKR60lF7iG3DBidvPPSoymB82BjvVpFAXBXmqtwCDt6Zq4iuV1OMseaiZmL/L0NWhCO/4U0qFbGOc81omhXIol3tlic1aZQIsL1pAgUEjuO1N2M2AvGKl6sEEUmzqeBUsc6tIcd/SofJfGDikEREiheCKHYZPMATxzVeYKBkZzVkboyc9xg0x9rAkKePSoTsUinhhgirazBYumG/nUO9QMEdKQnzCu3NW9dwuK5J+bPWgJkcnpVjyhs9zVeRwoxQvIGytJndwSaarYPen53Nx0pXG0DIFarsSWIHRuDVgQBjkdKzY2+b0NXoHYnBPFZzVthDpowOcj6VXbjIA71ddQyjnIqnMArH9aUNdAG7SRmmEgHHvS+aMY4xTdy7hzWiQrjsAnJFPSIE5HNMLA9OakVtuMUag2JIoDgA07r93qaazhyfUVNbR5YE9BTt3M2wvbkafpc9y3WNMqD3Y9B+dec6XcGG/R3w244JPqe9dH4+vtqW9ijfMf3sgB6D+EfzNccCcgjqK9XB07U7vqeRi6nNO3Y7h2RusaH8KjKw5/wBUn5VTsbjzrWNs84wan3e9Vy2MbndoeKVzxSLSSHapzXkR1Z2mD4luNsCx561wuqvukQe1dDr9z5t03PC1ytzJ5kpPavXw8OWJxVZXZ2Pw31LEs+mTNxIPNhHuPvD8ufwrtiuG45FeM2F3JY3sF1CfnhcOPf2r2VJ47qCK4h5ilQOv0Irhx1Llkprqd2DqXjyvoNk2v14xVC5JjcGtHIbjocdapzR5OG5ArgW56KKyXLZwM81aXLDk81SljMcg24IqaKbbw1NrsUXB8oqvcEAfL1pxn3DHb2ppXJqBFMH5zuxmpwQenX+dNeHccdKdFHgYb6ZqmxiPnGM1EYixyBzVibaV64psSYAYE0r6DQwbtuPSo8ydBnFTs2VIFC54z0oHckgxtAblqezegpVC4DKCD6UMcn09akVxjOyrwOarMfMcZHTrVmUDGc8+lVA5DHirig3JXIVTn0qCHBYsaSRmkIAGB3NOwsa+/eq2RJIpCkHmpyy7fl61lS3TA/LzTBdkkA5FP2bYXLczESZzxSQKXYEOciq+7fyCcVbtkI2uM4pSVkUmXI1yP3p4PGadNEAvHX2p4KsuO30qN328YPFYajuZ80R7Kc1Dgr04NXzKXbhfzqOYKM927itU31C5UMjkYyfzqEhs1Kcq/IpHcZzyDWq8hNkahy3IwKcUJ6+lKZCOh7dKjJY85q9SWxyrzkVZicR9TVElx3oy2eSc0ON9xXNNrkbSOlUpJs5qD5ycHpSFG3YojTSC45m+fIpWOB069ak8rcowKYVKnnpVJodx0JycGrLKFBJOTRb+Uq5NWFCudxIwKzb1JbK6xN97GKsxOI0Z5DiNQWYnsB1qJ2LybU+6KxPGV+LXTltIz+9uPvY7ID/WtKcHUkomFapyRbOP1a+bUdRmumPDt8o9FHAH5VXBqNcDOKcDXuJcqsjxG7ttmrpFwEYxsevStfcK5VGKurA8g5roopN8asO4qJrUaZ6VxtqlqM3lW0je1Wia57xLclYxGD16141GPMzum7I5bUZeHYnrWI1aGoPwF9TWeTXtRVkcDd2NPpXpXw7vvtOhvbk5ktXIA/2G5H65rzPqfrXS+AtQFjrixyNiK5HlN9f4f1/nWOKp+0pNfM2w8+SomeksAckdu9Qh/lIY9e9TzDYTnJXNV2AwSD+NeC9T2oshmjUsCDn1pwiBABAzTlKluf1pWPOB+dD2LuQuFRsA/WnBx19elMP3iSc0xnUAEmizY7kvJb60MuG64qLzcjpQ0pbAxS5RiPhSSaEkHIBxUb5PJP4UIASRxmqsAyTd2OKQB8DJzVgorR8k5pE44yMUXHcVJGBwRSyTAKBzmnGNdvXmoHhbJOaSsFwWQsCaBg/eqIZQexPSpDLk/KPzq7dhXHAjYD09qilYbCSce1RSbyeSAT/dqIsAPU1SiS2V3OGO457ipERJOCMGo3Vn7YqSJMdW59q12RFyaODa6/MfYVoRspOMe1ZoJXOHzj9akS4+b1FZSi2WmaQJVcClyP4ziqxl+XIHbrUQvABhlJPrWXIyixJ/rBsPPpUUkpRiWFQ/aF3AgYGeneklmD9elVyhcZ5gkkPGRmpJI1xkdPSiIooyOaR8MOGq+orkKDL4AB+tSvGAM1XLLGD82TUQnbNacrZLHyKwxk0+HOcMKb5qk8ipYXXj19KHewItCMbc45qCWBs5XIqdJCwPFK+T34rJNpgUgsmeOcU6RMLmQjPpVtQgX3qKYIcDvVKQiCKNiwz061ZRSWwDxSRxBRkn9amhIXJHXpVbktjvkiVmY7VUFmY9gBya8z1e/bUb+W4OQrHCj0XtXWeNtQ+zactsrYlueuOoQdfzrhk4WvRwVO0ednl4upd8qK5OHP1qZCCKsWNvHczssjEE9MVrf2JFjJZq7JSS3OVRbMEda1rK4AgAJ6VQurZradlPTsfWmK+0Yp7oWx7LM21c5ridZuPNun5yBxXVatMIrVzntXFKDNcBR1Zq8zBwvqdVaRNcaTE2lNcuWE23I5rl3PpXVeJLzyYVtUPOMH2rk2616j00OKNxMVJAxWVSDg560yhThh9ako9i0i9/tLSLe5bG5l2v7MODSyA888e1c38Pbgsbu0P3cCVfY9D/AErp51K524FeDXp+zquJ7VCfPBMgZWbkjP0pV5AGacuFPPWkypPHBrI6LiODg5waryJn5sVNKT2NRh+ORQkMjBwMYOfepo1GB3NMJDmgkjGDQx3FkXac4piFQcnrQ8nqBmmhCwzjA9aBluNhjoKhmKluPzFREtGeD07VFJKCRnikogWAxJwDUUs2w4JwaYJMHI6VBL8x3Y47VaiIkLhm+Y5Wkd8cL0qr82cnnFK7uy46CtOUlsUytyB07U3zAvuxqRIsDJ4HrVYrukOw5q0kS2Su5IycCmo3P3c0qQDgsSamCjkLmhtC3IwpkI4wKkaLaMAHIpyAqc9qmZiwzkn6Csm2aJECs3C5wKm8sbc5FRPGzsCQABxT4ApbDHkUPyKQxVAf5jn6VK0SEDNWNqKMjFNwpB6fnU3AhaJQMrUDwFuc/lVkNhsLQV5ySKadhFYW6DGeTQ8QxhR+NSTOFHB6dKqmaQE89a0V3qSwSEb8Matx2qk5B6VR3NnknipkuSq4wc05Rk9hXNAR4HWkJC9aoNdMeoI980gd2Bx0qFTfULliaXHKmoQW+939aRUJ4xUqRqBz0FXZIlscqvIMHp1qZSsSs8jAIoyxPQCmKWc4UcVz/jW/MMMdhFwZBvkPqOwrSnT9pLlRjVnyRuzmtav21DUZLls4J+RT2UdBVMy+Y54AFPYmTAx83bHerMFkqkNN949h2r11aKseSlKbuV7dmSTzFzhDya7C0YXFusi9GHSuTuSscIROrsWI9K2PC10olNu54blfY1M48wRfKy1rWnGa2MiDLpzXKE/nXpxUYII4IrjtW0N/tzmDOxuRTiraCep1fiSf5RGD9a5aa4a1ZZIz8wORWrrMxlvGx0Fc/qLEyBa58PDlii6ruyG8uZLmZpZeWaqtPbrSYrqMhuKBTu1GKAOz+HD51sp/z0gdfywa7qUAHDDmvNfAtwLfxDYsxwpk8s/RhivVb22OSVrxswVqifkepgneFjIdecGqsmQ1XGJUkMD9RUEgU8CuRM7UVWZycFTimF2VvmqcgrwOVqFly2R+tWmO4xp8AgfhUf2jkZ6091yCKgETA9KtJAiR2JYYGR6ZqxFKVGW7VHCit14NPCFSQBkVErFLzCafJ4XOagVCzcg4+lSPuB4xkU6KVwOVGe9C02GIICqnB4qBlYnHTHbFWTLnsaiLsrHjNNXJbIhG2DuPApAmBuGaVnYEnBqJrjcQD0FWrsm4svIG84x2qNMk4RcCp4o95zU6Qhff2obsIj8tQuCfelQhR9aeVOcDkmlCevaobAcq5/2qQgqGCN+BpUQ5+U9ajkk3HHRhU7s0WxD50kZyVyO9MeUE8HaasiMPgEkN6UhtSpJNWmhFcvMwIDDFJFJIG+bkVOoVVOVx+FJmMEnkVSlcQ9J1Ix0A9qZLchsKBk9qjILgkqcfWlWPnKqM0WSAFVW++Dmjy1DcCp1ba3zYzjpT2LEdM/SpchlZggGCMj1FNAjPIXp60548sBjFTxoQv3c1V7aisRBEfHHNSpFsGABTyuF4GKRFA6nOe9TcTG7OecUqxljUhGOAKfGp6D86dyGOijyQAOvauB8RRSXviC5cnEKtsHPYcV6DI62sEs7dI0LfjXncspZiScliTXZg07uSOevGMo+8EFvDGMooz60ybgnNOViOaJSCua7db6mcnGULJWMabJlf26U7T5WjkBBw6ncKCd02R3NMnUxTbh0Na+R5p6Np9yLu1SReD3+tTFcnNcv4XvdrvGWwjDP0reOo24OPNWo5uhpa+piTyb5GYnvmsW4ffKzH6CtG6fajGsk89aILQhsSjFLRViCigUEUAW9MkMNyjqcMjBwfcGvdIpVuLeOaI5SRQ4P1FeCWx2ygmvUfAOrCW0awlcGSH5o+eq+n4GvOzGk5Q5l0O3BVOWTi+pvXFurE+vrVCazPJXtWxLgnt+FN2jb8vNeIpNHr2uYIhfOKY1qd3BrXlhB5AyaiK/3hgetWpj5TOFqeyio5IWU85x7VpiPj5WqF43LHkYpqYWM54yMFV4p2WP3U6VeMZGAQKY8YA4JJ+lVzIZmSg5HHzHrSYIPSrbxsee3vTTCxwc8CrUibEBzjORimKWc44qwIx3H45qKSP5vlOT6VSkTYjljOOWqssQ3jrirUiMOtRgYGTk1alYViRcKcdTU8acc1FGyheRijzCTwOKh3YEp+9705QCmajP5GnIG5zjFSxocVIQlevaoXAfthxU4JYY6N71DKGLnrj3pRZYsZ3fK45HellGDgE496jid1bFWVIZhxn603oMjKqyL2PrURjzgBc/WrTJ82dvFGwE5IpcwrEGzacFRj1pfL5AHFWgC3C4p5tyRnAxSc7DSKwtizZA/Gm+UyvgEEe1aKIduM5pjRtzheO5qee40ig9uSTjqf0oMTLjJq6TkAgEUBGbOevvVc4+UoiF9p+Yj2pNrLwcY+laGxsYphX5ulNTIcSqI2JHerMabRnipMqq9s1m6xqkWm25kchnPCRjqx/wAKuKlN8sTGcoxV2UPFl5/oi2UZw8uGk9l9PxrlEgwcsc1C2ovd3cksjEzMcsD/AEqd5wBk17EKTpx5UcUK1Ko259NhXwO1UbyYJEVz8x6VJLJK8bGNTwOtZMjOwy3JreMbHNWrKb0JIPmlUDtVuRQ3DDIqhZvtnXd0NaEvDVTOYdaARyYUkZGK6WPw1auis1zMCRnAFc3ZfNdRr6nFegJwgHtWFWTVrGkFdHC6g/yhfXmqGasXx/ffQVVzWyVkQx1LUe6gvTES5pM1HvpC1AEuQKvaTcTaddJeQuQ6HKjPB9Qfasvk1qgAQIZDgBenrRyqWjGm07o9Z0bVodTtEuICMEfMp6qfQ1f8wA/KOK8Z0jU7qx1DzrdsJ0aM/dYe/wDjXo+ja7b6nGDGxEi/ejb7y/414WKwTpvmjsevh8Uqis9zoQB1XvTZBuG3AqATIQMHGaRZCD1zXBynamPA8sYwDUTDIywpzOCMA80wPk45xRZjImbJIBxTEQqckg1YIXPIFNZh0HX0qk9AuRS4KkVCOF6HPvUxJ6NgUw4AIGKaJbKzruzheKhcnJxwPQVYfDcDJNQ+QzN83FaJklV3Y5AFNCOfl4FaIgATgU7yxtwFye9VzroCRQ8hh3pyxkc45q2VABzljULgk/0pc1x2I1UZ5z61ZgUkn07VAAScE81ZVgF2ilJjGmLK5FJHGM88g1KTkKFGDn8qnaMDnFZc1ikUpbdVyw/KiKMMAQMVdUBm9SPWn+WOoHB9KfOOxVVCPXinKoJwABVtRt+8KRogrBwOPSlzXCw2OIDk8U5+cccetI6hhxkCk8t+pINLcexLtXHvTATwuOKQOVPT8KjmmU/dGKaTC5N5aDlgKZJt4I596rpKMnc2Pake4Tu2OKtQZLkTbsdKrvIB061TvNRhtkLSyKi+pOK5XVvFWQY9OX281hx+ArppYac9kc9XEQhub+r6xBpsRMhDSn7sYPJP9BXBXt7PfXRnuG3MTwB0UegqrJI88rSTMzyNyWY8mkUlW9R6V69DDxpLuzya1eVV+Q6SMPkjhx0IrS0Vo55DFcqPNA4J71SXa3Tg0khMEkU6n5kcZPqK3ZznWLboOAoAPtXOy2AD3cQHI+Za6eNtwDdiM1Wkizdo4/iG01mnYtq5wnKuPUGtWYfIp9qg1u1NpfupBCt8ymrMgJtkJ64FaMgs6FEJb5Cf4WGK7fFcj4XTNxu9Dmurc4I+lc1X4rGsFoedTyGWTJqPBqVY+akWPPaukyK200uw1bEVOEQpAU/LNPSHNXBF7VIseO1FwKqwVNcnkKOgFThKYYy0tOIEK4jjL9KqwzSwzCeKRkkB+VlOCKs3Ry21fuiq5U4A7CmG2qOo0zxhNHhL+PzB3kTg/lXT2Ou2V6o8mZGb+6ThhXlZPJo9xwfUVx1MFTnqlY66eMqQ0ep7KtwqkZPBpxcE5B/WvJbXVr+2UCK4cpz8r/MK2LTxbPHj7RAGHTKHBrinl01rHU64Y6D30PQixIoVjjGcfhXL2viuwkP7yRoj3Dr/AFrWg1qzlAEdxC3/AAIVyTw9SG6OiNaEtmaqnPO3NHlZOeAKrJeK4+V1x7GnfalxgsBWXLLsaXROyLwOBSlFAwDz6VU+1oD98Y+tIb63QZaaMH3cUckuwcyLYUZG7n8KV9mDWZNrViv/AC9wgj/bqu2v2OMLcox781ao1H0B1ILqaMjLn5efaoJCqnPasufXrQsQkqkjrzVR9VifkSpz/tVtHDT6oh14LqazTLkkdaWN88k8ViDUbcffuIwMZ+9Uw1iwRSDdJwM8ZNU6EtkifbQ7m7FcYwBz61oJICBzXFnXbNSdsrHHop5pB4mhjJCmRueu2peDqPoH1mmt2dscdQMn0qdGyBnGB1FcMPGCL/yxkY/lmm/8JrjG20bHu4qfqFbsN4ykup3bkEEdPSowCPvGuHPjYnObNj/wMVE/jVyMCz/N6ay+t2F9dpdzvSwAyCD61DJLgfewa4CXxjdlSFtowPdjVKbxNqMmQrRJ9FzWsMuqdSHj6SPRJZ48YB5+tZl3qVtbAmWZI/8AeYV57caje3BPm3MpHcA4FU2X5snnPOTzXVDL0viZhPMP5Udnd+K7WMEQLJK3+yMD8zWLd+Jb2YEQhIV9uT+dY232pcfSuuGGpw2RyTxVSfUJZJZ5C80jSN6sc0gHenYwKAM1utDn3EwRyDUigMOnIpq+9SpwwIoARVINLcLm3cfjT6X7yMPUGgDotHlMulwMTk7dufpVl87QV52kGs7wwS2lKB/CxFahGRg1i9y0WPHWiefoen6hEn3CFcj0rkrhAIgo6AV7Rolqmt+C57RsFwhX6EV4ld2s8E0kLudyMVINdE4WUWjCnO7cWa3hSPO8n3rXvpvLlC5/hFZ3hJSIJS3UHFQa/dBNQK56KK5WrzOiOiMgdTT1oorZmY5e1OFFFJgOSnrRRQMeKZ3aiiqgJlI/fNNk6UUUwKw6n60HotFFACHp+FL/AI0UUuoxOx/3abgZ6UUVaJ6kfmyK2FdgOehxTxcTcfvZOn940UVjM6FsBmkIOZHPH941KvOc88UUU6ZExSOv1FPH9aKK1e5kthU60N0H0NFFQ9wGdqP4j9RRRTQwHX8TTcnA+tFFUxAv8NKPuiiigAPQ/Skf+L6UUVAhD0P1pR/Wiiky0MPU/jTh1ooq2IH6D6UelFFIAH3qf2oooAQdaeOooooAcacn3PwNFFAG14V/5Bbf75rW9KKKxluWtj0D4WkmG8BPG7pXnHi9QPEl9gAfvDRRXXL+DE5IfxpDPDf+pn/36wfEpP8Aa0vPYUUVxr42dnQ//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer Health. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_30_34287=[""].join("\n");
var outline_f33_30_34287=null;
